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Abstract 
A critical feature of the pathogenesis of B. pseudomallei is its ability to invade, 
survive and replicate in both phagocytic and non-phagocytic cells, hence a 
thorough understanding of this intracellular stage is essential in order to develop 
novel therapeutic strategies. 
Bioinformatics analysis on B. pseudomallei and B. thailandensis has revealed the 
presence of two distinct putative sphingosine-1-phosphate lyases (S1PLs). The 
human S1PL homolog is responsible for the irreversible degradation of 
sphingosine-1-phosphate (S1P), a critical regulator of immune responses. It was 
hypothesised whether Burkholderia-encoded S1PLs could represent a strategy 
employed by the bacteria to subvert the normal cellular functions of the host cells 
and contribute to B. pseudomallei pathogenesis. 
Using B. thailandensis as a model, we confirmed that both bacteria-encoded 
S1PLs orthologues are functionally equivalent to eukaryotic S1PL and are 
secreted in a pH-dependent manner, with secretion being observed during 
intracellular infection in macrophages. S1PL-deficient B. thailandensis mutants 
exhibited increased sensitivity to the antimicrobial sphingosine, attenuation in the 
Galleria mellonella infection model, impaired intracellular replication in 
macrophages, and inefficient phagosomal escape. Moreover, treatment of B. 
thailandensis-infected macrophages with S1P enhanced bacterial colocalisation 
with LAMP-1. Furthermore, either single or double deletion of S1PLs in B. 
pseudomallei displayed similar defective intracellular growth. Additionally, single 
deletion of S1PL displayed attenuation in BALB/c infection model.  Macrophages 
infected with B. pseudomallei or B. thailandensis treated either with S1P or a 
specific agonist of S1P receptor 1 significantly enhanced phagocytic killing of 
intracellular bacteria. 
This study has highlighted the role of B. pseudomallei-encoded S1PL as a critical 
virulence determinant for intracellular survival, further establishing S1P-axis 
modulation as a strategy employed by Burkholderia to overcome the host immune 
response. In addition, herein has been demonstrated the potential therapeutic 
value of S1P pathway modulation for the treatment of intracellular infection. 
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Chapter 1 – Introduction  
1.1 Melioidosis 
A ‘glanders-like’ disease, presently known as melioidosis, was first identified in 
1911 by Alfred Whitmore and Krishnaswami in Rangoon, Burma (Whitmore and 
Krishnaswami, 1912). Melioidosis, caused by the soil-dwelling bacillus 
Burkholderia pseudomallei, is an infectious disease endemic in tropical regions 
between 20ºN and 20ºS (Adler et al., 2009). Melioidosis has received a growing 
importance over the years, particularly in endemic areas such as South East Asia 
and Northern Australia. However, as an emergent disease new cases have been 
reported in Asia, Central America, Africa, the Middle East, South America and Sri 
Lanka, (Cheng and Currie, 2005; Currie et al., 2008; Inglis and Sagripanti, 2006; 
Inglis et al., 2008; Taweechaisupapong et al., 2005). Notably, a recent study even 
suggests that melioidosis may be endemic to another 34 countries that have 
never reported the presence of the disease (Limmathurotsakul et al., 2016). 
Additionally, through a comprehensive mapping and modelling the latter study 
have predicted that the global distribution and burden of melioidosis is extremely 
underreported. Limmathurotsakul and colleagues estimated an incredible 165000 
cases of melioidosis per year worldwide, from which approximately 40% of the 
infected people die (Table 1.1) (Limmathurotsakul et al., 2016).   
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Table 1.1. Predicted burden of melioidosis in 2015. (Adapted from Limmathurotsakul et 
al., 2016) 
Region of the world 
Populatio
n at risk 
(Millions) 
Melioidosis 
cases 
(Thousands) 
Melioidosis 
deaths  
(Thousands) 
South Asia 
 
1,525 73 42 
East Asia and Pacific 
 
858 65 31 
Sub-Saharan Africa 
 
602 24 15 
Latin America and Caribbean 
 
246 2 1 
Middle East and North Africa 
 
49 <1 <1 
Europe and Central Asia 
 
0 0 0 
North America 
 
    0     0     0 
Global 3,280 165 89 
 
The community-acquired infection is typically via inhalation, ingestion or contact 
of skin wounds with contaminated soil or water (Wiersinga et al., 2006). In 
Northern Thailand it is responsible for 20% of all community-acquired 
septicaemia and is already the third most common cause of death from an 
infectious disease after HIV/AIDS and tuberculosis (Galyov et al., 2010; 
Limmathurotsakul et al., 2010). In Northern Australia, melioidosis accounts for 
32% of community-acquired bacteremic pneumonia and is responsible for 6% of 
all bacteraemia reported in the region (Allwood et al., 2011). The clinical 
manifestation of melioidosis varies from an acute septic illness to a chronic 
infection, which may mimic other infections such as glanders, tuberculosis, 
typhoid fever and sepsis, hence melioidosis has been termed “the great 
mimicker” (Estes et al., 2010; Overtoom et al., 2008).  
 
Despite the enormous progress made on the pathogenesis and genetics of the 
bacterium over the last 100 years since its discovery, there are no licensed 
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vaccines or prophylactic therapies available for B. pseudomallei infections. 
Treatment of infection is complicated by the intrinsic resistance of B. 
pseudomallei to many antibiotics, and despite prolonged and intensive antibiotic 
therapy, infection relapse after cessation of treatment is a frequent occurrence 
(10-15%) (White, 2003). 
 
1.1.1 Host immune response 
The toll-like receptors (TLRs) and nucleotide-binding oligomerisation domain 
(NOD)-like receptors are critical factors for detection of B. pseudomallei and in 
establishing the innate and adaptive immunity (Wiersinga et al., 2006). This has 
been demonstrated in part through the high mortality rate observed in mice 
lacking MyD88, which is an essential TLR-associated protein (Akira et al., 2006).  
 
Clinical and experimental studies demonstrated that Burkholderia infection 
rapidly triggers an innate immune response in the host. Furthermore, it is 
recognised now that a functional innate immune system is essential to control the 
early infection (Hodgson et al., 2011). An efficient response to infection typically 
requires the actions of monocytes and natural killer cells. Macrophages also play 
a major role in the early stage of infection by controlling the bacteria replication 
(Easton et al., 2007; Breitbach et al., 2006). 
 
Both innate and adaptive immune systems are important in controlling B. 
pseudomallei infection, namely via the production of cytokines, interleukins (IL-1, 
IL-6, IL-10, IL-12, IL-15 and IL-18), tumour necrosis factor (TNF), interferon 
gamma (IFN-γ) and the activation of the complement system (Wiersinga et al., 
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2012, Wiersinga and van der Poll, 2009, Wiersinga et al., 2007). In patients who 
have recovered from melioidosis, both humoral and cellular immune responses 
have been reported. In particular, CD4+ and CD8+ T-cells responses have been 
suggested to contribute to host resistance against B. pseudomallei infection 
(Tippayawat et al., 2009). 
 
1.1.2 Treatment 
As soon as melioidosis is diagnosed, appropriate antimicrobial therapy should 
commence, since a very high mortality rate is associated with ineffective or 
delayed therapy (Chaowagul et al., 1999). The melioidosis treatment is divided 
into two phases, intravenous and oral. The switch from intravenous to oral 
therapy should be made once there is clear improvement in the health of the 
patient (Chaowagul et al., 1999). Typically is required 10 to 14 days of 
intravenous administration of ceftazidime or a carbapenem (e.g. meropenem) 
followed by 3-6 months of oral eradication therapy using trimethoprim-
sulfamethoxazole (Wiersinga et al., 2012). However, approximately 13% of the 
B. pseudomallei isolates from Thailand exhibit resistance against trimethoprim-
sulfamethoxazole, whilst resistance rates in Australia are 0-2.5 %. (Wuthiekanun 
et al., 2011; Cheng and Currie, 2005). In such cases of resistance, an alternative 
therapy consisting of amoxicillin–clavulanate should be applied, though it is 
associated with a higher rate of relapse. Similarly, if the oral eradication therapy 
is undertaken for 2 months or less the relapse infection rates can increase up to 
30% (Currie et al., 2000). Altogether, these studies highlight the necessity to 
follow the recommended duration of the antimicrobial therapy and the urgent 
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need to develop an alternative and/or improved therapeutic strategy for 
melioidosis. 
 
1.2 Burkholderia pseudomallei 
B. pseudomallei is an aerobic, motile, Gram-negative saprophyte bacterium that 
resides in soil and water in tropical regions of the world (Cheng and Currie, 2005). 
This bacterium belongs to Burkholderia genus, which includes over 40 different 
species ranging from plant symbionts to lethal pathogens in humans and animals. 
Among the latter group, besides B. pseudomallei, it also includes Burkholderia 
mallei, the causative agent of glanders in equids and a  human pathogen (Galyov 
et al., 2010) and the Burkholderia cepacia complex species, which can cause 
opportunist infections in humans, with great incidence in cystic fibrosis patients 
(Drevinek and Mahenthiralingam, 2010). 
 
The complete genome sequencing of B. pseudomallei K96243 revealed a large 
genome comprising two chromosomes. Chromosome 1 is 4.07 Mb, encoding 
3460 ORFs carrying mainly genes involved in core functions associated with cell 
metabolism and growth. In contrast, the smaller chromosome 2 is 3.17 Mb 
encoding 2395 ORFs and carries the larger portion of virulence-associated genes 
and secondary metabolism functions correlated to adaption and survival in 
different environments (Holden et al., 2004). In addition, the B. pseudomallei 
genome encodes various mechanisms potentially associated to antibiotic 
resistance, such as efflux pumps, β-lactamases and aminoglycoside 
acetyltransferase (Holden et al., 2004). 
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Due to the lack of available vaccines, low infectious dose and potential aerosol 
transmission, B. pseudomallei was recently listed as a category B agent by the 
US Centers for Disease Control and Prevention (CDC) and a potential biowarfare 
threat (Thomas et al., 2013). Thus, increasing the demand for a better 
understanding of B. pseudomallei pathogenesis and the development of novel 
therapeutic strategies. 
 
1.2.1 Virulence determinants  
B. pseudomallei encodes a wide range of virulence determinants involved in 
pathogenesis. These include the capsular polysaccharide, lipopolysaccharide, 
the T3SS, flagella, pili, quorum-sensing molecules, the T6SS and many secreted 
extracellular proteins such as haemolysins, proteases, lecitinases and lipases 
(Stone et al., 2014). In table 1.2 are described some of the most relevant 
virulence determinants identified in B. pseudomallei. Notably, a number of the 
virulence-associated factors identified by mutagenesis studies in B. pseudomallei 
are involved in bacterial invasion and/or survival within phagocytic and non-
phagocytic cells, while evading the host immune response. This remarkable 
adaptation of the bacteria to an intracellular life style, further highlights this vital 
stage in melioidosis pathogenesis (Allwood et al., 2011; Adler et al., 2009), which 
is described in detail in the following section.
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Table 1.2 Identified virulence determinants in B. pseudomallei. 
Virulence 
factor 
Role Reference 
Capsule Epithelial cells attachment; resistance to 
complement and opsonophagocytosis, 
required for full virulence in vivo 
Reckseidler et al., 
2001; Warawa et 
al., 2009 
 
LPS Resistance to complement and defensins, 
required for full virulence in vivo 
 
Arjcharoen et al., 
2007; Wikraiphat 
et al., 2009 
 
Flagella Motility; adhesion; required for full virulence 
in vivo 
DeShazer et al., 
1997; Chua et al., 
2003 
Pili IV Epithelial attachment; microcolony 
formation; required for virulence in vivo 
Essex-Lopresti et 
al., 2005; Boddey 
et al., 2006 
 
Quorum-
Sensing 
Gene regulation, including secreted 
enzymes and oxidative stress protein; 
biofilm formation; required for full virulence 
in vivo 
Ulrich et al., 
2004; Wiersinga 
et al., 2006 
 
T3SS-3 Invasion and vacuolar escape; required for 
full virulence in vivo 
Stevens et al., 
2002; Warawa 
and Woods, 2005 
 
T2SS Secretion of exoproducts such as 
phospholipase C, proteases and lipases; 
impairs host immune response; required for 
full virulence in vivo 
 
DeShazer et al., 
1999; Tan et al., 
2010 
 
T6SS-1 Required for full virulence in vivo;  
intracellular replication; formation of  MNGC 
Burtnick et al., 
2011 
 
Phospholipase 
C 
 
Plaque formation 
 
Korbsrisate et al., 
2007 
 
LfpA Required for full virulence in vivo 
 
Boddey et al., 
2007 
 
IrlR Two-component response regulator; 
invasion in epithelial and phagocytic cells; 
Jones et al., 
1997; Wiersinga 
et al., 2008 
 
RelA and SpoT Role in global stress response and 
regulation of virulence genes; Intracellular 
replication; required for full virulence 
 
Muller et al., 2012 
 
BimA Actin-based motility; intracellular survival; 
cell-to-cell spread 
Stevens et al., 
2005 
 
RpoS Invasion and vacuole escape in 
macrophages; formation of MNGC 
Utaisincharoen et 
al., 2006 
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1.2.2 Intracellular life style 
B. pseudomallei is a facultative intracellular pathogen that can invade and grow 
inside eukaryotic cells, including epithelial cells, neutrophils, macrophages and 
dendritic cells (Stone et al., 2014; Charoensap et al., 2009; Jones et al., 1996). 
The bacteria’s ability to survive and replicate intracellularly is considered one of 
the key aspects of melioidosis pathogenesis, since the initial human infection 
likely occurs with either the bacteria invasion at the epithelial cells of the skin or 
at the mucosal surface of the respiratory tract. Importantly, the success of that 
first contact with the host cells may dictate the infection outcome (Galyov et al., 
2010). Namely, macrophages play a key role in controlling B. pseudomallei 
replication during the early stage of infection in vivo (Breitbach et al., 2006). 
Importantly, macrophages from healthy controls exhibited enhanced uptake of B. 
pseudomallei and more efficient phagolysosome fusion than macrophages from 
melioidosis patients (Puthucheary and Nathan, 2006). These studies further 
highlight the importance of understanding the mechanisms of B. pseudomallei 
survival on these particular immune cells. 
 
Adhesion to the host cells is considered the first step of the intracellular cycle and 
precedes the internalisation of the bacteria. The B. pseudomallei type IV pili, 
flagella and capsule play a critical role in bacteria attachment to epithelial cells, 
though the interactions at the molecular level with the host cell surface remain to 
be elucidated (Warawa et al., 2009; Boddey et al., 2006; DeShazer et al., 1997). 
For the bacteria internalisation in non-phagocytic cells the T3SS3 components 
(i.e. BsaQ, BopE and BipD) are required and it has been shown to be a process 
dependent of actin polymerisation (Warawa and Woods, 2005).  
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In phagocytic cells the T3SS3 play a minor role in bacteria uptake (Gong et al., 
2011; Warawa and Woods, 2005; Stevens et al., 2004; Stevens et al., 2003; 
Stevens et al., 2002). Presently, little is known about the initial steps following the 
Burkholderia pseudomallei interaction with macrophages. Some studies suggest 
that the presence of the capsule may reduce the number of bacteria phagocytised 
by human neutrophils (Warawa et al., 2009, Reckseidler-Zenteno et al., 2005). 
Yet, apart from evidence suggesting the participation of C3b complement 
receptor in B. pseudomallei phagocytosis, other host cell molecules involved in 
the bacteria uptake remain to be identified (Reckseidler-Zenteno et al., 2005).  
 
Following internalisation B. pseudomallei is able to escape from the phagosome 
into the host cell cytoplasm by disrupting the phagosome membrane therefore 
avoiding the bacteria degradation by the lysosomal system (Allwood et al., 2011). 
The rapid escape from the phagosome is facilitated in part by the T3SS3. Results 
by Culliane et al. and others have shown that BopA plays an important role in 
phagosome escape (Gong et al., 2011; Whitlock et al., 2009; Cullinane et al., 
2008). Interestingly, strains lacking a functional T3SS3 are still capable of 
delayed phagosome escape (Burtnick et al., 2008; Muangsombut et al., 2008). In 
addition, neither B. pseudomallei T3SS1 nor T3SS2 are required for late escape 
from phagosomes, suggesting that mechanisms other than T3SS are involved in 
the evasion of endosomes (Burtnick et al., 2008).  
 
Once in the cytoplasm the B. pseudomallei is able to replicate and promote their 
own survival by avoiding the activation of the interferon regulatory factor-1 and 
IFN-β production (Utaisincharoen et al., 2003). In addition, the bacteria 
suppresses the host bactericidal response, such as the cytokine signalling 3 
23 
 
(SOCS3) and cytokine-inducible Src homology 2-containing protein (CIS), thus 
disrupting the JAK-STAT signalling pathway and associated nitric oxide synthase 
(iNOS) activation (Ekchariyawat et al., 2007; Ekchariyawat et al., 2005).  
 
B. pseudomallei is able to move intracellularly via actin-based motility mediated 
by bacterial BimA protein (Stevens et al., 2005). This actin-based motility can 
induce the formation of membrane protrusions, thus resulting in bacterial spread 
into neighbouring cells and the establishment of an additional round of 
intracellular infection (Stevens et al., 2006; Kespichayawattana et al., 2000). In 
addition, B. pseudomallei is able to promote cell-to-cell fusion and subsequent 
formation of multinucleated giant cells (MNGCs) in a wide range of cell types 
(Kespichayawattana et al., 2000). It has been demonstrated that T6SS, RpoS 
and BipB are involved in the MNGC formation (Burtnick et al., 2011; 
Utaisincharoen et al., 2006; Suparak et al., 2005). Although the exact role MNGC 
in pathogenesis remains poorly understood, it is conceivable that it could 
represent a mechanism explored by B. pseudomallei to spread into neighbouring 
cells while avoiding the detection by the host immune system.  
 
1.3 Burkholderia thailandensis as a model organism 
Until late 1990s, the environmental saprophyte bacterium B. thailandensis was 
frequently mistaken for a B. pseudomallei strain due to related morphology and 
biochemical characteristics (Brett et al., 1998). With the technology advances, 
several studies have now identified key differences with regards to genotypic and 
phenotypic features that allows the classification of B. thailandensis as a distinct 
species from B. pseudomallei. Notably, among those differences are the ability 
of B. thailandensis to assimilate L-arabinose, the lack of a 3)-2-O-acetyl-6-deoxy-
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β-D-manno-heptopyranose-(1 capsule and the relative attenuated virulence in 
humans and animals (Deshazer, 2007; Glass et al, 2006; Kim et al., 2005).  
 
Despite apparent non-pathogenicity towards mammals, B. thailandensis is able 
to produce numerous homologs of virulence-associated determinants expressed 
by B. pseudomallei, such as T3SS and T6SS, lipopolysaccharide and quorum-
sensing systems (Chandler et al., 2009; Duerkop et al., 2009; Haraga et al., 2008; 
Brett et al., 2003). In addition, B. thailandensis can invade and multiply inside 
non-phagocytic and phagocytic cells and exhibit a similar intracellular lifestyle as 
B. pseudomallei (Wand et al. 2011; Haraga et al., 2008). These include the ability 
to escape from endocytic vesicles, actin-based motility, inter-cellular spreading 
and MNGCs (Boddey et al., 2007; Stevens et al., 2006). 
 
In contrast with B. pseudomallei, B. thailandensis does not require a biosafety 
level 3 containment facility, therefore it can be manipulated under standard 
laboratory conditions and there is no restriction on the use of antibiotic-resistance 
markers, which are routinely limited in pathogenic Burkholderia. Based on the 
attributes enumerated, B. thailandensis is considered an attractive tractable 
model system to study the pathogenesis of B. pseudomallei and hasten the 
melioidosis research (Haraga et al., 2008).  
 
 
1.4 Sphingolipids metabolic pathway 
The focus of this thesis is the ability of B. pseudomallei and B. thailandensis to 
impair host cell function through the degradation of sphingosine-1-phosphate 
(S1P), a bioactive sphingolipid metabolite. 
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In mammalian cells, sphingolipids typically possess a long sphingoid base 
(sphingosine) backbone linked to fatty amino alcohol of 18 carbons and are 
considered the building block of cell membranes as well as reservoirs of important 
bioactive lipids (Newton et al., 2015, Kihara, 2013). Sphingolipids are essential 
constituents of all eukaryotic membranes and play an important role in numerous 
cellular processes (see Figure 1.1). The sphingolipids signalling and metabolism 
is a highly intricate system (for review see, Maceyka and Spiegel, 2014), herein 
we will focus mainly on the metabolism and biological function of the shingosine-
1-phosphate (S1P)-axis.  
 
In response to diverse stimuli, plasma membrane sphingolipids (e.g. 
sphingomyelin) can be readily metabolized to ceramide, and subsequently to 
sphingosine. Two sphingosine kinases (SphKs) phosphorylate sphingosine to 
generate S1P, levels of which are tightly regulated by balancing SphK activity 
with the activity of enzymes responsible for S1P degradation, namely S1P lyase 
(S1PL) and S1P phosphatases (S1PP) (Olivera et al., 2013). This sphingolipid 
metabolic pathway occurs in most mammalian cells, with the exception of 
erythrocytes and platelets as they do not possess the S1P degrading enzymes 
(S1PL and S1PP) (Pappu et al., 2007). Therefore, the S1P levels are generally 
high in blood and lymph, with concentrations ranging from low micromolar to 
hundred-nanomolar, respectively. Whereas in tissues, the S1P concentration is 
kept low, mainly due to the high activity of S1PL and S1PP (Spiegel and Milstien, 
2011; Rivera et al., 2008). This tightly regulated gradient between the S1P levels 
in circulation and in tissues play a major role in controlling the immune cells 
homing and egress from and to lymphoid tissues (Chi, 2011; Schwab et al., 
2005).  
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Figure 1.1. Synthesis and metabolism of mammalian sphingolipids. Diagram 
showing the enzymes involved in sphingolipid metabolism and respective regulatory 
factors and biological effect on cells. Cerase, ceramidase ; CerSyn, ceramide synthase 
; GCase, glucosyl ceramidase; GCS, glucosylceramide synthase; SphK, sphingosine 
kinase; Hydrolase, sphingomyelinase; Synthase, sphingomyelin synthase; S1PP, 
sphingosine 1-phosphate phosphatase; SPT, serine palmitoyl transferase; S1PL, S1P 
lyase. Adapted from Liu et al., 2012.  
  
1.4.1 S1P 
S1P is a bioactive sphingolipid metabolite of eukaryotic plasma membranes and 
a vital signalling regulator of many physiological and pathophysiological 
processes (Hisano et al., 2012; Spiegel and Milstien, 2011; Rivera et al., 2008). 
S1P mediates the regulation of a variety of cell functions including apoptosis, cell 
proliferation, cell migration, actin cytoskeleton reorganization, and adherens 
27 
 
junction assembly (Kihara, 2013). Notably, this signalling regulator is highly 
conserved through evolution, being detected in lower organisms such as yeasts, 
worms and flies (Skoura and Hla, 2009; Phan et al., 2007; Saba and Hla, 2004; 
Mendel et al., 2003). 
 
S1P exerts such pleiotropic effects as it can function as an intracellular second 
messenger by targeting prohibitin 2 (Strub et al., 2011), TNF receptor-associated 
factor 2 (TRAF2) (Alvarez et al., 2010), and histone deacetylase (HDAC) (Hait et 
al., 2009), as well as acting in an autocrine and/or paracrine manner to activate 
five distinct G protein-coupled cell surface receptors (GPCRs; S1PR1-5) (Spiegel 
and Milstien, 2011). In mammals, the S1PR1-5 expression are dependent on the 
cell type or tissue. S1PR1-3 are ubiquitously expressed, whilst S1PR4 is present 
only on lung and lymphoid tissues, and S1PR5 is restricted to brain and skin 
(Kumar and Saba, 2009). 
 
The intracellular role of S1P is more ambiguous, but recent studies have shown 
it to be involved in the regulation of NFkB activation, epigenetic regulation of gene 
transcription, mitochondrial function and calcium homeostasis (Chi, 2011; Young 
and Nahorski, 2002). S1P can be exported across the cell membranes via 
specific S1P transporters, such as Spinster homolog 2 (SPN2) and the ATP-
binding cassette (ABC) transporters, ABCA1 and ABCC1 (Hisano et al., 2011; 
Lee et al., 2007).  
 
As a ligand of S1PR1-5, S1P regulates many of the immune and inflammatory 
responses, namely the immune cell trafficking, regulation of vascular 
permeability, differentiation, cytokine and chemokine production as well as some 
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other vital cellular functions common to most cells, such as proliferation, motility 
and cell survival (Aguilar and Saba, 2012; Hisano et al., 2012; Chi, 2011; Spiegel 
and Milstien, 2011; Rivera et al., 2008; Young and Nahorski, 2002). 
 
In the context of the innate immune response, S1P is also a critical regulator of 
macrophage function, influencing phagosome-lysosome fusion by triggering the 
mobilization of intracellular Ca2+ (Blom et al., 2005). In addition, S1P plays a vital 
role in protecting the macrophages from apoptosis through the regulation of PI3K, 
ERK1/2, and Ca2+-dependent survival pathways and the respective increase of 
antiapoptotic proteins such as Bcl-2 and Bcl-XL (Weigert et al., 2006). Recent 
studies also have shown that the activation of S1PR2 by S1P is crucial in 
controlling the macrophages proinflammatory response and cytokine production 
(Okamoto et al., 2011), whereas in another study it was established that S1P is 
able to promote the macrophages shift from proinflammatory to an 
antiinflammatory phenotype via the activation of S1PR1 downstream signalling 
(Hughes et al., 2008).  
 
Given the critical role of S1P on cell fate and immune response, an increasing 
interest has emerged and small molecules targeting S1P signalling have been 
developed. Much of the attention has been focused on targeting the S1P 
receptors, namely the S1P1, with the first compound being approved by the 
American Food and Drug Administration in 2010 for the treatment of multiple 
sclerosis, under the name of Gilenya (commonly known as FTY720) (Brinkmann 
et al., 2010). FTY720 is a sphingosine analogue, which is phosphorylated in vivo 
by SphK2 and can act as a functional antagonist of S1PR1. Of note, is the clinical 
efficiency of FTY720 in promoting the retention of naïve and central memory T 
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cells in the lymph nodes in a situation of inflammatory disorder, without 
compromising the circulation of peripheral effector memory T cells (Spiegel and 
Milstien, 2011). 
 
Alternatively to S1P receptors agonists and antagonists developed over the last 
decade, it was discovered recently that the attenuation of the S1P gradient via 
inactivation of S1PL by the application of THI, a food colorant, also inhibited the 
lymphocyte trafficking (Serra and Saba, 2010). Recently, the oral S1PL inhibitor, 
LX2931 from Lexicon® pharmaceuticals that is under preclinical Phase II trials, 
has been shown to block the activity of S1PL in mouse and rat models of arthritis, 
resulting in increased levels of S1P in the lymphoid tissues and consequently 
impairing the lymphocytes migration from the lymph nodes (Bagdanoff et al., 
2010). Additionally, in a high-throughput screen using a biochemical assay, 
Weiler and colleagues (2014) have found (4-benzylphthalazin-1-yl)-2-
methylpiperazin-1-yl]nicotinonitrile, a new class of compounds able to inhibit the 
catalytic activity of S1PL by binding to the active site of the enzyme. Moreover, in 
a rat model of multiple sclerosis it was shown that after an oral dosage, the 
compound induced a marked reduction of peripheral T cell levels and conferred 
a significant protection in the animals (Weiler et al., 2014). 
Taken together, these preclinical studies show the potential of S1PL as a 
therapeutic target for immune modulation in abnormal inflammatory conditions. 
 
Presently, several compounds are already approved for use in humans or in 
clinical trials (for review, see Kunkel et al., 2013), confirming that the S1P 
pathway can be targeted safely in humans and that it has therapeutic potential 
for the treatment of a wide range of autoimmune and inflammatory diseases. In 
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addition, new evidence also suggest promising results on the treatment of 
infectious diseases in which the S1P signalling pathway is being targeted by the 
pathogen (Arish et al., 2015).  
 
In table 1.3 is depicted some of the most significant S1P signalling modulators in 
the context of infectious diseases relevant for this study. For instance, in 
situations of bacterial sepsis, in which the host response is characterised by an 
exacerbated activation of inflammatory pathways, it has been shown that the 
immunomodulatory effect of FTY720 could be beneficial in the treatment of 
bacterial infections (Pewzner-Jung et al., 2014, St John et al., 2014, Graler, 
2012). Pewzner-Jung and colleagues have demonstrated that the application of 
FTY720 on susceptible mice rescued the animals from Pseudomonas aeruginosa 
infection and prevented the bacterial-associated inflammatory response 
(Pewzner-Jung et al., 2014). Similarly, a recent study revealed that the 
administration of FTY720 diminished the infection by Yersinia pestis in the spleen 
and lung of infected mice, resulting in enhanced survival (St John et al., 2014). In 
the same study, the authors also showed that targeting the S1PR1 with a specific 
receptor agonist (SEW2871), significantly limited the Y. pestis progression during 
the infection in C57BL/6 mice (St John et al., 2014). Furthermore, in mice infected 
with the Influenza virus H1N1, the treatment with the S1PR1-specific agonist 
CYM-5442 displayed reduced mortality. This observation was associated with a 
lessened innate immune response, which was confirmed by the weakened 
expression of cytokines and chemokines in the lungs of the infected mice, 
therefore reducing the immunopathology during the H1N1 infection, instead of 
decreasing the viral load (Teijaro et al., 2011).  
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Table 1.3. Small molecules targeting S1P-axis in the regulation of microbial infections. Bovine viral diarrhea virus (BVDV); Respiratory syncytial virus 
(RSV); lymphocytic choriomeningitis virus (LCMV).  
Compounds Target 
molecule 
Target pathogen Mechanism References 
SKI-II SphK BVDV ↑ viral RNA level 
 
Yamane et al., 2009 
  H1N1 ↓ production of viral protein 
 
Seo et al., 2013 
  Measles virus ↓ production of viral protein 
 
Vijayan et al., 2014 
  M. bovis BCG Hamper CCL5 production Mendez-Samperio et al., 2007 
     
DHS SphK M. bovis BCG Hamper CCL5 production 
 
Vesosky et al., 2010 
  M. smegmatis ↓ production of pro-
inflammatory and 
antimicrobial factors 
 
Yadav et al., 2006 
 
  C. perfringens Blocks α-Toxin-induced 
hemolysis 
Ochi et al., 2004 
     
DMS SphK H1N1 ↓ production of viral protein 
 
Seo et al., 2013 
  Measles virus ↓ production of viral protein 
 
Vijayan et al., 2014 
  RSV Prevents ERK and Akt 
activation 
Monick et al., 2004 
 
     
FTY720 S1PR Yersinia pestis ↓ infection 
 
St John et al., 2014 
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FTY720  T. cruzi ↑ parasitemia 
 
Dominguez et al., 2012 
  LCMV ↓ CD8+ and CD4+ effector 
T cells activity 
 
Pinschewer et al., 2000 
  HSV ↓ ocular lesions 
 
Sehrawat and Rouse, 2008 
  P. aeruginosa ↓ infection 
 
Pewzner-Jung et al., 2014 
     
AALR S1PR H1N1 Prevents production of 
cytokines and chemokines 
 
Marsolais et al., 2009 
  LCMV ↑ dendritic cell maturation 
and T cell expansion 
Seo and Hahm, 2014 
     
SEW2871 S1PR1 Yersinia pestis ↓ infection St John et al., 2014 
     
SK1-I SphK1 H1N1 ↓ production of viral protein Seo et al., 2013 
     
CYM-5442 S1PR1 H1N1 ↓ mortality during infection Teijaro et al., 2011 
     
JTE013 S1PR2 Vaccinia virus ↑ viral load Wang et al., 2012 
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1.4.2 Sphingosine-1-phosphate lyase 
The first S1PL gene cloned was from Saccharomyces cerevisiae (Dpl1) and 
following a genetic approach was demonstrated that the sphingosine metabolic 
process is conserved throughout eukaryotic evolution from humans to plants 
(Nishikawa et al., 2008; Saba et al., 1997). The deletion of yeast Dpl1 resulted in 
hypersensitivity to D-erythro sphingosine. This sensitive phenotype, which was 
reverted by Dpl1 complementation, was demonstrated to be due to the inability 
to metabolise S1P thus leading to an endogenous hyperaccumulation of the 
bioactive lipid (Saba et al., 1997). Interestingly, it was shown that protein 
oligomerisation is required for its function in vivo (Mukhopadhyay et al., 2008). 
Notably, the yeast model system has been used since then to functionally 
characterise putative S1PL orthologues and helped to characterise the first 
mammalian S1PL (Bourquin et al., 2010; Degtyar et al., 2009; Zhou and Saba et 
al., 1998).  
 
The human S1PL homolog encodes a 568 amino acids protein with a predicted 
molecular mass of 63.5 kDa belonging to the PLP (pyridoxal 5’-phosphate)-
dependent enzymes superfamily (Van Veldhoven et al., 2000). S1PL shows a 
conserved stretch of amino acids spanning positions 344–364, which contains 
predicted cofactor-binding lysine residues at position K353 and K359 and two 
cysteines residues C218 and C317 that are required for proper enzyme activity 
(Van Veldhoven et al., 2000). S1PL is an endoplasmic reticulum-resident enzyme 
with its N-terminal catalytic site facing the cytosol where it cleaves S1P at the C2–
C3 carbon–carbon bond, resulting in formation of phosphoethanolamine and 
hexadecenal (Olivera et al., 2013).  S1PL is the last enzyme of the sphingolipids 
degradative pathway, since it is responsible for the irreversible degradation of 
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S1P (Figure 1.2), thus playing an important role as gatekeeper of S1P levels and 
respective signalling pathway (Kumar and Saba, 2009). 
 
Figure 1.2. Biosynthesis & catabolism of S1P. S1P is synthesized from sphingomyelin 
and other complex sphingolipids, and is irreversibly degraded by S1P lyase. Cerase, 
ceramidase; CerSyn, ceramide synthase; SphK, sphingosine kinase; S1PP, S1P 
phosphatase. 
 
1.4.2.1 Bacterial Sphingosine-1-phosphate lyase 
With exception of some bacteria genera, such as Sphingobacterium, 
Sphingomonas, Bacteroides, Roseiflexus, Myxococcus, Stigmatella and 
Bdellovibrio, most prokaryotics cell do not possess or metabolise sphingolipids 
(Rolando et al., 2016, Heung et al., 2006). Though S1PL-like proteins have been 
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detected in few bacteria species. Herein is described some of the most relevant 
studies made with bacterial S1PLs.   
 
The identification and study of Symbiobacterium thermophilum’s S1PL (StSPL) 
provided the first structural characterisation of a prokaryotic S1PL (Bourquin et 
al., 2010). StSP was shown to form a symmetric dimer with each subunit 
containing a N‐terminal disordered region, spanning residues 1–57, and a folded 
core including residues 58–507 (Bourquin et al., 2010). The StSPL core can be 
divided into an N‐terminal domain (residues 58–97), a large domain containing 
the cofactor-binding K311 (residues 98–382) and a small C‐terminal domain 
(residues 383–471). In addition, this study clearly demonstrated the functional 
and structural similarity between a prokaryotic S1PL and the eukaryotic 
counterpart (Bourquin et al., 2010).   
 
Recently, Degtyar and collaborators identified the first S1PL belonging to a 
pathogenic bacteria (i.e. Legionella pneumophila). They revealed that LegS2 was 
likely acquired from a protozoan organism throughout evolution. The study 
suggests that the LegS2 gene underwent many changes, in particular at the C-
terminal end of the protein sequence, in order to be translocated via the bacteria 
Icm/Dot type IV secretion system and without losing the S1PL enzymatic function. 
Despite LegS2 targeted to the host cell mitochondria instead of the endoplasmic 
reticulum (ER), there was no effect on the intracellular growth of Legionella from 
HL-60 derived human macrophages (Degtyar et al., 2009). Accordingly, Khweek 
and colleagues also have shown that Legionella LegS2 does not play a role in 
pathogenesis. The characterisation of a legS2 mutant strain revealed that the 
bacteria was able to replicate more efficiently both in mice Bone Marrow-Derived 
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Macrophages and human Monocyte-Derived Macrophages in comparison with 
the wild-type, suggesting that the LegS2 ordinarily contributes to the restriction of 
intracellular replication. In addition, this observation was neither correlated to 
caspase-1, caspase-7 or caspase-3 activation, therefore not associated to 
impaired fusion of the Legionella containing vacuole (LCV) to the lysosome,  nor 
due to deficient phagosome-lysosome fusion (Khweek et al., 2016). On the other 
hand, a recent study has shown that LegS2 is ER-targeted, proposing that it 
perhaps localises to the contact points between the two organelles, mitochondria 
and ER (Rolando et al., 2016). In addition, the authors importantly demonstrated 
that Legionella LegS2 is indeed required for efficient infection in a mice model 
and to inhibit the autophagy response during macrophages infection, highlighting 
the impact of disrupting the host sphingolipids pathway by a bacterial S1PL, 
therefore contributing to the pathogenesis of Legionella pneumophila  (Rolando 
et al., 2016).   
 
In the course of studies investigating bacterial enzymes involved in sphingolipid 
biosynthesis and metabolism (Raman et al., 2010), putative S1PL-encoding 
genes were identified within the genomes of B. pseudomallei and B. 
thailandensis. A closer analysis of these S1PL-like proteins revealed that the 
catalytic regions are well conserved as they contain most of the amino acids 
reported to be essential for human S1PL activity. Furthermore, in collaboration 
with  Dr. Dominic Campopiano’s group (University of Edinburgh) we have cloned, 
expressed and purified the two putative S1PLs of B. pseudomallei K96243 
(BPSS2021 and BPSS2025), and have confirmed that they possess the 
anticipated S1PL enzymatic activity in vitro (McLean et al., unpublished data). 
Based on these findings, the identification of a functional B. pseudomallei-
37 
 
encoded S1PLs prompted the investigation the putative role of S1PL in bacterial 
pathogenesis, which constitutes the main body of work presented in this 
dissertation.  
 
1.5 Sphingosine-1-phosphate axis in microbial pathogenesis 
Given the importance of S1P in cell survival and host immune responses, it is no 
surprise that some pathogens have developed mechanisms to disrupt the S1P 
signalling pathway in order to benefit the microorganism survival (Heung et al., 
2006). Herein we will focus mainly on examples of bacterial infections, though it 
has similar strategies have been employed by other microorganisms such as 
protozoan, virus and fungus (see Table 1.4).  
 
Recent reports have shown that most of S1P-axis dysregulation caused by 
pathogens is through either increasing or reducing S1P levels via SphK activation 
or deactivation (Kim et al., 2014; Vijayan et al., 2014; Carr et al., 2013; Seo et al., 
2013; Prakash et al., 2010; Malik et al., 2003). This is exemplified by Shigella 
flexneri, which has recently been reported to suppress the host inflammatory 
response by lowering S1P levels through the two branches of the S1P pathway; 
promoting the transcriptional upregulation of host genes encoding the S1P lyase 
and phosphatase enzymes and the parallel downregulation of SphK-encoding 
genes leading to putative reduction in S1P levels (Kim et al., 2014).  
 
Similarly, Thompson and colleagues have shown that Mycobacterium 
tuberculosis inhibits the activity and localisation of SphK to phagosomes in 
macrophages, thus blocking the S1P-dependent increase in cytosolic Ca2+ and 
impairing phagosome maturation and subsequent killing of bacteria (Thompson 
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et al., 2005). Interestingly, it was shown in tuberculosis patients that the levels of 
S1P in the lungs are significantly lower compared to other non-tuberculosis lung 
disorders (Garg et al., 2006). Furthermore, recent studies suggest that SphK1 
plays a critical role in Mycobacterium smegmatis and Mycobacterium avium 
intracellular infection in macrophages (Prakash et al., 2010; Yadav et al., 2006). 
Prakash and colleagues revealed that SphK1 is required for appropriate 
expression of iNOS and LAMP-2 during RAW macrophage infection with M. 
smegmatis. Additionally, the respective SphK1 overexpression in macrophages 
conferred increased resistance to infection, thus suggesting an important 
antibacterial role of SphK1 in mycobacterial infections (Prakash et al., 2010). 
Overall, these studies suggest that S1P signalling is targeted during 
Mycobacterium intracellular lifestyle and plays a fundamental role in the outcome 
of the infection. Remarkably, the molecular events that underlie the disruption of 
the sphingosine signalling pathway by such pathogens remain to be defined. 
 
In addition to targeting the host SphK, other mechanisms targeting the 
sphingosine metabolism have been described. A study on Pseudomonas 
aeruginosa identified a specific transcriptional response induced by host 
sphingosine, which was crucial for bacterial survival in murine lung infections. 
However, the mechanism responsible for the bacterial survival in vivo remains to 
be identified (LaBauve and Wargo, 2014). Furthermore, Oizume et al. suggested 
that a Pseudomonas aeruginosa-derived neutral ceramidase, isolated from a 
patient with atopic dermatitis, contributes to the production of inflammatory 
cytokines, such as IL-8 and TNFα in keratinocytes via S1P synthesis from 
ceramide (Oizume et al., 2014). 
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Based on the recognition of S1P-axis as an emerging field in bacterial 
pathogenesis, we hypothesised that the recently identified Burkholderia-encoded 
S1PLs may represent a strategy employed by the bacteria to subvert the S1P 
cellular functions of the host cells and contribute to B. pseudomallei 
pathogenesis.  
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Table 1.4. Role of S1P signalling in viral, bacterial, protozoan and fungal infections. Bovine viral diarrhea virus (BVDV); Dengue virus type-2 (DENV-
2); Human cytomegalovirus (HCMV); Respiratory syncytial virus (RSV). 
Infectious Diseases Target Biological effect References 
Viral infection  
BVDV ↓ SphK ↑ viral replication 
 
Yamane et al., 2009 
DENV-2 ↓ SphK ↑ viral-induced death 
 
Carr et al., 2013 
HCMV  ↑ activity of SphK1 Impact on viral gene expression and 
growth 
 
Machesky et al., 2008 
Influenza virus ↑ activity of SphK1 Impact on viral gene expression and 
growth 
 
Seo et al., 2013 
Measles virus ↑ activity of SphK1 Impact on viral gene expression and 
growth 
 
Vijayan et al., 2014 
RSV ↑ activity of ceramidase and 
SphK 
↑ cell survival during infection Monick et al., 2004 
 
Bacterial infection 
 
   
M. tuberculosis  ↓ SphK1 
 
Prevents phagosome maturation 
 
Malik et al., 2003 
M. smegmatis ↑ activity of SphK1 ↑ pro-inflamatory and  
↓ antimicrobial factors 
 
Prakash et al., 2010; 
Yadav et al., 2006 
 
Yersinia pestis S1PR1 Aid Systemic infection 
 
St John et al., 2014 
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Clostridium perfringens ↑ ceramide and S1P levels Hemolysis Ochi et al., 2004 
P. aeruginosa ↑ S1P synthesis ↑ TNF-α and ↑ IL-8  
 
Oizumi et al., 2014 
S. flexneri ↓ S1P levels ↓ inflammatory response Kim et al., 2014 
L. pneumophila ↓ sphingolipids levels 
 
Prevents autophagossome maturation 
 
Rolando et al., 2016 
Protozoan infection    
 
Trypanosoma cruzi ↓ SphK activity and ↑ S1PR1 ↑ expression of IL-17 and TNFα Lepletier et al., 2014; 
Dominguez et al., 
2012 
 
Plasmodium berghei ↓ S1P levels Anomalous inflammatory response Finney et al., 2011 
Protozoan infection   
 
Leishmania donovani SphK Survival and virulence Zhang et al., 2013 
 
Fungal infection 
 
Cryptococcus neoformans  SphK1 Protective role during infection McQuiston et al., 
2010 
 
 S1PR2 ↑ macrophage phagocytosis 
 
McQuiston et al., 
2011 
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1.6 Aims of this study  
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite implicated 
in numerous biological processes. S1P activity has been extensively studied in 
the context of immune and inflammatory responses, where (in addition to cell 
growth and survival) its roles include differentiation, vascular integrity, immune 
cell trafficking and function, and influencing production of cytokines and 
chemokines. Levels of S1P are tightly controlled by activity of host S1P lyase 
(S1PL), an enzyme which catalyses the irreversible degradation of S1P. In the 
course of our studies, we observed that Burkholderia pseudomallei and 
Burkholderia thailandensis each encode two putative S1PL orthologues. 
 
In this project we used B. pseudomallei and B. thailandensis as model organisms 
to study the role of bacterial encoded S1PLs in pathogenesis. Specifically, for this 
PhD project we proposed to: 
 
1. Investigate the nature and activity of the Burkholderia S1PLs, including their 
oligomeric state, function and secretion; 
 
2. Assess the role of Burkholderia S1PLs in virulence and bacterial physiology, 
by exploring a range of standard phenotypes, including virulence in Galleria 
mellonella, invasion and survival assays in macrophage/epithelial cells, response 
to defined stresses and resistance to antimicrobial sphingolipids; 
 
3. Determine the impact of Burkholderia S1PLs on host cells during infection, 
namely through cytotoxicity assays, effect on S1P levels within host cells, 
intracellular target and phagosome maturation; 
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4. Study the effect of S1P-axis pathway modulators for the treatment of 
intracellular pathogens, by performing infections in vitro in the presence of 
available S1P receptor agonists. 
 
 
44 
 
Chapter 2 - Materials and methods  
2.1 Bacterial/Yeast strains and cell lines 
2.1.1 E. coli and Burkholderia strains 
E. coli and Burkholderia strains used in this study are listed in Table 2.1. Unless 
stated otherwise, bacteria were grown with aeration in Luria Bertani (LB) broth at 
37°C overnight. As required, antibiotics were used at the following 
concentrations: kanamycin 25 μg/ml or 50 μg/ml; gentamicin 50 μg/ml; 
trimethoprim 50 μg/ml or 100 μg/ml; tetracycline 25 μg/ml or 100 μg/ml. Antibiotics 
were filtered sterilised using 0.22 µM filters before adding to culture media. 
 
2.1.2 Saccharomyces cerevisiae strains  
The S. cerevisiae strains used in this study are listed in Table 2.2. Unless stated 
otherwise, yeast were grown in YPD (yeast extract peptone dextrose) broth at 
30ºC overnight with agitation. As required, yeast strains were grown in Yeast 
Nitrogen Base (YNB) selective Drop-out broth at 30ºC overnight with agitation 
prior to phenotypical characterisation. 
 
2.1.3 Mammalian cell lines 
The cell lines used in this study were J774A.1 BALB/c mouse macrophages and A549 
human lung epithelial cells (from our laboratory stock). Both cell lines were routinely 
cultured in 15 mL of Dulbecco’s modified Eagle’s medium (DMEM; GE Healthcare) 
supplemented with 10% fetal bovine serum (FBS; Gibco) at 37ºC under 5% CO2 
atmosphere, according to the ATCC guidelines, unless otherwise stated. 
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Table 2.1 Burkholderia and E. coli strains used in this study 
Bacterial Strains Description 
 
Reference 
 
Burkholderia     
      B. thailandensis E264 Environmental isolate 
 
Lab strain collection 
      B. multivorans ATCC 17616 Environmental isolate 
 
Lab strain collection 
      BTH_II0309 E264, pGPΩTp::BTH_II0309, TpR 
 
This study 
      BTH_II0311 E264, pGPΩTp::BTH_II0311, TpR 
 
This study 
      BTH839 E264, pGPΩTp::BTH_II0839, TpR 
 
This study 
      pDA17::BTH_II0309 E264, pGPΩTp::BTH_II0309, pDA17::BTH_II0309, TpR TetR 
 
This study 
      pDA17::BTH_II0311 E264, pGPΩTp::BTH_II0309, pDA17::BTH_II0311, TpR TetR 
 
This study 
      E264-GFP E264, pDA17::GFP, TetR 
 
This study 
      E264-RFP E264, pBHR4-groS-RFP, CmR 
 
This study 
      BTH_II0309-RFP BTH_II0309, pBHR4-groS-RFP, TpR, CmR 
 
This study 
      BTH_II0311-RFP BTH_II0311, pBHR4-groS-RFP, TpR, CmR 
 
This study 
      BTH_II0309-FLAG E264, pDA17::BTH_II0309-C-terminal FLAG tag, TetR 
 
This study 
      BTH_II0311-FLAG E264, pDA17::BTH_II0311-C-terminal FLAG tag, TetR 
 
This study 
      BTH839+309-FLAG BTH839, pDA17::BTH_II0309-C-terminal FLAG tag, TetR This study 
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      BTH839+311-FLAG BTH839, pDA17::BTH_II0311-C-terminal FLAG tag, TetR 
 
This study 
      BTH_II0309-6His 
 
E264, pGPΩTp::BTH_II0309-6His, TpR This study 
      BTH_II0311-6His 
 
E264, pGPΩTp::BTH_II0311-6His, TpR This study 
      B. pseudomallei K96243 
 
Clinical isolate  
 
Lab strain collection 
      B. pseudomallei ΔBPSS2025 
 
K96243 derivative, unmarked deletion ΔBPSS2025 This study 
B. pseudomallei 
ΔBPSS2025+ΩTp::BPSS2021 
 
K96243 derivative, Double S1PLs mutant - unmarked deletion ΔBPSS2025 + 
pGPΩTp::BPSS2021, TpR   
This study 
      B. pseudomallei 
ΔBPSS2025+BPSS2025 
K96243 derivative, unmarked deletion ΔBPSS2025+pDA17::BPSS2025, 
TetR, 
 
This study 
E. coli         
 
      TOP10 F− mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 ΔlacX74 recA1  
araD139 Δ(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG λ− 
Invitrogen 
      GT115 F− mcrA Δ(mrr-hsdRMS-mcrBC) ϕ80lacZΔM15 ΔlacX74 recA1 rpsL (StrA) 
endA1 Δdcm uidA(ΔMluI) : : pir-116 ΔsbcC-sbcD 
Invitrogen 
      K-12 F− λ− ilvG- rfb-50 rph-1 
 
Lab strain collection 
      pRK2013 supE44 ΔmcrC-mrr) recA13 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5 mtl-1 
leuB6 thi-1 pRK2013 (KmR oriColE1 RK2-Mob+ RK2-Tra+ 
Lab strain collection 
      DHMI F-, cya-854, recA1, endA1, gyrA96 (Nal r), thi1, hsdR17, spoT1, rfbD1, 
glnV44(AS) 
Euromedex 
 
 CmR, chloramphenicol resistance; TetR, tetracycline resistance; TpR, trimethoprim resistance; KmR, kanamycin resistance and GenR, gentamicin 
resistance. 
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Table 2.2. S. cerevisiae strains used in this study. 
 
Yeast Strains 
 
Description 
 
Reference 
 
Saccharomyces 
cerevisiae  
  
      BY4741 MATa  his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
 
K. Haynes, 
Exeter 
      YDR294C BY4741 derivative, ΔDPL1 
 
K. Haynes, 
Exeter 
      Wt+ vector BY4741 derivative, pDEST413, HIS3 
 
This study 
      ΔDpl1+ vector YDR294C derivative, pDEST413, HIS3 
 
This study 
      ΔDpl1+ Dpl1 YDR294C derivative, pDEST413::Dpl1, HIS3 
 
This study 
      ΔDpl1+ 
BTH_II0309 
YDR294C derivative, 
pDEST413::BTH_II0309, HIS3 
 
This study 
      ΔDpl1+ 
BTH_II0311 
YDR294C derivative, 
pDEST415::BTH_II0311, LEU2 
 
This study 
      ΔDpl1+ 
BTH_II0309     
+BTH_II0311 
YDR294C derivative, 
pDEST413::BTH_II0309, 
pDEST415::BTH_II0311, HIS3, LEU2 
This study 
 
2.1.4 Growth media  
The media used in this study to grow bacterial and yeast strains are listed in 
Table 2.3.
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Table 2.3. Growth media used in this study. 
 
Media 
 
Composition 
 
 
Luria Bertani (LB) 
broth 
1% (w/v)  tryptone peptone, 0.5% (w/v) Bacto 
yeast extract, 0.5% (w/v) sodium chloride 
 
 
M9 minimal media 
 
0.34% (w/v) Na2HPO4, 0.15% (w/v) KH2PO4, 
0.5% (w/v) NH4Cl 0.25% (w/v) NaCl 
 
 
MacConkey agar 
 
5% (w/v) MacConkey agar base, 1 mM IPTG, 
1% (w/v)  maltose  
 
SOB broth 
2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 
8.5 mM NaCl, and 250 mM KCl 
 
 
YPD broth 
20 g tryptone, 10 g yeast extract, 20 g 
glucose, 1 L Milliq water 
 
 
YNB broth 
0.69% (w/v) yeast nitrogen base without 
amino acids, 740 mg complete supplement 
mix, 2% (w/v)  glucose 
 
 
YNB - HIS Drop out 
 broth 
0.69% (w/v) yeast nitrogen base without 
amino acids, 0.074% (w/v)  mg complete 
supplement mix drop-out:-HIS, 2% (w/v) 
glucose 
 
 
YNB - LEU Drop out 
broth 
0.6.9% (w/v)   yeast nitrogen base without 
amino acids, 0.074% (w/v)   complete 
supplement mix drop-out:-LEU, 2% (w/v)  
glucose 
 
 
YNB - HIS - LEU Drop 
out broth 
0.69% (w/v)  yeast nitrogen base without 
amino acids, 0.074% (w/v)  complete 
supplement mix drop-out:-HIS -LEU, 20% 
(w/v)  glucose 
 
When appropriate 2% (w/v)   of agar was added to growth media. 
 
2.2 Bioinformatic tools 
2.2.1 Bioinformatic characterisation of Burkholderia-encoded S1PLs 
The genomic sequences of B. pseudomallei K96243 (Holden et al., 2004) and B. 
thailandensis E264 (Kim et al., 2005) were those of the published annotations by 
Winsor et al. 2008 (The Burkholderia Genome Database: facilitating flexible 
queries and comparative analyses). The sphingosine-1-phosphate lyase protein 
sequences from eukaryotic and prokaryotic organisms were compiled from the 
Entrez Protein database (http://www.ncbi.nlm.nih.gov/). To identify homologs of 
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these known S1PL, their protein sequences were compared to those of the 
translated B. pseudomallei K96243 or B. thailandensis E264 genome by the use 
of the Burkholderia Genome Database Search Tool 
(http://www.burkholderia.com/blast.jsp). An E value of 1 × 10-5 or less was 
considered significant.  
S1PL multiple protein sequences were aligned using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) web-free program (McWilliam et al., 
2013) and visualised by the JalView software. S1PLs putative domains and 
function were characterised using the online platform for protein prediction, I-
TASSER server (Zhang, 2008). 
 
2.3 Molecular Biology 
2.3.1 Plasmids 
The plasmids used in this study are listed in Table 2.4. 
 
50 
 
Table 2.4. List of plasmids used in this study 
 
Plasmids Description Reference 
      pGPΩTp oriR6K, ΩTpR cassette, mob+ Flannagan et al. (2007) 
      pRK2013 oricolE1, RK2 derivative, KanR, mob+tra+ Figurski & Helinski (1979) 
      pDA17 oripBBR1, TetR, mob+, Pdhfr Flannagan et al. (2008) 
      pDM4 
 
oriR6K, suicide vector and sacBR of Bacillus subtilis, CmR 
 
Logue et al., 2009 
      pDM4::BPSS2025 
 
pDM4 carrying a BPSS2025 mutant allele that deletes BPSS2025   This study 
      pDM4::BPSS2021 
 
pDM4 carrying a BPSS2021 mutant allele that deletes BPSS2021   This study 
      pGPΩTp::BTH_II0309 pGPΩTp, 554 bp internal fragment from E264 BTH_II0309, TpR 
 
This study 
      pGPΩTp::BTH_II0311 pGPΩTp, 578 bp internal fragment from E264 BTH_II0311, TpR 
 
This study 
      pGPΩTp::BTH_II0839 pGPΩTp, 545 bp internal fragment from E264 BTH_II0839, TpR 
 
This study 
      pGPΩTp::BPSS2021 
 
pGPΩTp, 563 bp internal fragment from Bp K96243 BPSS2021, TpR 
 
This study 
      pDA17::BTH_II0309 pDA17, 1421 bp fragment encoding the E264 BTH_II0309 protein, TetR 
 
This study 
      pDA17::BTH_II0311 pDA17, 1421 bp fragment encoding the E264 BTH_II0311 protein, TetR 
 
This study 
      pDA17::BPSS2025 
 
pDA17, 1421 bp fragment encoding the Bp K96243 BPSS2025 protein, TetR 
 
This study 
      pDA17::GFP pDA17, encoding green fluorescent protein (GFP), TetR 
 
Lab collection 
      pGPΩTp::BTH_II0309-6His 
 
pGPΩTp, 572 bp fragment encoding the E264 BTH_II0309 including 6 x Histidine nucleotide 
sequence before stop codon, TpR 
This study 
      pGPΩTp::BTH_II0311-6His pGPΩTp, 572 bp fragment encoding the E264 BTH_II0311 including 6 x Histidine nucleotide 
sequence before stop codon, TpR 
 
This study 
      pDA17::BTH_II0309-C-terminal FLAG tag pDA17, 1445 bp fragment encoding the E264 BTH_II0309 with FLAG tag nucleotide sequence 
before stop codon, TetR 
 
This study 
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      pDA17::BTH_II0311-C-terminal FLAG tag pDA17, 1445 bp fragment encoding the E264 BTH_II0311 with FLAG tag nucleotide sequence 
before stop codon, TetR 
 
This study 
      pDONR™221 Gateway vector, KanR 
 
K. Haynes, Exeter 
 
      pBHR4-groS-RFP Broad-host range vector containing far-red fluorescent protein TurboFP635, CmR 
 
Wand et al.(2011) 
      pDEST413 Gateway vector, AmpR, HIS3, CEN ORI ccdB 
 
K. Haynes, Exeter 
 
      
      pDEST415 
 
Gateway vector, AmpR, LEU2, CEN ORI ccdB 
 
 
K. Haynes, Exeter 
 
      pDEST413::Dpl1 
 
Gateway vector, AmpR, HIS3, CEN ORI ccdB, Dpl1 This study 
      pDEST413::BTH_II0309 
 
Gateway vector, AmpR, HIS3, CEN ORI ccdB, synthesised BTH_II0309 This study 
      pDEST415::BTH_II0311 Gateway vector, AmpR, LEU2, CEN ORI ccdB, synthesised BTH_II0311 
 
This study 
CmR, chloramphenicol resistance; TetR, tetracycline resistance; TpR, trimethoprim resistance; KmR, kanamycin resistance and AmpR, ampicillin 
resistance. 
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2.3.2 Genomic DNA extraction from B. pseudomallei and B. thailandensis 
B. pseudomallei genomic DNA was extracted by lysis and precipitation method. 
1 mL of an overnight culture was centrifuged at 13000 rpm for 5 min and the pellet 
re-suspended in 1 mL TNE buffer (10 mM Tris; 10 mM NaCl; 10 mM EDTA; pH 
8). Following the centrifugation step, the pellet was re-suspended in 270 μl TNE-
X buffer (TNE buffer + 1% TritonX-100) and 30 μl lysozyme (5 mg/ml) was added 
and incubated at 37ºC for 20 min. Next, 15 μl proteinase K (20 mg/ml) was added 
and incubated at 65ºC for 2hrs until clear, followed by 15 μl of 5M NaCl and 500 
μl of absolute ethanol. Following centrifugation, 1 mL of 70% of ethanol was 
added and the samples re-centrifuged for 10 min at 13000 rpm. The resulting 
DNA pellet was re-suspended in 200 μl of ultrapure nuclease-free water.   
B. thailandensis genomic DNA was extracted using the DNeasy Blood & Tissue 
Kit (Qiagen) as per manufacturer’s instructions.  
 
2.3.3 Crude DNA extraction 
Bacterial crude DNA extraction was prepared by re-suspending 2-4 colonies 
grown on appropriate agar plates in 20 μl of alkaline lysis solution (0.25% SDS, 
0.05 M NaOH). The bacterial suspension was incubated for 15 min at 95ºC to 
lyse the cells. Next, 180 μl of nuclease-free water was added to the solution and 
centrifuged for 5 min at 13000 rpm. 1 μl of cell lysate was used as template DNA 
for later PCR reaction. 
S. cerevisiae DNA was extracted by suspending one yeast colony from selective 
agar plates in 100 µl of 200 mM LiAc, 1% SDS solution. The cells were incubated 
for 5 min at 70ºC, then 300 µl of 100% ethanol was added and the solution 
vortexed. The DNA and cell debris were spun down at 13000 rpm for 3 min and 
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the pellet washed with 70% ethanol. Next, the pellet was dissolved in 100 µl of 
nuclease-free water and cell debris spun down for 15 sec at 13000 rpm. 2 µl of 
supernatant was used for PCR. 
 
2.3.4 Plasmid DNA extraction  
Plasmid DNA was extracted from bacteria grown overnight in LB broth with 
appropriate antibiotics using the GeneJET Plasmid Miniprep Kit 
(ThermoScientific), as per manufacturer’s instructions. 
 
2.3.5 Polymerase chain reaction (PCR) 
 A typical PCR reaction was carried out using Taq DNA Polymerase (NEB) in 25 
µl reaction volumes, containing 1x NEB standard reaction buffer, 200 nM of 
forward and reverse oligonucleotides, 250 µM of dNTPs, 4% (v/v) of dimethyl 
sulphoxide (DMSO), 100 ng of DNA, 0.625 U of Taq DNA polymerase and 
nuclease-free water to a final volume of 25 µl. 
 
The PCR reaction was carried out as shown below. 
Typical reaction: 
Step 1 - 95°C (Denaturing) for 10 min 
Step 2 - 95°C (Denaturing) for 30 sec 
Step 3 - 57°C (Annealing) for 30 sec                         40 cycles 
Step 4 - 68°C (Extension) for 30 sec per kb               
Step 5 - 68°C (Final Extension) for 10 min 
Step 6 - 4°C (Hold) 
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2.3.6 Agarose gel electrophoresis 
For 1% (w/v) agarose gel electrophoresis, 1 g of agarose was dissolved into 100 
mL of 1 × Tris-acetate-EDTA (TAE) buffer and 5 µl of SYBR® green Safe stain 
(Invitrogen) was added for visualisation of fragments/amplicons. The PCR and 
plasmid samples were mixed with 6X loading dye (Fermentas) before loading and 
the gel run for 35 min at 100 V. Bands were visualised using a BioRad gel 
transilluminator and imaged using Quantity One version 4.6.9. 
 
2.3.7 PCR purification 
The PCR amplicons necessary for downstream applications were purified using 
GeneJet PCR Purification Kit (ThermoScientific), as per manufacturer’s 
instructions. 
 
2.3.8 DNA digestion using restriction enzymes 
A typical DNA digestion consisted of 1 µg of plasmid or linear DNA, 10 units of 
each restriction enzyme (New England BioLabs), 1X NEB appropriate reaction 
buffer according to the manufacturer’s instructions and nuclease-free water to a 
final volume of 50 µl. The reaction mixtures were incubated in a water-bath at 
37ºC for 2 hours before running agarose gel electrophoresis to visualise the 
digestion products and purify. 
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2.3.9 DNA Gel Purification 
The DNA fragments of interest were excised from the agarose gel with a razor 
blade following electrophoresis and purified using the GeneJet Gel Extraction Kit 
(ThermoScientific), as per manufacturer’s instructions.   
 
2.3.10 DNA ligation 
Ligation reactions consisted of 150 ng of digested vector, 1 µl T4 ligase enzyme 
(New England BioLabs), 1X T4 DNA ligase buffer, insert and nuclease-free water 
to a final volume of 20 µl. Reactions were incubated at 16ºC overnight.  
Cloning of PCR products into the pGEM-TEasy (Promega) vector followed 
manufacturer’s instructions, with the ligation reaction incubated at 4ºC overnight. 
For both DNA ligation methods the amount of insert was calculated using the 
equation detailed below, to give a vector to insert ratio of 3:1. 
  Amount of insert = (150 (size of insert (kb) / size of vector (kb)) x 3 
 
2.3.11 Gateway vector cloning 
Entry Gateway® plasmids were generated by cloning attB-PCR product encoding 
the target gene with the Gateway® Donor vector using Gateway® BP Clonase™ 
II enzyme mix (Invitrogen), according to manufacturer’s instructions as it follows: 
1-7 µl of attB-PCR product (≥10 ng/µl; final amount ~15-150 ng), 1 µl Donor vector 
(150 ng/µl), and TE buffer, pH 8.0 up to 8 µl. Next, 2 µl of BP Clonase™ II enzyme 
mix was added to the reaction and mixed well by vortexing. The reaction was 
incubated at 25°C for 3 h prior to E.coli TOP10 transformation as described in 
section 2.4.1. 
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Following the construction of Entry Gateway® plasmids, the target gene was 
transferred to expression Gateway® plasmids using LR Clonase™ II enzyme mix 
(Invitrogen) and mixing the appropriate Destination Gateway® vector with the 
Entry plasmids. Briefly, the cloning reaction contained: 1-7 µl of Entry plasmid 
(50-150 ng), 1 µl Destination vector (150 ng/µl), and TE buffer, pH 8.0 up to 8 µl. 
Next, 2 µl of LR Clonase™ II enzyme mix was added to the reaction and mixed 
well by vortexing. The reaction was incubated at 25°C for 3 h prior to E.coli TOP10 
transformation. 
 
2.4 Transformation 
2.4.1 Heat shock transformation 
Calcium competent cells (50 µl per reaction) were thawed for 5 min on ice before 
adding 2 µl of plasmid DNA (100 µg/µl) or ligation reaction and chilled on ice for 
30 min. The bacteria mixture was heat shocked at 42ºC for 45 seconds and 
returned to ice for 2 min. 250 µl of LB was added to the cells and incubated at 
37ºC for 1 h with 200 rpm. The ligation mixture was plated onto appropriate 
selective LB agar plates and incubated at 37ºC overnight. The next day, colonies 
were sub-cultured in fresh LB agar plates containing the appropriate antibiotics 
and incubated for 37ºC overnight. Finally, crude DNA extractions (section 2.3.3) 
were performed and template DNA used for PCR validation.  
 
2.4.2 Triparental mating conjugation 
The helper strain E. coli pRK2013 harbouring a kanamycin resistance cassette 
was used for all triparental conjugations. 10 mL cultures of the helper strain, 
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donor strain and B. thailandensis or B. pseudomallei strains were grown at 37ºC 
overnight in LB with appropriate antibiotic selection. Next, bacterial cultures were 
centrifuged at 4000 rpm for 3 minutes and samples were re-suspended in 10 mL 
of PBS. Mating mixtures were combined in a 1:1:5 helper, donor and recipient 
ratio and 100 µl of the mixture bacterial culture was added either to SOB or LB 
plate and left as a pool to allow plasmid exchange. Plates were incubated 
overnight at 37ºC prior to harvest the bacterial lawn with 1 mL of LB broth. 100 µl 
volumes were then plated onto LB agar plates containing gentamicin to kill the 
helper and donor E. coli strains plus other antibiotic as appropriate and incubated 
for 2-3 days at 37ºC for colonies to grow. Colonies were then sub-cultured onto 
selective agar plates and subjected to appropriate PCR validation. 
 
2.4.3 High efficiency LiAc-mediated Saccharomyces cerevisiae 
transformation 
S. cerevisiae strains were transformed with the appropriate plasmids using high 
efficiency LiAc-mediated yeast transformation method as described (Agatep et 
al., 1998), with minor modifications. Briefly, 1 mL of overnight cultures of 
appropriate S. cerevisiae strains were inoculated into 50 mL of YPD and 
incubated at 30ºC with aeration for 3-4 h. The cells were harvested by 
centrifugation and washed with 10 mL of sterile water. Next, 1 mL of the sample 
was transferred to a microtube and centrifuged for 30 s. The supernatant was 
removed and the cells resuspended in 1 mL of 100 mM LiAc and incubated for 
10 min at 30ºC. In the meantime, carrier DNA (2 mg/mL) was denatured in boiling 
water bath for 5 min followed by chilling immediately in ice. After cells’ incubation, 
the LiAc was removed by centrifugation and transformation mix prepared by 
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adding the following reagents: 240 µL of PEG (3500), 36 µL of LiAc (1M), 52 µL 
of Carrier DNA (10 mg/mL), 32 µL of plasmid DNA (100 ng final concentration) + 
water. After vortexing vigorously the cells, the sample was incubated for 30 min 
at 30ºC then heat-shocked at 42ºC for 20 min. Next, the transformation mix was 
removed by centrifugation and 500 µL of sterile water added onto the pellet and 
incubated for 5 min at room temperature. Finally, the cells were re-suspended by 
vortexing and plated onto appropriate drop-out medium and incubated at 30ºC 
for 2-4 days. 
2.5 Mutant construction and complementation 
2.5.1 Insertional inactivation mutagenesis 
Inactivation of the B. thailandensis and B. pseudomallei S1PL-encoding genes 
(BTH_II0309, BTH_II0311 and BPSS2021) was performed using pGPΩTp as 
described previously (Flannagan et al., 2007). The same method was used to 
inactivate BTH_II0839, which encodes BsaZ of the Bsa T3SS. Briefly, a 500-600 
bp region internal to each target gene was PCR-amplified from B. thailandensis 
E264 or B. pseudomallei K96243 and cloned into pGPΩTp to facilitate 
homologous recombination and thus insertional inactivation of the target gene. 
The PCR products were digested and cloned into XbaI/EcoRI sites of the suicide 
plasmid pGPΩTp. The resulting plasmids, pGPΩTp::BTH_II0309, 
pGPΩTp::BTH_II0311, pGPΩTp::BTH_II0839 and pGPΩTp::BPSS2021 were 
individually introduced in E. coli calcium competent cells by heat-shock 
transformation and then conjugated either into the wild-type strain B. 
thailandensis (pGPΩTp::BTH_II0309, pGPΩTp::BTH_II0311 or 
pGPΩTp::BTH_II0839) or into B. pseudomallei ΔBPSS2025 
(pGPΩTp::BPSS2021) by triparental mating with the helper plasmid pRK2013 
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(Figurski and Helinski, 1979). Transformants were selected by using gentamicin 
in conjunction with trimethoprim LB agar plates and plasmid insertion confirmed 
by PCR using the pGPΩTp specific RSF1300 primer (Flannagan et al., 2007) 
with appropriate forward checking primer, specific for region upstream the 
targeted insertion site. All mutant strains were confirmed by appropriate PCR 
validation and DNA sequencing of the PCR amplicon. 
 
2.5.2 SacB-based unmarked deletion mutagenesis 
Unmarked deletion of BPSS2025 was carried out with the method based on sacB 
counter-selection (Logue et al., 2009). First, to delete the S1PL gene, specific 
primers were designed to amplify a region of homology downstream and 
upstream of the target gene. Afterwards, a PCR was performed to splice the 
downstream and upstream regions and the obtained amplicons cloned into 
pGEM-Teasy vector. The inserts containing the spliced downstream and 
upstream regions of both target genes were confirmed by DNA sequencing. The 
insert from the holding plasmid was removed by digestion and cloned into the 
suicide plasmid pDM4, resulting in the deletion plasmid pDM4::BPSS2025 (Table 
2.4), and then conjugated into B. pseudomallei K96243 by triparental mating. The 
first cross over integrants were confirmed by plating onto chloramphenicol plates 
to check for resistance. Next, the merodiploid integrants were selected for 
deletion plasmid excision from the genome in a second recombination by plating 
onto LB agar lacking sodium chloride but containing 10% sucrose and incubated 
at 24ºC for 2-4 days. After the sacB counter-selection, the sucrose resistant 
colonies were screened for chloramphenicol sensitivity by plating simultaneously 
a single colony onto LB agar plate and LB plate supplemented with 
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chloramphenicol. The chloramphenicol-sensitive colonies were screened for the 
plasmid excision and gene deletion by PCR using flanking region primers and 
primers internal to the S1PL-encoding gene. Following PCR validation, the 
putative deletion mutants were further validated by whole genome sequencing. 
 
2.5.3 Whole genome sequencing of B. pseudomallei´s S1PL putative 
mutants 
Genomic DNA from B. pseudomallei´s S1PL putative mutants was extracted as 
described elsewhere (section 2.3.2) and sent for whole genome sequencing 
(Exeter Sequencing Services, University of Exeter) using 300 bp paired end 
reads on the MiSeq Illumina platform. Reads were mapped to B. pseudomallei 
K96243 reference genome, enabling the confirmation of target gene deletion 
without the disruption of surrounding genes. 
 
2.5.4 Construction of B. thailandensis and B. pseudomallei complemented 
strains 
Complementation of the resulting mutants was achieved using the previously 
described pDA17 vector (Flannagan et al., 2008), that drives constitutive 
expression of the cloned gene from a dhfr promoter. Briefly, the ORF of either 
BTH_II0309, BTH_II0311 or BPSS2025 were PCR amplified and cloned into 
pDA17 vector (Flannagan et al., 2008) via XhoI/NdeI sites. Next, the resulting 
complementation plasmids, pDA-17::BTH_II0309 or pDA-17::BTH_II0311 were 
mobilised into B. thailandensis S1PLs mutants and  pDA-17::BPSS2025 into B. 
pseudomallei ΔBPSS2025 by triparental mating as described elsewhere (section 
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2.4.2). Complemented strains were validated by PCR using primers specific to 
amplify full-length target genes and tetracycline cassette.  
 
2.5.5 Complementation of Saccharomyces cerevisiae Δdpl1 
The BTH_II0309 and BTH_II0311 genes were codon-optimised for S. cerevisiae 
expression by gene synthesis (Invitrogen) and cloned into the Gateway® donor 
vector pDONR221 (Life Technologies) to create pENTR::BTH_II0309 and 
pENTR::BTH_II0311 respectively. The BTH_II0309 and BTH_II0311 sequences 
were subsequently cloned from the pENTR vector into pAG413GPD-ccdB and 
pAG415GPD-ccdB yeast destination Gateway® vectors respectively, using LR 
Clonase™ recombination (Invitrogen), generating the expression plasmids 
pDEST413::BTH_II0309 and pDEST415::BTH_II0311. A similar process was 
used to construct pDEST413::dpl1, expressing the S. cerevisiae S1PL 
orthologue. The S. cerevisiae BY4741 (parental strain) and YDR294C (Δdpl1) 
strains were transformed with the appropriate plasmids using high efficiency 
LiAc-mediated yeast transformation method as described before (section 2.5.4). 
Transformants were selected for on the basis of histidine (pAG413GPD-ccdB) 
and/or leucine (pAG415GPD-ccdB) prototrophy and plasmid mobilisation 
confirmed by PCR using primers to internal region of target genes. 
 
2.6 Introduction of a His-Tag on B. thailandensis S1PLs 
Primers were designed to specifically amplify >500bp of the 3´ end of each target 
gene (BTH_II0309 and BTH_II0311) and introduced a six histidine sequence 
immediately upstream of the stop codon. The PCR-amplified fragments 
containing a 6His-tag were cloned into the suicide plasmid pGPΩTp and 
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subjected to sequence confirmation by DNA sequencing.  Next, the plasmid was 
conjugated into the wild-type strain B. thailandensis E264 by triparental mating, 
giving rise to pGPΩTp::BTH_II0309-6His and pGPΩTp::BTH_II0311-6His strains 
(Table 1). The plasmid integration within the target gene was confirmed by PCR 
and DNA sequencing of PCR amplicon. 
 
2.7 His-tagged protein purification 
Cells from mid-log phase bacterial cultures (1000 mL LB broth) were harvested 
by centrifugation and disrupted by sonication. The cell lysates containing His-
tagged proteins were purified using His-Select® Nickel affinity gel (Sigma) column 
chromatography, following the manufacturer’s instructions for native conditions. 
The column was equilibrated with 50 mM sodium phosphate, 0.3 M sodium 
chloride and 10 mM imidazole, pH 8. The sample was loaded onto the column 
and washed with equilibration buffer. Bound His-tagged proteins were eluted from 
the column under native conditions using 50 mM sodium phosphate with 0.3 M 
sodium chloride and 500 mM imidazole elution buffer. 
 
2.8 Protein quantification assay 
Protein quantification was performed using the Bio-Rad protein assay (Bio Rad) 
as per manufacturer’s instructions. The Bio-Rad protein dye reagent was 
prepared by diluting 1 part Dye Reagent Concentrate with 4 parts distilled, de-
ionized water. 50 µl either protein or BSA standard was added to 2.5 ml diluted 
dye reagent and incubated for 15 min at room temperature. The absorbance was 
read at 595 nm and protein concentration determined against a bovine serum 
albumin (BSA) standard curve. 
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2.9 Protein Gels 
For denaturing conditions, protein samples were mixed with 4X NuPAGE® LDS 
Sample Buffer to a final 1X concentration and heated at 95ºC for 10 minutes. The 
NuPAGE® 4-12 % Bis-Tris Gels (Novex) were secured into an XCell SureLock® 
mini cell and submerged in 1X NuPAGE® MES SDS Running Buffer 
(LifeTechnologies). A total of 20 µl of protein preparation was loaded into each 
well of the gel. A 5 µl sample of the Odyssey® Protein Molecular Weight Marker 
(Licor) was loaded for protein size comparison, and the gel was then run at 180 
V for 50 min. 
For native conditions, protein samples were mixed with cold 4X NativePAGE® 
sample buffer and run on 4-16% NativePAGE®  Bis-Tris  gel (Novex) submerged 
in 1X NativePAGE® Cathode Buffer. 5 µl of NativeMark® Unstained Protein 
Standard was loaded as protein ladder and the gel was run at 150 V for 120 min.  
 
2.10 Gel staining 
Either NuPAGE® or NativePAGE® gels were stained with 25 mL of Simply Blue 
Stain (Invitrogen) for 30 sec intervals in the microwave until protein bands were 
visible. Following staining the gels were washed with de-ionised water 3 times 
and incubated overnight at room temperature with agitation in 50 mL of water to 
de-stain the gel.  
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2.11 Western Blot 
Proteins were transferred either to a nitrocellulose membrane (denaturing 
conditions) or to a methanol treated PVDF membrane (native conditions) 
included in the iBlot® Transfer Stacks (Novex) using the iBlot® Dry Blotting 
System (Invitrogen). After transfer was complete, the PVDF membrane was 
incubated in 20 mL of 8% acetic acid for 5 min with shaking prior to 5 min washing 
step with water and left to air-dry overnight. Next, the PVDF membrane was 
prepared for immunodetection by incubating in 20 mL methanol 3 times for 30 
sec each with shaking, then a last wash in 20 mL water for 5 min. 
Both nitrocellulose and PVDF membranes were blocked with blocking buffer 
PBS-T (0.1% (v/v) Tween-20 in PBS) supplemented with 3% (w/v) of skimmed 
milk powder and incubated at 4ºC overnight. When appropriate, membranes were 
then incubated with either primary 1:500 mouse anti-His polyclonal antibody 
(Novagen); 1:1000 mouse anti-FLAG antibody (Invitrogen); 1:1000 rabbit anti-
BopE antibody or 1:2500 rabbit anti-GFP antibody (Abcam) made up in blocking 
solution for 60 minutes at room temperature with rocking. Following incubation 
the membrane was washed with PBS-T for 10 minutes rocking and removed. This 
washing step was repeated 3 times before the secondary either 1:15000 goat 
anti-mouse LI-COR® 731 IRDye 800cw (Licor) or 1:15000 goat anti-rabbit LI-
COR® IRDye 800cw fluorescent antibody made up in blocking buffer was applied 
for 60 minutes at room temperature with rocking. The secondary antibody was 
then removed following the wash steps as described previously. The membrane 
was scanned using the Odyssey CLx infra-red scanner (Licor) and imaged using 
Image Studio, version 4.0. 
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2.12 Mass spectrometry 
Protein samples were run on native conditions and the gel stained to allow band 
visualisation. The protein bands of interest were excised from the gel and stored 
at 4ºC. The samples were sent to University of Bristol (Mass Spectrometry 
Facility) for in-gel tryptic digestion and protein sequence determined by Liquid 
chromatography–mass spectrometry (LC-MS). Proteome Discoverer™ software 
(ThermoScientific) was used and the peptides sequence run on SEQUEST 
search algorithm against the Uniprot Burkholderia thailandensis E264. 
 
2.13 Bacterial Adenylate Cyclase Two-Hybrid System (BACTH) 
S1PLs protein interactions were assessed using the BACTH System Kit 
(Euromedex), following the manufacturer’s instructions. Briefly, ORF of either 
BTH_II0309 or BTH_II0311 were PCR amplified and sub-cloned into pKT25 and 
pUT18C vectors in frame with the T25 and T18 fragment. Next, the recombinant 
plasmids encoding the T25-BTH_II0309, T18-BTH_II0309, T25-BTH_II0311 and 
T18-BTH_II0311 were co-transformed in pairs in all combinations possible into 
competent DHM1 reporter cells. The transformation mixtures were plated onto 
selective LB agar plate containing ampicillin and kanamycin. Next, the interaction 
of the target proteins was detected by plating 10 µl of overnight cultures of 
appropriate transformants onto MacConkey/maltose agar plates and incubated 
either at 30ºC or 37ºC for 2 days. The formation of red colonies was considered 
positive protein-protein interaction and if no interaction occurred the colonies 
were colourless. 
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2.14 Construction of FLAG-tagged B. thailandensis S1PLs 
To fuse a FLAG-tag on the C-terminal of B. thailandensis S1PLs, the ORF of 
BTH_II0309 and BTH_II0311 (without stop codon) were PCR amplified and 
cloned into pDA17 vector via XhoI/NdeI sites (in frame with a FLAG tag encoded 
downstream of the cloning site). Next, the resulting expression plasmids, pDA-
17::BTH_II0309-FLAG and pDA-17::BTH_II0311-FLAG (Table 4) were 
individually introduced in E.coli TOP10 by heat-shock transformation and then 
conjugated into either wildtype B. thailandensis or BTH389 mutant strain by 
triparental mating as described above. Transconjugants were selected by using 
gentamicin and tetracycline plates and plasmid mobilisation confirmed by PCR 
analysis. 
 
2.15 Detection of FLAG-tagged B. thailandensis S1PLs in bacterial lysates 
and culture supernatant  
B. thailandensis wildtype and BTH839 constitutively expressing either FLAG-
tagged BTH_II0309, FLAG-tagged BTH_II0311 or GFP (as non-secreted protein 
control) were grown to mid-log phase in LB broth adjusted to either pH 7 or pH 
4.5 and cells harvested by centrifugation. Bacterial cells were lysed in 4X 
NuPAGE® LDS Sample Buffer (Novex), whilst culture supernatants were filtered 
and proteins precipitated with 10 % (v/v) trichloroacetic acid and quantified as 
described previously (section 2.8). Proteins recovered from the whole cell lysates 
and culture supernatants were separated on NuPAGE® 4-12 % Bis-Tris Gels 
(Novex) gel and transferred to nitrocellulose membrane. Both BTH_II0309-FLAG, 
BTH_II0311-FLAG and GFP proteins were detected by Western blot as 
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described in section 2.11. The protein bands were visualised with the LI-COR® 
Odyssey scanner using Image Studio, version 4.0. 
 
2.16 Minimal media growth curve analysis 
Growth curves were performed by sub-culturing appropriate bacterial strains into 
M9 minimal media (Table 2.3). Overnight bacterial cultures were re-adjusted to 
OD590nm of 1.0 and 50 µl of bacterial suspension added to 10 mL of M9 minimal 
media and incubated at 37ºC with agitation for 24 h. Samples were taken at 
designated hourly time points and the absorbance read at OD590nm.   
  
2.17 Nutrient Deprivation assay 
Bacterial strains grown overnight in 5 mL of appropriate LB media were pelleted 
by centrifugation at 4000 rpm for 10 min and the supernatant discarded. The 
pellets were washed in 5 mL of sterile de-ionised water and centrifuged for 10 
min at 4000 rpm prior to re-suspending the cell in 5 mL of sterile water. The 
bacterial suspensions were incubated for 24 h at 37ºC with shaking then 10-fold 
serial dilutions were prepared in sterile de-ionised water and plated onto LB agar 
plates for enumeration of viable bacteria.  
 
2.18 Galleria mellonella infection model 
The virulence towards G. mellonella larvae was assessed by killing assays as 
described previously (Wand et al., 2011). Briefly, G. mellonella larvae were 
challenged with approximately 25 colony-forming units (cfu) in 10 μl volumes 
injected into the foreleg of 10 larvae per bacterial strain and incubated statically 
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at 37ºC. Control larvae were either injected with 10 μl of sterile PBS to measure 
potential injection trauma, or not injected to assess the effect of 37ºC incubation. 
The larvae survival was recorded after 40 hours post-infection and larvae were 
considered dead when they presented no movement in response to gentle touch 
with a pipette tip. The input inoculum was measured by plating serial dilution onto 
LB agar plates. 
 
2.19 BALB/c mice infection model 
Groups of 5 female BALB/c mice of 6-8 weeks of age were separately challenged 
intraperitoneally with three different inocula per strain, corresponding 
approximately to 4 x 103 – 4 x 105 CFU of B. pseudomallei K96243 wild-type, 4 x 
104 – 4 x 106 CFU of ΔBPSS2025 mutant or 4 x 103 – 4 x 105 CFU of 
complementation strain. Mice were monitored for signs of disease for 35 days. At 
the end of the study any survivors were culled and bacteria enumerated in lungs, 
liver and spleen. Organs were weighed at culling to allow CFU values to be given 
in either CFU/mg or CFU/organ as required. 
 
2.20 Sphingosine antimicrobial assay 
The antimicrobial activity of D-erythro-sphingosine C-18 (Cayman chemical; MI, 
USA) was assessed as described previously (Possemiers et al., 2005), with minor 
modifications. Briefly, standardised bacterial suspensions (106 CFU/mL) derived 
from overnight cultures were incubated for 2 hours at 37ºC with agitation in a 
saline solution supplemented with varying concentrations of D-erythro-
sphingosine (0, 25, 50, 100 or 150 μM, dissolved in ethanol). After incubation, 
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serial dilutions were plated onto LB agar plates for enumeration of CFU. Survival 
was determined by comparison to ethanol only controls. 
 
2.21 Saccharomyces cerevisiae sphingosine resistance assay 
S. cerevisiae strains were grown in selective minimal liquid culture medium at 30 
°C overnight with agitation. Serial dilutions of standardised culture were spotted 
onto YNB agar with or without supplementation with 10 µM D-erythro-sphingosine 
C-18. Plates were incubated at 30 °C for 48-72 h prior to visual assessment of 
growth. 
 
2.22 Tissue Culture 
2.22.1 A549 invasion assay 
The bacterial invasion assay used in this study was based on previous published 
protocols (Burns et al., 1996). In summary, A549 cells were seeded in 24-well 
plates at 1 x 105 cells per mL and cultured overnight (37 °C, 5 % CO2) in 
Dulbecco’s Modified Eagle Medium (GE Healthcare) supplemented with 10 % 
foetal bovine serum. Bacteria were harvested from overnight LB broth cultures, 
washed in PBS, and re-suspended in Leibovitz L-15 medium (GE Healthcare) 
prior to addition to the A549 monolayers (MOI 50). After 2 h incubation at 37 °C 
to allow bacterial internalisation, the medium was replaced with fresh L15 
supplemented with kanamycin (1000 µg/mL) to kill extracellular bacteria. At 2 and 
4 hpi, the A549 monolayers were washed twice with PBS and lysed with 0.1 % 
(v/v) Triton X-100. Serial dilutions of cell lysates were plated onto LB agar for 
enumeration of intracellular bacteria. 
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2.22.2 Macrophage intracellular survival assay 
Bacterial uptake and subsequent intracellular survival in macrophages was 
assessed using a modified kanamycin protection assay as described previously 
(Wand et al., 2011). In summary, J774A.1 macrophages were seeded in 24-well 
plates at 2.5 x 105 cells per mL and cultured overnight (37 °C, 5 % CO2) in 
Dulbecco’s Modified Eagle Medium (GE Healthcare) supplemented with 10 % 
foetal bovine serum. Bacteria were harvested from overnight LB broth cultures, 
washed in PBS, and resuspended in Leibovitz L-15 medium (GE Healthcare) 
prior to addition to the J774A.1 monolayers (MOI 10). After 2 h incubation at 37 
°C to allow bacterial internalisation, the medium was replaced with fresh L-15 
supplemented with kanamycin (1000 µg/mL) to kill extracellular bacteria. At 2, 4 
and 6 hpi, the J774A.1 monolayers were washed twice with PBS and lysed with 
0.1 % (v/v) Triton X-100. Serial dilutions of macrophage lysates were plated onto 
LB agar for enumeration of intracellular bacteria. 
 
2.22.3 Cytotoxicity assays on infected macrophages 
J77A.1 cells were seeded into 24 well plates at a density of 2.5x105 cells per mL, 
and incubated at 37oC overnight with 5% CO2. Cells were overlaid with 1 mL 
overnight B. thailandensis cultures re-suspended in L-15 media at a density of 
2.5x106 cfu/mL equating to a MOI of 10. B. thailandensis-infected macrophages 
were then incubated at 37oC for 24 hours. Infections were performed in triplicate 
for each strain and negative control consisting of macrophages overlaid with 1mL 
L-15 media performed on each 24-well plate. At 2, 6, 12 and 24 hpi the 
supernatant was removed and centrifuged at 5000 rpm for 5 minutes. Cytotoxicity 
was assessed by measuring the release of lactate dehydrogenase (LDH) from 
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the J774A.1 macrophages using the CytoTox 96® Non-Radioactive Cytotoxicity 
Assay kit (Promega) in accordance with the manufacturer’s instructions. In brief, 
50 µl of supernatant was removed and mixed with 50 µl of LDH substrate in a 96 
well plate and incubated in the dark at room temperature for 30 minutes. 
Following incubation, 50 µl of stop solution was added and the absorbance read 
at OD490nm using a Bio-Rad model 680 microplate reader. Cell damage was 
calculated via the equation: OD490 infected cells-OD490 uninfected cells. 
 
2.22.4 Host cell S1P quantification by enzyme-linked immunosorbent 
assay (ELISA) 
S1P levels in B. thailandensis-infected macrophages were analysed using a S1P 
competitive ELISA kit (Echelon Biosciences) according to the manufacturer’s 
instructions, with minor modifications. In summary, J77A.1 cells cultured up to 
80-90% confluence in T75 cm2 flasks were infected with B. thailandensis strains 
(MOI 10) as described before (section 2.21.2) or left uninfected for 2, 6 and 24 
hpi. Macrophages were lysed in 400 µl of lysis buffer with 1X Protease inhibitor 
cocktail without EDTA (Invitrogen) and frozen immediately at -80ºC. Protein 
concentration was measured as described elsewhere (section 2.8). Next, the 
diluted samples (1:2 in delipidised human sera) were added at 75 μg protein/well 
to the Echelon S1P ELISA plate and the absorbance measured at 450 nm using 
the Bio-Rad model 680 microplate reader. 
 
2.22.5 S1P and S1PR1 agonist treatment of macrophages 
A 1.25 mM stock solution of S1P (Cayman Chemical) was prepared in methanol 
and stored at -20 °C in amber glass vials. CYM-5442, a selective agonist of S1P 
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receptor 1 (S1PR1), was obtained from Tocris Biosciences (Bristol, UK), and a 
stock solution of 5 mM was prepared in ultrapure distilled water and stored at -20 
°C. S1P or CYM-5442 was added to infected J774A.1 monolayers (after a 2 h 
infection period) at final concentrations of 5 µM and 0.5 µM respectively. For 
experiments utilising S1P, the same volume of methanol was added to the control 
group. Intracellular survival and/or colocalisation of bacteria with LAMP-1 were 
then assessed as described elsewhere (section 2.22.2 and section 2.23.1 
respectively). 
 
2.23 Immunofluorescence microscopy  
2.23.1 Bacteria/Lysosomal-associated membrane protein-1 (LAMP-1) 
colocalisation studies 
B. thailandensis E264 and the BTH_II0309 and BTH_II0311 deficient mutants 
were transformed with the reporter plasmid pBHR4-groS-RFP (Wand et al., 
2011). J774A.1 macrophages seeded onto 12 mm diameter glass coverslips 
were infected with the relevant strains (MOI 10) as previously described. After 
treatment with kanamycin (1000 µg/mL) to kill extracellular bacteria, monolayers 
were washed twice with PBS and fixed with paraformaldehyde (4 % w/v in PBS; 
15 min, room temperature). Cells were permeabilised with saponin (0.5 % v/v in 
PBS; 1 h) and non-specific binding sites blocked with 1 % (v/v) bovine serum 
albumin (BSA) in PBS. LAMP-1 was stained with 1:100 rabbit polyclonal antibody 
(Abcam) and the bound antibody was detected with 1:400 goat anti-rabbit IgG-
Alexa 488 (Molecular probes). The stained cells were washed three times with 
PBS, mounted onto slides using Vectashield (Vector Laboratories) and visualised 
using a Zeiss Axioplan epifluorescent microscope equipped with an oil immersion 
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lens (Zeiss 100× A-plan). Image analysis and processing was performed using 
Fiji (Schindelin et al., 2012). A minimum of 100 bacteria were counted per 
strain/condition for each experiment. 
 
2.23.2 Fluorescent staining of FLAG-tagged S1PLs in infected 
macrophages 
J774A.1 cells were infected with B. thailandensis expressing either FLAG-tagged 
BTH_II0309 or FLAG-tagged BTH_II311 (MOI of 50). Following killing of 
extracellular bacteria (1000 µg/mL kanamycin, 2 hours), infected cells were fixed 
with paraformaldehyde and permeabilised with saponin as described above. 
Non-specific binding sites were blocked with Image-iT® FX signal enhancer (Life 
technologies) for 30 min at room temperature. To detect the FLAG-tagged S1PLs 
proteins we used 1:250 mouse anti-FLAG antibody (Invitrogen). The different 
host cell compartments were stained individually as described: 1:250 rabbit anti-
Calnexin (Abcam) for endoplasmic reticulum; 1:250 rabbit anti-MEK1/2 (Abcam) 
for cytosolic compartment; the host mitochondria was stained live for 15 min with 
100 mM MitoTracker Red-CMXRos (Invitrogen) before cell fixation. Each primary 
antibody was diluted in 10% normal goat serum / 0.1 % PBS-Tween 20 and 
incubated overnight at 4ºC. Bound antibodies were detected with 1:400 dilutions 
of goat anti-mouse Alexa 488 and goat anti-Rabbit Alexa 594 (Molecular probes). 
Following washing, the stained cells were mounted and visualised as described 
above. In addition, image convolution was processed with the (default) threshold 
algorithm of the Fiji software. 
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2.24 RNA-seq analysis of macrophages treated with S1P and S1PR1 
agonist 
2.24.1 RNA extraction and mRNA enrichment 
J774A.1 macrophages were seeded into 24 well plates at a density of 2.5x105 
cells per mL, and incubated at 37ºC overnight with 5% CO2 in Dulbecco’s 
Modified Eagle Medium (GE Healthcare) supplemented with 10% foetal bovine 
serum. Next, complete media was removed and cells washed once with Leibowitz 
L-15 medium before replacing with fresh L-15 medium and the cells left to starve 
for 4 h at 37ºC static. After starvation period, S1P or CYM-5442 was added to 
J774A.1 cells at final concentrations of 5 µM and 0.5 µM respectively and 
incubated for 1 h. Next, the cells were re-suspended in 1 mL of PBS at 4ºC and 
RNA extraction/mRNA enrichment was performed using Dynabeads® mRNA 
DIRECT™ Kit (Ambion), according to manufacturer’s instructions. Resulting 
mRNA was subjected to one further round of purification using Dynabeads® 
mRNA DIRECT™ Kit to eliminate putative rRNA contamination. Final mRNA was 
eluted from the beads with 15 µl of RNase-free water (Ambion) and stored at -
80ºC until further use. RNA concentration and quality was assessed on the 
Agilent Bioanalyzer (RNA Eukaryote Nano kit series) using the RNA 6000 Nano 
kit (Agilent). 
  
2.24.2 RNA-seq data analysis 
RNA-seq analysis libraries were prepared in collaboration with Exeter 
Sequencing Services (University of Exeter) using 100 bp paired end reads on the 
HiSeq 2500 platform (Illumina). Paired reads are quality (Q<=20) trimmed and 
sequencing adaptors removed using FastqMcf from ea-utils.1.1.2-537. RNA 
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ERCC spike-in control (Ambion) sequences were removed using Bowtie version 
1.0.0. The remaining trimmed reads were aligned using TopHat2 version 2.0.8b 
to the reference Mus_musculus_NCBI_GRCm38 from NCBI (National Center for 
Biotechnology Information) database. For the Cuffdiff analysis, Cufflinks v2.1.1 
was used to quantify expression of genes and isoforms and Cuffmerge to merge 
the transcripts obtained from cufflinks, then Cuffdiff v2.1.1 was applied to find 
differentially expressed genes and isoforms. CummeRbund v2.8.2 was used to 
create the plots.  
 
2.25 Statistical analysis 
Statistical differences were assessed either by one-way analysis of variance 
(ANOVA) test or Student's t-test (t-test) using GraphPad Prism version 6.0. P < 
0.05 was considered significant. 
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Chapter 3 - Identification and initial 
characterisation of Sphingosine-1-
phosphate lyases in B. pseudomallei 
and B. thailandensis 
3.1 Introduction  
Sphingolipids are a class of molecules essential for eukaryotic cell membrane 
structure and as signalling molecules contribute to regulation of numerous 
physiological and pathological processes, such as cancer (Newton et al., 2015), 
inflammation (Maceyka and  Spiegel, 2014) and infectious diseases (Arish et al., 
2015; Heung et al., 2006; Hanada, 2005).  
 
The human S1PL homolog belongs to the PLP (pyridoxal 5’-phosphate)-
dependent enzymes superfamily (Bourquin et al., 2010) and is responsible for the 
irreversible degradation of sphingosine-1-phosphate (S1P), thus playing an 
essential role in controlling the S1P pools in the host and maintaining the lipid 
homeostasis (Serra and Saba, 2010). S1P has been shown to play a critical role 
in diverse immune functions in mammals (Kihara, 2013; Aguilar and Saba, 2012; 
Hisano et al., 2012; Spiegel and Milstien, 2011; Chi, 2011; Riviera et al., 2008; 
Young and Nahorski, 2002). 
 
Most prokaryotic cells do not synthesise sphingolipids, though in the course of 
studies investigating bacterial enzymes involved in sphingolipid biosynthesis and 
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metabolism (Raman et al., 2010), putative S1PL-encoding genes were identified 
within the genomes of selected Burkholderia species, specifically B. 
pseudomallei and B. thailandensis. Additionally, other prokaryotic S1PL 
homologues have been described, namely in Symbiobacterium thermophilum 
and the pathogenic bacteria Legionella pneumophila (Bourquin et al., 2010; 
Degtyar et al., 2009). The Legionella S1PL (LegS2) is secreted by the bacterium 
and targets the host cell mitochondria (Degtyar et al., 2009). Curiously, a recent 
study has shown that the Legionella LegS2 mutant displays heightened 
replication in macrophages, which is associated with reduced pro-inflammatory 
cytokines production during infection, suggesting that LegS2 does not contribute 
for Legionella pathogenesis (Khweek et al., 2016). 
 
A growing body of evidence suggests that numerous pathogens are capable of 
hijacking the host S1P signalling pathway to promote their intracellular survival. 
However, the molecular events that underlie the disruption of S1P-pathway by 
intracellular pathogens remains to be defined. Hence, the molecular 
characterisation of bacterial-encoded S1PL would pave the way to better 
understand such strategies employed by pathogenic bacteria as well as the 
development of novel therapeutic targets. 
 
In the present chapter, bioinformatic tools were utilised to identify and 
characterise putative S1PLs encoded by B. pseudomallei and B. thailandensis. 
Furthermore, using B. thailandensis as model organism, a 6x His-tag was 
inserted into each S1PL gene to allow the purification of recombinant proteins 
and subsequent characterisation by western blot and mass spectrometry 
analysis. Moreover, using a Bacterial Two-Hybrid system we investigated the 
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oligomeric form of both S1PLs in vivo. Based on the complementation of S1PL-
yeast deficient strain we confirmed that the Burkholderia-encoded S1PLs are 
functionally equivalent to eukaryotic S1PL. Additionally, following an insertional 
inactivation approach, B. thailandensis S1PL-deficient mutants were assessed 
for resistance to antimicrobial sphingolipids and defective growth in minimal 
media. 
 
3.2 Results  
3.2.1 Bioinformatic identification and characterisation of Burkholderia 
S1PLs  
3.2.1.1 Identification of putative Sphingosine-1-phosphate lyase 
homologues in Burkholderia pseudomallei and Burkholderia thailandensis 
Using the Burkholderia genome database (Winsor et al., 2008) and B. 
pseudomallei K96243 and B. thailandensis E264 as model strains, two putative 
S1PLs were identified in each species – encoded by BPSS2021 and BPSS2025 
in B. pseudomallei K96243, and BTH_II0309 and BTH_II0311 in B. thailandensis 
E264. Within B. pseudomallei and B. thailandensis, the two S1PLs encoded by 
each strain show a high degree of similarity to each other, exhibiting 87 % identity 
at the amino acid levels. The Burkholderia proteins show approximately 33-40 % 
amino acid identity to the well-characterised yeast and human S1PL orthologues 
(Figure 3.1 and Table 3.1). Notably, all amino acids reported to be essential for 
the activity of the yeast S1PL orthologue (Dpl1) (Mukhopadhyay et al., 2008) are 
conserved in the Burkholderia S1PLs (Figure 3.1). Taken together, these 
observations strongly suggest that B. thailandensis and B. pseudomallei encode 
two functional sphingosine-1-phosphate lyases.  
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Figure 3.1. Amino acid alignment of representative Burkholderia and eukaryotic 
S1PLs. Sequence alignment of BPSS2025, BPSS2021, BTH_II0309, BTH_II0311, 
human & yeast S1PL. Asterisks indicate amino acid residues that are important for the 
enzymatic activity of the yeast protein (Mukhopadhyay et al., 2008), all of which are 
conserved in the Burkholderia orthologues. Accession numbers: Human S1PL, 
CAA09590; Yeast S1PL, AHY75267. Alignment generated using Vector NTI Advance 11 
(Invitrogen), with blue, green and yellow shading indicating similarities (“conserved”, 
“block of similar”, and “identical” respectively). 
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Table 3.1. Putative sphingosine-1-phosphate lyase encoded by B. pseudomallei K96243 
(BPSS2021 and BPSS2025) and B. thailandensis E264 (BTH_II0309 and BTH_II0311). 
Identified by annotation, the conserved domains and amino acid identity to human and 
yeast S1PL. 
Gene name 
Genome 
annotation 
Predicted 
domains 
Sequence 
identity to  
Human S1PL 
Sequence 
identity to  
S.cerevisiae 
S1PL 
 
     BPSS2021 
 
 
Decarboxylase 
 
43- 440 aa - 
Glutamate 
decarboxylase 
and related PLP-
dependent 
proteins 
39.1% 33.2% 
 
     BPSS2025 
 
 
Decarboxylase 
 
54 - 469 aa - 
Glutamate 
decarboxylase 
and related PLP-
dependent 
proteins 
 
38.1% 
 
32.7% 
     BTH_II0309 
Sphingosine-1-   
phosphate lyase 
21 – 401 aa - 
Glutamate 
decarboxylase 
and related PLP-
dependent                  
proteins 
40.8% 35.2% 
     BTH_II0311 
Sphingosine-1-
phosphate lyase 
23 – 434 aa - 
Glutamate 
decarboxylase 
and related PLP-
dependent                  
proteins 
39.4% 35.0% 
 
3.2.1.2 Phylogenetic tree analysis of representative prokaryotic and 
eukaryotic S1PLs  
As Burkholderia thailandensis and B. pseudomallei do not appear to encode other 
sphingolipid metabolising enzymes we questioned whether Burkholderia S1PLs 
have been acquired by gene transfer from bacterial species, or from an eukaryotic 
organism as proposed for the Legionella LegS2 (Degtyar et al., 2009).  To 
investigate the putative origin of Burkholderia S1PLs, we constructed a 
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phylogenetic tree based on S1PL sequences of various species. As shown in 
figure 3.2, B. thailandensis and B. pseudomallei S1PLs form a distinct branch of 
the phylogenetic tree, yet the closest matches are clearly bacterial (highlighted in 
red), represented by the bacterial species Streptomyces, Erythrobacter,  
Symbiobacterium, Plesiocystis, Myxococcus and Stigmatella. Notably, the 
closest eukaryotic S1PLs were from several plant-derived S1PL sequences, such 
as Physcomitrella, Ricinus, Oryza and Zea. In contrast, the bacterial species 
Legionella formed a separate group with the Entamoeba S1PL, a protozoan 
species. Altogether, the data presented herein suggest that B. thailandensis and 
B. pseudomallei S1PL proteins appear to be of bacterial origin, in contrast with 
the protozoan origin of Legionella LegS2. 
3.2.1.3 Characterisation of Burkholderia S1PL proteins  
The theoretical molecular weight (MW), subcellular location, signal peptides and 
transmembrane helices of B. pseudomallei and B. thailandensis S1PLs were 
predicted using the I-TASSER (Iterative Threading ASSEmbly Refinement) 
protein structure and function prediction software (Table 3.2). The predicted MWs 
of the mature proteins ranged in size from approximately 52 kDa to 55 kDa. 
Burkholderia S1PLs were predicted to be located in the cytoplasm of the bacterial 
cell, in contrast with LegS2 that has been predicted to be an extracellular protein 
and by experimental evidence shown to be secreted via Icm/Dot type IV secretion 
system (Degtyar et al., 2009). In addition, neither signal peptide nor 
transmembrane helices were found in the Burkholderia-encoded S1PLs. 
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Figure 3.2. Rooted S1PL phylogenetic tree. Phylogenetic tree was constructed based 
on the consensus sequences of S1PL homologous proteins. Sequences were aligned 
with MUSCLE (v3.8.31) configured for highest accuracy. After alignment, ambiguous 
regions (i.e. containing gaps and/or poorly aligned) were removed with Gblocks (v0.91b). 
The phylogenetic tree was reconstructed using the maximum likelihood method 
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implemented in the PhyML program. The protein sequence of Francisella novicida 
glutamate decarboxylase was used as outgroup. Blue section shows that the B. 
thailandensis and B. pseudomallei S1PLs form a distinct monophyletic group. Putative 
S1PLs identified in B. cenocepacia and B. gladioli do not cluster with the other 
Burkholderia S1PLs. Red and green sections indicate the closest matches from 
prokaryotic and eukaryotic S1PLs, respectively, relative to B. thailandensis and B. 
pseudomallei protein sequences. The scale bar indicates distance in substitutions per 
nucleotide. 
 
Table 3.2. Predicted mature molecular weights (MW); subcellular locations; signal 
peptides and transmembrane domains of putative S1PL from B. pseudomallei K96243, 
B. thailandensis E264 and Legionella pneumophila (LegS2) identified using I-TASSER 
platform. N.I. - not identified. 
Protein name 
Theoretical MW 
(kDa) 
Predicted 
subcellular 
location 
Signal peptide 
Transmembrane 
domain 
BPSS2021 54.3 Cytoplasm N.I. N.I. 
BPSS2025 55.7 Cytoplasm N.I. N.I. 
BTH_II0309 52.5 Cytoplasm N.I. N.I. 
BTH_II0311 52.1 Cytoplasm N.I. N.I. 
LegS2 66.5 Extracellular N.I N.I 
 
3.2.2 Functional and structural characterisation of Burkholderia 
thailandensis S1PLs  
Structural studies on S. cerevisiae and Symbiobacterium thermophilum 
sphingosine-1-phosphate lyase revealed that both proteins form homo-dimers or 
multiples of dimers. Moreover, in yeast it has been shown that the oligomerisation 
of Dpl1 is required for proper S1PL enzymatic activity in vivo. Comparable to both 
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studies, recombinant Burkholderia pseudomallei S1PLs (BPSS2021 and 
BPSS2025) expressed in E.coli purify as dimers (McLean et al., Unpublished 
data). However, in contrast with S. cerevisiae and Symbiobacterium 
thermophilum, Burkholderia strains encode two nearly identical S1PL-like 
proteins, which raises the intriguing question whether the two proteins form 
hetero-dimers when expressed by the bacteria and whether both are therefore 
required for optimal enzymatic activity. 
In addition to the enigmatic encoding of two S1PLs, the analysis of the predicted 
annotated genes sequences of Burkholderia S1PLs has revealed some 
uncertainty regarding the exact start of the protein. Within available annotated 
Burkholderia genomes (http://www.burkholderia.com), there is inconsistent 
annotation of the S1PLs with regards the predicted position of the N-terminus, 
namely for B. pseudomallei strains, whilst in B. thailandensis S1PLs are 
consistently predicted to start on MDLEEG sequence (Figure 3.3). Therefore, to 
address these important questions, a 6x His-tag coding sequence was integrated 
into the genome of B. thailandensis at the 3’ end of either the genes BTH_II0309 
or BTH_II0311, through homologous recombination (see section 2.6 for details). 
Next, each of the His-tagged S1PL was utilised in an anti-His pull-down and 
subsequent mass spectrometry in an attempt to determine whether pull-down of 
the His-tagged S1PL resulted in the copurification of the non-tagged S1PL, thus 
supporting the hypothesis that the two proteins form hetero-oligomers. 
Furthermore, depending on the peptide sequence coverage, this analysis may 
provide insight as to the actual N-terminus of the Burkholderia S1PLs.   
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Figure 3.3. Alignment of the N-terminal region of representative Burkholderia 
S1PLs. Alignment of the N-terminal region of selected Burkholderia orthologues drawn 
from the Burkholderia genome database (Winsor et al., 2008) reveal inconsistencies in 
the prediction of the N terminus. Sequences depicted: BPSS2021 and BPSS2025 (B. 
pseudomallei K96243), BTH_II0309 & BTH_II0311 (B. thailandensis E264), A2756 & 
A2761 (B. pseudomallei 1106a) and A2912 & A2918 (B. pseudomallei 668). Alignment 
generated using Vector NTI Advance 11 (Invitrogen), with blue, green and yellow 
shading indicating similarities (“conserved”, “block of similar”, and “identical” 
respectively). 
 
3.2.2.1 His-Tagged B. thailandensis S1PLs pull-down by affinity 
chromatography 
The B. thailandensis strains encoding a His-tag at the C-terminal end of each 
S1PL genes, BTH_II0309-6His and BTH_II0311-6His, were subjected 
individually to S1PL protein purification by column chromatography. Large scale 
protein purification was performed from a mid-log phase of 1 L bacteria cultures 
growth at 37ºC with agitation. The pellets from the bacterial cultures were 
harvested by centrifugation and cells disrupted by sonication. The proteins from 
the bacterial pellets were applied to a His-Selective Nickel affinity gel column and 
washed with equilibration buffer. His-tagged proteins bound to the column were 
eluted under native conditions using 500 mM imidazole elution buffer. Samples 
of the eluted protein were separated by NativePAGE gel electrophoresis and 
visualised by staining with coomassie blue and the presence of the target 
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recombinant protein assessed by Western-Blot, with anti-His antibodies (Figure 
3.4). Whilst each gene is predicted to encode a protein of approximately 52 kDa, 
herein native PAGE and respective Western-Blot analysis of purified His-tagged 
BTH_II0309 or BTH_II0311 revealed the presence of two prominent bands 
comprising sizes around ~300 kDa and ~150 kDa for each purified protein (Figure 
3.4, lanes 2 and 3, which are absent in the negative control (lane 1). This result 
suggests the formation of an oligomeric S1PL complex in native conditions, an 
observation consistent with the yeast S1PL orthologue (Dpl1) which is also 
oligomeric, occurring as a dimer or multiple of dimers (Mukhopadhyay et al., 
2008). Therefore, to investigate whether Burkholderia S1PLs form hetero-
oligomers, the target protein bands were excised from the gel and sent for mass 
spectrometry analysis in an attempt to detect whether both S1PLs peptide 
sequences were identifiable within each purified BTH_II0309-His or BTH_II0311-
His protein sample.  
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Figure 3.4. Purification of His-tagged BTH_II0309 and BTH_II0311 by column 
chromatography. (A) BTH_II0309 and BTH_II0311 proteins separated on 4-16% 
NativePAGE gel electrophoresis and stained with Simply Blue Stain (Invitrogen). 
(B) Western Blot: Proteins were transferred to a PVDF membrane and detect 
using anti-His polyclonal antibody (1:500 dilution). MW - Protein marker; Lane 1 
- Protein pellet of B. thailandensis E264 (negative control); Lane 2 - His-tagged 
BTH_II0309 and Lane 3 - His-tagged BTH_II0311. Red arrows indicate putative 
S1PL oligomeric complexes. kDa ladder shows the size of marker proteins. 
 
3.2.2.2 S1PLs peptide sequencing and putative hetero oligomerisation 
identification by LC-MS 
In order to provide further information whether S1PLs form hetero or homo-
oligomers and to depict the peptide sequence of the proteins and their initial start 
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codon, purified BTH_II0309 and BTH_II0311 proteins were analysed by mass 
spectrometry. The correspondent protein bands detected as S1PL-His by 
western blot were excised from the NativePAGE gel and sent for LC-MS analysis 
(University of Bristol, Mass Spectrometry Facility). Unfortunately, due to low 
purity, the results gathered from this analysis were inconclusive. Only for the 
bands designated as BTH_II0309 Top Band and Low Band (Figure 3.4-A; 
corresponding to upper and lower red arrow, lane 2) was possible to detect the 
predicted S1PL proteins, together with numerous non-specific proteins (Table 
3.3). Lastly, the identification of the N-terminal sequence of either BTH_II0309 or 
BTH_II0311 was hindered by the poor protein coverage and significant 
background (data not shown). Nevertheless, previous characterisation of 
recombinant Burkholderia pseudomallei S1PLs revealed that the proteins only 
bound the PLP co-factor and exhibited S1PL activity when cloned from the 
conserved MDLEEG sequence (McLean et al., Unpublished data), suggesting 
that it also might be the initial codon for B. pseudomallei S1PLs. Therefore, the 
conserved MDLEEG sequence was adopted as the N-terminal sequence for both 
S1PLs and used in subsequent cloning/complementation assays. 
 
Table 3.3. LC-MS analysis of His-tagged B. thailandensis BTH_II0309. * Position in the 
list based on the score of identified proteins. N.D. – not detected 
Sample Proteins Identified (n) BTH_II0309* BTH_II0311* 
BTH_II0309 
Top Band 
102 64/102 57/102 
BTH_II0309 
Low Band 
127 94/127 N.D. 
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3.2.2.3 Screening for putative B. thailandensis S1PLs hetero or homo-
oligomerisation by Bacterial Adenylate Cyclase Two-Hybrid System 
(BACTH) 
Given the inconclusive data regarding the oligomeric structure of B. thailandensis 
S1PLs following a mass spectrometry approach, a bacterial two-hybrid system    
based on adenylate cyclase (CyaA) reconstitution (Euromedex) was performed 
to identify putative BTH_II0309-BTH_II0311 interactions. The protein interaction 
specificity using BACTH was validated by means of negative and positive controls 
according to Karimova et al. (1998) and performed at both 30 and 37ºC. As 
expected, no spontaneous complementation between the two fragments could 
be detected, giving rise to colourless colonies (Figure 3.5, sections 1 and 3-6). 
As shown in Figure 3.5, bacterial cells co-transformed with T18::BTH_II0309 and 
T25::BTH_II0309, displayed red bacterial colonies on the MacConkey/maltose 
plate resultant from the functional complementation between the adenylate 
cyclase fragments, T18 and T25, indicating a positive BTH_II0309-BTH_II0309 
interaction. However, no interaction occurred when BTH_II0309 was co-
transformed with BTH_II0311 (either fused with T18 and T25 or T25 and T18, 
respectively; sections 9-10). In addition, co-transformation with both BTH_II0311 
plasmids did not show any positive interaction (Figure 3.5, section 8). Altogether, 
the bacterial two-hybrid system data suggests that BTH_II0309 protein is able to 
form homo-oligomers, whilst BTH_II0311 does not form oligomeric structures 
with either BTH_II0309 or BTH_II0311.   
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Figure 3.5. Putative B. thailandensis S1PLs protein-protein interaction assessed 
by Bacterial Adenylate Cyclase Two-Hybrid System. Either BTH_II0309 or 
BTH_II0311 were PCR amplified and cloned into pKT25 and pUT18C vectors in 
frame with the T25 and T18 adenylate cyclase fragments. The recombinant 
plasmids encoding the T25::BTH_II0309, T18::BTH_II0309, T25::BTH_II0311 
and T18::BTH_II0311 were co-transformed in pairs in all combinations possible 
into competent DHM1 reporter cells (E. coli strain deficient in endogenous 
adenylate cyclase) and the interaction of the target proteins was detected by 
plating 10 µl of overnight cultures of appropriate transformants onto 
MacConkey/maltose agar plates incubated either at 30ºC or 37ºC for 2 days. The 
formation of red colonies was considered positive for protein-protein interaction 
and if no interaction occurred the colonies were colourless. The result shown is 
representative of three independent experiments. 
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3.2.2.4 Burkholderia S1PLs are functionally equivalent to the eukaryotic 
S1PL 
The eukaryotic S1PL catalyses the irreversible degradation of S1P (Saba et al., 
1997). In yeast, the S1PL knock-out mutant (Δdpl1) is highly sensitive to D-
erythro-sphingosine due to its incapacity to degrade sphingosine that 
accumulates inside the cells and consequently causing growth arrest (Zhou and 
Saba, 1998).  Based on the sequence conservation between the Burkholderia 
S1PLs and Dpl1 (Figure 3.1), we predicted that BTH_II0309 and BTH_II0311 
would restore D-erythro-sphingosine resistance to a Δdpl1 S. cerevisiae mutant. 
Herein, we used a similar yeast system as described in Degtyar et al., 2009 to 
validate this hypothesis. The synthesised bacterial S1PL-encoding genes were 
codon optimised for yeast expression and cloned into a yeast expression plasmid 
under the control of a yeast GPD promoter. S. cerevisiae Δdpl1 strain was 
complemented either with BTH_II0309, BTH_II0311 or both BTH_II0309 and 
BTH_II0311, and the ability to revert the Δdpl1 yeast sphingosine-sensitive 
phenotype was assessed by plating the strains on minimal media supplemented 
with D-erythro-sphingosine. The result obtained with this experiment 
demonstrated that yeast transformants expressing either BTH_II0309 or 
BTH_II0311 partially restored sphingosine-resistance to yeast Δdpl1 strain, whilst 
the co-expression of both Burkholderia S1PLs fully restored the resistance to D-
erythro-sphingosine (Figure 3.6). To exclude any putative effect from gene 
dosage, we repeated the experiment with S. cerevisiae Δdpl1 complemented with 
two vectors both harbouring only BTH_II0309 
(Δdpl1+BTH_II0309+BTH_II03109) or BTH_II0311 
(Δdpl1+BTH_II0311+BTH_II0311), to replicate the same gene dosage as the 
Δdpl1+BTH_II0309+BTH_II0311 strain. We observed a relative increase in 
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resistance when either BTH_II0309 or  BTH_II0311 were expressed from  two 
distinct vectors, yet still did not fully restore the resistance to D-erythro-
sphingosine as seen for co-expression of both BTH_II0309 and BTH_II0311 
(data not shown). Taken together, in addition to confirming that the bacterial 
S1PLs are functionally equivalent to their well characterised eukaryotic 
orthologues, these observations also suggest that optimal S1PL enzymatic 
activity requires both Burkholderia proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wt+Vecto
r 
ΔDpl1+Vect
or 
ΔDpl1+ BTH_II0309 
ΔDpl1+ BTH_II0311 
 
ΔDpl1+BTH_II0309+BTH_II031
1 
ΔDpl1+ Dpl1 
YNB YNB + 10 µM Sphingosine 
Figure 3.6. The S1PLs of B. thailandensis functionally complement S1PL-deficient 
yeast. Burkholderia S1PLs codon-optimized for expression in yeast were synthesised and 
cloned into S1PL-deficient S. cerevisiae Δdpl1. Serial dilutions of transformants were 
spotted onto YNB agar ± 10 μM D-erythro-sphingosine. The results are representative of 
three independent experiments following 48-72 h incubation, and confirm that the 
Burkholderia proteins functionally complement the yeast mutant. 
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3.2.3 Initial characterisation of Burkholderia thailandensis S1PLs in vitro 
3.2.3.1 Insertional inactivation mutagenesis  
The B. thailandensis S1PL mutagenesis production strategy adopted in this study 
is outlined in figure 3.7. First, the pGPΩTp insertional inactivation construct 
containing either a BTH_II0309 or BTH_II0311 internal region was transformed 
into E. coli GT115. The mutagenesis plasmid was transferred by conjugation into 
wildtype B. thailandensis E264. The insertional inactivation plasmid integrated 
into the host chromosome within the target gene by homologous recombination, 
thus leading to gene disruption. Integrants were identified on selective media 
containing 50 μg/ml gentamicin and 100 μg/ml trimethoprim and confirmed by 
colony PCR (Figure 3.8). Owing to the genetic intractability of B. thailandensis, it 
was not possible to construct double mutants lacking both BTH_II0309 and 
BTH_II0311. 
 
Figure 3.7. Production of B. thailandensis S1PL insertional inactivation mutant 
using pGPΩTp vector.  A >500 bp internal region within BTH_II0309 and BTH_II0311 
was amplified by PCR (step 1) and cloned into pGPΩTp (step 2). Through homologous 
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recombination the mutagenesis plasmid integrated into the target gene, resulting in 
individual S1PL insertional inactivation (step 3). For more detail see section 2.5.1. 
 
 
Figure 3.8. PCR confirmation of B. thailandensis S1PL insertional inactivation 
mutants. Plasmid insertion was confirmed by PCR using the pGPΩTp specific RSF1300 
primer (Flannagan et al., 2007) with appropriate forward checking primer, specific for 
region upstream the targeted insertion site. Left PCR shows the confirmation of 
BTH_II0309 insertional inactivation, with an expected product of ~830 bp. Right PCR 
shows the confirmation of BTH_II0311 insertional inactivation, with an expected product 
of ~850 bp  Lanes 1-4 – putative BTH_II0309 mutants; Lanes 5-8 – putative BTH_II0311 
mutants; Wt – B. thailandensis E264 gDNA; N – negative control (water); M – DNA ladder 
marker Gene Ruler™ 1000 bp Plus (Invitrogen). 
 
3.2.3.2 Role of B. thailandensis S1PLs in response to defined stress 
conditions 
Previous transcriptional profiling in B. pseudomallei K96243 strain, conducted by 
Ooi et al. (2013), has revealed apparent co-ordinated transcription of both S1PLs 
in response to stresses, namely nutrient deprivation and growth in minimal media  
(Table 3.4) (Ooi et al., 2013). Although, the gene organisation displayed in the 
S1PL-encoding genomic region indicates that both S1PLs genes are not 
contained in an operon (Figure 3.9). To study the role of Burkholderia S1PLs in 
response to defined stress, we compared the growth of B. thailandensis wildtype 
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(Wt) with the insertional inactivation mutants of each S1PL (BTH_II0309 and 
BTH_II0311) in M9 minimal media supplemented with glucose. Our results 
revealed that both mutants displayed similar growth in minimal media relative to 
the wildtype strain (Figure 3.10).  
In addition, we assessed the bacteria survival following nutrient deprivation. After 
three independent experiments, we observed no difference between wild-type 
and S1PL mutant strains survival following 24 hours nutrient deprivation (Figure 
3.11). 
 
Table 3.4. The nutrient deprivation transcriptomic analysis was performed in distilled 
H2O after 24 h incubation and compared relative to LB incubation. Minimal medium 
(CDM, chemically-defined medium) was measured at mid-log phase in CDM, relative to 
mid-log phase in LB. Adapted from Ooi et al., 2013. 
Gene Nutrient Deprivation Minimal Media 
BPSS2021 
3.5-Fold 
Down-regulated 
5.0-Fold 
UP-regulated 
BPSS2025 
5.6-Fold 
Down-regulated 
4.0-Fold 
UP-regulated 
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Figure 3.9. S1PL-encoding genomic regions of B. pseudomallei K96243 and B. 
thailandensis E264.  Each organism possesses two S1PL-encoding genes (highlighted 
in black) located within the same genomic region. A high degree of synteny exists 
between the S1PL-encoding regions of each species. For ease of comparison, the B. 
thailandensis genomic region is depicted in reverse orientation. 
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Figure 3.9. The growth of B. thailandensis wildtype, BTH_II0309 and BTH_II0311 
mutants in M9 minimal media supplemented with 20 mM of glucose at 37°C with agitation 
(200 rpm). Growth was monitored over 26 hours by absorbance reading at 590 nm. The 
values are representative of an experiment done in triplicate.  
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Figure 3.10. Survival of B. thailandensis wildtype, BTH_II0309 and BTH_II0311 
mutants in sterile distilled water at 37°C.  After 24 hours incubation samples were 
removed and plated onto LB agar plates for viable bacteria enumeration. Values are the 
mean + SEM of three independent experiments. 
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3.2.3.3 Burkholderia S1PLs confer resistance to the antimicrobial 
sphingolipid, D-erythro-sphingosine 
Sphingolipids are described to possess antimicrobial activity for a variety of 
Gram-positive and Gram-negative bacteria (Fisher et al., 2012; Possemiers et 
al., 2005). To determine whether Burkholderia-encoded S1PLs play a role in 
sphingosine resistance, B. thailandensis wildtype, BTH_II0309 and BTH_II0311 
mutants were assessed for bacterial survival in a saline solution supplemented 
with D-erythro-sphingosine (sphingosine). Notably, B. thailandensis exhibited a 
higher level of resistance to D-erythro-sphingosine than representative bacterial 
species that do not encode predicted S1PLs (Figure 3.12). Furthermore, this 
relative resistance of B. thailandensis to D-erythro-sphingosine was at least in 
part conferred by BTH_II0309 and BTH_II0311 as both individual mutants 
exhibited increased sensitivity - a phenotype that was fully restored by 
complementation (Figure 3.13). 
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Figure 3.11. B. thailandensis exhibits higher D-erythro-sphingosine resistance 
compared to representative Gram-negative bacteria that lack predicted S1PLs. The 
strains B. thailandensis E264, E. coli K12 and B. multivorans ATCC 17616 were 
assessed for sphingosine susceptibility in a saline solution supplemented with 25 μM of 
D-erythro sphingosine. The percentage of bacterial survival is indicated relative to a 
saline control for each strain; mean +SEM of three independent experiments. *** p < 
0.0001. 
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Figure 3.12. The S1PLs of B. thailandensis confer resistance to D-erythro-
sphingosine. B. thailandensis strains (wild-type, BTH_II0309 & BTH_II0311 mutants, 
and respective complemented strains) were incubated with 25 μM D-erythro-sphingosine 
for 2 hours prior to enumerating viable CFU. Percentage survival for each strain is 
indicated relative to a saline control, confirming that both genes contribute to D-erythro-
sphingosine in B. thailandensis. Mean +SEM of three independent experiments. * p < 
0.05; ** p < 0.01; *** p < 0.0001. 
 
3.3 Discussion   
The success of various intracellular bacteria relies on the expression of 
orthologues of eukaryotic proteins that are capable of hijacking important cellular 
pathways, thus promoting pathogen survival and proliferation inside the host cells 
(Adler et al., 2009; Degtyar et al., 2009). Following a bioinformatic approach, 
S1PL orthologues were identified in B. thailandensis and B. pseudomallei. 
Interestingly, the Burkholderia S1PLs conserve the key residues for the S1PL 
enzymatic activity (Mukhopadhyay et al., 2008) and herein B. thailandensis 
S1PLs were shown to be functionally equivalent to eukaryotic S1PL. Given the 
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importance of S1P in controlling vital cellular and immune functions in humans 
(Hisano et al., 2012; Spiegel and Milstien, 2011; Rivera et al., 2008), it strongly 
suggests the potential role of Burkholderia-encoded S1PL in bacterial 
pathogenesis (see Chapter 4 and 5).  
 
B. thailandensis and B. pseudomallei do not appear to encode the other 
sphingolipid metabolising enzymes and both species S1PLs pyridoxal 5'-
phosphate-dependent decarboxylase domains are homologous to the eukaryotic 
S1PL. Hence, we investigated whether the Burkholderia S1PLs were acquired 
from a eukaryotic organism during evolution, as demonstrated for the Legionella 
LegS2 S1PL (Degtyar et al., 2009). In contrast with LegS2, the phylogenetic 
analysis of the S1PLs suggest that both B. thailandensis and B. pseudomallei 
proteins were likely acquired from bacterial species (Figure 3.2). Consistently, all 
the bacterial S1PLs that clustered together with the Burkholderia proteins are 
from soil-dwelling organisms, as are B. thailandensis and B. pseudomallei. This 
observation suggests that throughout Burkholderia evolution a genetic exchange 
may have occurred within the microbial community in the soil, therefore allowing 
the acquisition of a S1PL gene. 
 
Previous functional and structural studies of S1PL orthologues from other species 
(notably of yeast and the bacterial species, Symbiobacterium thermophilum) 
(Bourquin et al., 2010) provide us with valuable clues as to the structure and 
catalytic activity of the Burkholderia proteins. However, several questions remain 
to be answered, particularly relating to protein oligomeric state and the N-terminal 
leading sequence. To our knowledge, there are no other instances of organisms 
possessing two distinct S1PL-encoding genes, as is evident in B. thailandensis 
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and B. pseudomallei. The high amino acid sequence homology between 
BTH_II0309 and BTH_II0311 or BPSS2021 and BPSS2025 suggests that they 
may present equivalent enzymatic function. Phenotypically, the two S1PL-
deficient mutants described in this Chapter are indistinguishable. These 
observations strongly suggest that a gene duplication event may have occurred 
throughout Burkholderia evolutionary process. In addition, neither gene lost the 
function or disappeared from the genome, which corroborates with the hypothesis 
that retained paralogs possibly represents a competitive advantage to the 
bacteria (Bratlie et al., 2010). In this particular situation, the conserved S1PL 
paralog has likely been crucial for the adaptation of Burkholderia to new harsh 
environments, such as the one encountered in mammalian hosts, where a higher 
S1PL gene dosage may be required for survival (Bratlie et al., 2010).  
 
Whilst each of the B. thailandensis S1PL proteins possess enzymatic activity 
individually, the higher degree of sphingosine resistance conferred by co-
expression of BTH_II0309 and BTH_II0311 in S. cerevisiae Δdpl1 suggests that 
a hetero-oligomer may be required for optimal enzymatic activity. Such a scenario 
would explain why each of the individual mutants characterised herein display a 
comparable phenotype, as each would disrupt the hetero-oligomer. If that were 
the case, the single inactivation mutants that we constructed and initiated the 
phenotypic characterisation would represent the “full” phenotype of Burkholderia 
S1PLs. Consequently, to confirm that hypothesis the ideal approach to follow 
would be the construction of a double S1PL-deletion mutant and characterise 
phenotypically. However, after repeated attempts to produce a B. thailandensis 
double S1PLs mutant, using different mutagenesis systems based either on the 
homing endonuclease I-SceI (Flannagan et al., 2008) or on the sacB counter-
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selection (Logue et al., 2009), we were unable to make  individual or double S1PL 
unmarked deletion mutants. Both mutagenesis systems rely on the expression of 
either I-SceI or sacB to promote the second recombination event and the 
respective target gene deletion, therefore one can speculate that due to the non-
Burkholderia origin of the promotors present in both pDAI-Sce I and pDM4 
plasmids can lead to a lack of an adequate expression of those proteins in B. 
thailandensis, which may explain the failure of getting the second cross-over. 
Subsequent studies using the more genetically-tractable B. pseudomallei 
enabled the construction of single and double mutants, allowing the relative role 
of the two S1PLs to be investigated (see Chapter 5).  
 
Additionally, in order to address whether BTH_II0309 and BTH_II0311 form homo 
or hetero-oligomers, the co-precipitation of one S1PL following anti-His pull-down 
of the other was investigated by peptide sequencing via LC-MS. This way the 
presence of peptide sequences belonging to both S1PLs would confirm a positive 
interaction between BTH_II0309 and BTH_II0311 and the putative formation of 
hetero-oligomers. In the course of S1PL purification by column chromatography, 
we were only able to purify the recombinant proteins on native conditions and 
subsequent native PAGE gel staining revealed protein bands with MW markedly 
above the ones expected for B. thailandensis S1PLs. Interestingly, it has been 
shown that yeast S1PL can form oligomers and that the enzymatic function in 
vivo is dependent on its oligomeric state (Mukhopadhyay et al., 2008). 
Furthermore, a study carried out by McLean and colleagues has demonstrated 
that both BPSS2021 and BPSS2025 purify as homo-dimers when expressed in 
E. coli using size exclusion chromatography (McLean et al., personal 
communication). Therefore, consistent with the native PAGE data (Figure 3.4), 
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our results suggest that Burkholderia S1PLs may appear as oligomeric proteins 
as described in yeast. Unfortunately, given the lack of specificity we were unable 
to confirm whether they form homo or hetero-oligomers.  
 
As an alternative to LC-MS analysis, a bacterial two-hybrid system was used to 
detect and characterise putative BTH_II0309-BTH_II0311 interactions in vivo. 
Observations from the BACTH system assay suggest that BTH_II0309 is able to 
form homo-oligomers, whereas neither BTH_II0311-BTH_II0309 nor 
BTH_II0311-BTH_II0311 interactions were detected. Given the high degree of 
homology between BTH_II0309 and BTH_II0311, we were anticipating 
comparable phenotypes with regards to protein interaction. In addition, the lack 
of BTH_II0311-BTH_II0311 interaction is inconsistent with the fact that the 
recombinant S1PL proteins purify as homodimers from E. coli (McLean et al, 
unpublished data). This lack of interaction could be due to unexpected proteolytic 
degradation of the proteins or to the instability of chimeric proteins upon 
interaction in E. coli, thus resulting in deficient functional complementation of the 
adenylate cyclase.  
Whilst we have observed oligomeric Burkholderia S1PLs and putative homo-
oligomerisation of BTH_II0309, due to inconsistent data we have been unable to 
determine whether Burkholderia S1PL can appear as hetero-oligomeric proteins. 
Therefore, the reason why Burkholderia encodes two distinct S1PL genes 
remains open to discussion and further biochemical characterisation of the 
proteins would be necessary to address that question. 
 
Sphingolipids have been described to play an important role as innate 
immunologic barrier, thus protecting the oral mucosa and human skin from 
105 
 
bacterial colonisation (Fisher et al., 2013a; Possemiers et al., 2005; Arikawa et 
al., 2002; Bibel et al., 1992). Recent studies have finally unravelled the 
bactericidal mechanism of sphingolipids (D-erythro-sphingosine, 
dihydrosphingosine, and phytosphingosine), confirming to be via direct damage 
of bacterial membranes (Fisher et al., 2013a; Fisher et al., 2013b). Herein, our 
results showed that Burkholderia S1PLs are responsible for conferring resistance 
to D-erythro-sphingosine. How the bacteria avoids the damage of the bacterial 
membrane is still unclear, but we can speculate that the putative secretion or the 
surface-exposed Burkholderia S1PLs may protect the membranes from the 
bactericidal effect of sphingosine via the depletion of sphingosine surrounding the 
bacteria. However, this observation raises intriguing questions as the only 
function described for a eukaryotic S1PL is to promote S1P degradation (Aguilar 
and Saba, 2012; Bourquin et al., 2011). Consequently, the mechanism by which 
the Burkholderia-encoded S1PLs putatively catabolise D-erythro-sphingosine 
remains unclear. Additionally, a correlation has been described between low 
levels of sphingosine and increased Staphylococcus aureus skin colonisation 
(Arikawa et al., 2002). Interestingly, one of the main routes of infection by 
Burkholderia pseudomallei is via percutaneous inoculation (Barnes and 
Ketheesan, 2005). Thus, it is tempting to speculate whether Burkholderia-
encoding S1PLs represent a bacterial adaptation to resist the skin’s innate 
immunity, while contributing to the subcutaneous infection.  
 
In conclusion, following a bioinformatic approach we identified two distinct S1PLs 
homologues from B. thailandensis and B. pseudomallei. Remarkably, the 
Burkholderia S1PLs conserve the key residues for the anticipated S1PL 
enzymatic activity. Initial characterisation of S1PLs in B. thailandensis revealed 
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that Burkholderia-encoded S1PLs may adopt an oligomeric structure in a similar 
fashion as the S. cerevisiae S1PL, yet whether they form hetero-oligomers 
remain unclear. In addition, we confirmed that Burkholderia S1PLs are 
functionally equivalent to the eukaryotic S1PL, with both proteins being required 
for optimal enzymatic activity. Moreover, bacterial S1PLs play a role in conferring 
resistance to antimicrobial sphingosine. Further characterisation of B. 
thailandensis and B. pseudomallei S1PLs, and their role in pathogenesis, will be 
investigated in the following chapters (see Chapters 4 and 5). 
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Chapter 4 – Role of Burkholderia 
thailandensis S1PLs in pathogenesis 
 
4.1 Introduction  
In the course of our studies, we observed that B. pseudomallei and B. 
thailandensis genomes encode two distinct sphingosine-1-phosphate lyases 
(S1PLs) and are functionally equivalent to eukaryotic S1PL (Chapter 3). The well-
characterized eukaryotic S1PL orthologues are responsible for the irreversible 
degradation of sphingosine-1-phosphate (S1P), a bioactive sphingolipid that 
regulates diverse cellular processes, including lymphocyte trafficking, vascular 
epithelial and endothelial permeability, cytokine and chemokine production, and 
modulation of macrophage innate immune responses (Spiegel and Milstien, 
2011; Weigert et al., 2009). In common with the majority of prokaryotes, 
Burkholderia species do not synthesize sphingolipids, nor do they appear to 
possess other components of sphingolipid metabolism. We thus hypothesized 
that these Burkholderia-encoded S1PLs play a role in infection by disrupting the 
host cell S1P signalling pathways pertaining to immune function. 
 
Herein, Burkholderia thailandensis was used as a model for B. pseudomallei. B. 
thailandensis has extensive chromosomal synteny with B. pseudomallei, and 
whilst it is highly attenuated or avirulent relative to B. pseudomallei, it displays a 
similar intracellular phenotype with endosomal escape, intracellular replication 
and actin-based motility (Wand et al., 2011). As such, B. thailandensis is a 
valuable model for studying the intracellular lifestyle of B. pseudomallei. 
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In the present chapter, we report that both B. thailandensis S1PL orthologues 
play a role in pathogenesis, particularly in relation to intracellular survival within 
macrophages. Herein, we showed that both S1PLs are secreted in a pH-
dependent manner and can be observed during intracellular infection. Moreover, 
the impact of B. thailandensis infection on the host S1P levels was investigated 
by ELISA. Furthermore, both S1PLs are required for full virulence in Galleria 
mellonella infection model. Taken together, the results reported in this chapter 
establish a role for Burkholderia S1PLs in pathogenesis. 
 
4.2 Results  
4.2.1 Characterisation of S1PLs secretion in B. thailandensis  
4.2.1.1 Secretion of B. thailandensis S1PLs is pH-dependent 
The secretion of virulence determinants is a fundamental aspect of B. 
pseudomallei and B. thailandensis ability to survive and proliferate intracellularly, 
since it contributes to the manipulation of host cell functions (Gutierrez et al., 
2015; Allwood et al., 2011). To assess whether the Burkholderia S1PLs are 
secreted, we generated B. thailandensis strains constitutively expressing FLAG-
tagged BTH_II0309 or BTH_II0311, enabling detection of FLAG-tagged proteins 
in cell pellets and culture supernatants by anti-FLAG immunoblotting. Both of the 
FLAG-tagged S1PLs were detected in whole-cell lysates from bacteria grown in 
LB medium, irrespective of the pH (Figure 4.1). However, the S1PLs were only 
detected in the culture supernatants when bacteria were grown at pH 4.5. To 
exclude the possibility of S1PL secretion being an artefact arising from their 
constitutive overexpression whilst under acid-related stress, we confirmed that a 
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non-secreted protein (GFP) when expressed in B. thailandensis under the same 
conditions was not detectable in culture supernatant by Western blot analysis 
(Figure 4.2). Together, these results support the pH-dependent secretion of the 
B. thailandensis S1PLs. 
 
 
 
Figure 4.1. Secretion of B. thailandensis S1PLs is pH-dependent. Wildtype B. 
thailandensis and B. thailandensis constitutively expressing FLAG-tagged BTH_II0309 
or BTH_II0311 were cultured at pH 7 or pH 4.5. Proteins from whole-cell lysates and 
culture supernatants (8 μg of total protein loaded per lane) were separated by 4-12% 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with anti-FLAG 
antibody. The S1PL proteins were only detected in culture supernatant from B. 
thailandensis cultured at pH 4.5. No anti-FLAG reactivity was observed for the wildtype 
B. thailandensis, thus excluding cross-reactivity with endogenous proteins. 
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Figure 4.2. Constitutively-expressed GFP protein is only detectable in bacterial 
lysates. Proteins from whole-cell lysates and culture supernatant (8 μg of total protein 
loaded per lane) of B. thailandensis expressing pDA17::GFP grown in LB pH 7 or pH 4.5 
were separated by 4-12% SDS-PAGE, transferred to a nitrocellulose membrane and 
probed with anti-GFP antibody. Irrespective of the pH, GFP was only detected in lysates 
from cell pellets. 
 
4.2.1.2 Burkholderia-encoded S1PLs are not secreted via Bsa Type III 
secretion system 
A critical virulence factor of B. pseudomallei and B. thailandensis is the Bsa Type 
III secretion system that facilitates escape from endocytic vacuoles and 
intracellular survival (Stevens et al., 2002). In B. thailandensis, the activity of the 
orthologous system is stimulated by acidic pH (Jitprasutwit et al., 2010). To 
assess whether the pH-dependent secretion of the Burkholderia S1PLs is 
facilitated by the Bsa system, we inactivated bsaZ (BTH_II0839), a structural 
component of the Bsa secretion apparatus (Stevens et al., 2002). Secretion of 
the known T3SS effector BopE was not detected when the resulting Bsa-deficient 
mutant was cultured at acidic pH, confirming that the Bsa system was functionally 
inactive (Figure 4.3 (A)). In contrast, the pH-dependent secretion of BTH_II0309 
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and BTH_II0311 was still evident (Figure 4.3 (B)), indicating that they are not 
secreted via the Bsa system. 
 
 
 
Figure 4.3. The pH-dependent secretion of the Burkholderia S1PLs is independent 
of the Bsa type III secretion system. (A) B. thailandensis Bsa T3SS mutant was 
constructed by insertional inactivation of bsaZ (BTH_II0839) in order to assess the 
impact on the acid induced S1PL secretion. (A) When cultured at pH 4.5, secretion of 
the known T3SS effector BopE was abolished in the bsaZ mutant (BTH839), confirming 
the inactivation of the Bsa secretion system. (B) FLAG-tagged BTH_II0309 or 
BTH_II0311 were expressed in the bsaZ mutant cultured at pH 4.5. Secretion of both 
proteins was still detected, despite the inactivation of the Bsa system. 
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4.2.1.3 B. thailandensis S1PLs are secreted during intracellular infection 
Eukaryotic S1PL is predominantly localised to the endoplasmic reticulum (ER) 
membrane where the S1P substrate is abundant (Ikeda et al., 2004).To assess 
whether the Burkholderia proteins similarly target the host ER, we infected 
macrophages with the FLAG-tagged S1PL-expressing strains described above 
and assessed the localisation of the FLAG-tagged proteins 2 hours post infection 
(hpi). Although the strains constitutively express the S1PLs, different patterns of 
anti-FLAG reactivity were evident (Figure 4.4), consistent with secretion being 
influenced by environmental stimuli. In some infected macrophages, the FLAG-
tagged S1PLs were entirely restricted to the bacterial cells themselves, indicative 
of non-secretion. In contrast, other infected macrophages exhibited diffuse anti-
FLAG reactivity indicative of S1PL secretion, though we did not detect clear 
colocalisation with host ER. Both BTH_II0309-FLAG and BTH_II0311-FLAG 
strains showed similar secretion phenotypes.  
Secretion of the S1PL orthologue of Legionella pneumophila (LegS2) has been 
observed intracellularly during infection of host cells (Degtyar et al., 2009). 
Degtyar and colleagues (2009) reported that LegS2 targets the host 
mitochondria, whereas in a more recent study the authors observed that in 
eukaryotic cells transfected with LegS2, the protein localises with the 
endoplasmic reticulum (Rolando et al., 2016). Therefore, attempts to define 
whether Burkholderia-secreted S1PLs target the host mitochondria or the 
endoplasmic reticulum were carried out. Once more, we could not detect a clear 
localisation with the host cell compartment (Figure 4.5 (A)). Lastly, as shown in 
Figure 4.5 (B), the S1PL colocalisation assay to determine whether the proteins 
target the host cell cytoplasm failed to detect a clear colocalisation. Altogether, 
whilst these results indicate that B. thailandensis S1PL secretion occurs during 
113 
 
intracellular infection, attempts to define the targeting of secreted S1PLs within 
infected macrophages were inconclusive, as the proteins showed only limited 
colocalisation with each of the cellular compartments studied (endoplasmic 
reticulum, mitochondria, and cytoplasm; Figures 4.4 and 4.5, panels A, B and C).  
 
 
Figure 4.4. Secretion of B. thailandensis S1PLs can be observed during 
intracellular infection. J774A.1 cells were infected with B. thailandensis expressing 
BTH_II0309-FLAG or BTH_II0311-FLAG (MOI 50). The macrophage endoplasmic 
reticulum was stained with rabbit anti-Calnexin and goat anti-rabbit IgG-Alexa 594. 
S1PL-FLAG proteins were stained with mouse anti-FLAG and goat anti-mouse IgG-
Alexa 488 and cell nuclei were stained with DAPI. Middle panels show FLAG-tagged 
S1PL detection restricted to bacterial cells, whilst bottom panels show staining indicative 
of S1PL secretion. Right insets represent magnified images of boxed areas. White 
arrows indicate intracellular bacteria, whilst the arrow head indicates secreted S1PL. 
Scale bar represents 10 µ
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Figure 4.5. Investigating the localization of secreted B. thailandensis S1PLs during 
macrophage infection. J774A.1 cells were infected (MOI 50, 2 hours) with B. 
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thailandensis expressing either BTH_II0309-FLAG or BTH_II0311-FLAG. Following 
killing of extracellular bacteria with kanamycin (1000 μg/mL, 2 hours), staining of cellular 
compartments and anti-FLAG detection was performed. (A) Mitochondria were stained 
with MitoTracker Red-CMXRos. (B) The cytosolic compartment stained with anti-
MEK1/2. The B. thailandensis S1PL-FLAG proteins were detected with anti-FLAG. (C) 
For colocalization presentation clarity, images were convoluted and processed with the 
(default) threshold algorithm of the Fiji software (Schindelin et al., 2012). Common to 
panels A-C, no FLAG reactivity was detected in macrophages infected with wildtype B. 
thailandensis (not shown). Colocalization is shown in yellow. Scale bars represent 10 
μm. 
 
4.2.2 Role of B. thailandensis S1PLs in virulence 
4.2.2.1 The S1PLs of B. thailandensis are required for full virulence in 
Galleria mellonella 
Due to the high degree of functional homology between the innate immune 
system of insects and mammals, numerous studies have successfully applied the 
Galleria mellonella infection model to assess bacterial virulence. With particular 
relevance to the studies described herein, the Galleria model has been validated 
for several Burkholderia species, including B. thailandensis (Wand et al., 2011). 
In order to determine the role of B. thailandensis S1PLs in virulence, G. mellonella 
larvae were challenged with approximately 25 CFU of the relevant B. 
thailandensis strains and larval survival assessed at 40 hpi. As shown in figure 
4.6 (A), larvae infected with the BTH_II0309 or BTH_II0311 mutants typically 
exhibited 50-60% survival at 40 hpi compared to approx. 10% survival for those 
infected with wildtype (p < 0.005). Complementation of both mutants fully restored 
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larval killing to wildtype levels (Figure 4.6, panels B and C). Thus the B. 
thailandensis S1PLs are required for full virulence in G. mellonella. 
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Figure 4.6. B. thailandensis S1PLs are required for virulence in the Galleria 
mellonella infection model. Groups of 10 larvae were injected with approx. 25 CFU of 
bacteria and percentage larval survival determined at 40 hpi. For each independent 
experiment, multiple inoculations were performed for each strain and exact CFU counts 
for each inoculum were determined to ensure comparisons between strains were robust 
(as minor variation from the intended 25 CFU inoculum impacted on larval survival).  (A) 
Comparison of wildtype and individual BTH_II0309 and BTH_II0311 mutants. Results 
represent the mean +SEM of three independent experiments. ** p < 0.005. (B-C) When 
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including the complemented strains, the BTH_II0309 and BTH_II0311 strains were 
studied independently from each other, so as to accommodate the multiple inoculations 
per strain. This is reflected in the differing larval survival observed between panels B and 
C, which show mean +SEM of two independent experiments. * p < 0.05. When studied 
alongside each other, there is no difference between the two mutants (panel A). 
 
4.2.2.2 B. thailandensis S1PLs do not play a role in the invasion or 
intracellular survival in A549 epithelial cells  
To determine whether S1PL inactivation affects the ability of B. thailandensis to 
invade and initiate intracellular growth in epithelial cells, we infected A549 cells 
with B. thailandensis E264, BTH_II0309 and BTH_II0311 inactivation mutants, at 
a MOI of 50. After 2 hours incubation to allow the bacterial invasion, the remaining 
extracellular bacteria were killed with antibiotic for 2 hours. After the enumeration 
of the viable bacteria at 2 and 6 hpi, the results showed no significant defect in 
the S1PLs mutants to invade or survive within A549 cells, relative to the wildtype 
strain (Figure 4.7). 
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Figure 4.7. Invasion and net intracellular replication of B. thailandensis BTH_II0309 
and BTH_II0311 mutants in A549 epithelial cells. Cells incubated with bacteria for 2 
hours at a MOI of 50. Extracellular bacteria were killed with 1 mg/ml kanamycin for 2 
hours and intracellular bacteria determined at 2 and 6 hpi. Percentage values are relative 
to input inoculum. Results are the mean +SEM of three independent experiments. 
 
4.2.2.3 Inactivation of B. thailandensis S1PLs results in impaired 
intracellular replication in macrophages 
Given the documented role of S1P in immune cell activation during microbial 
infections (Arish et al., 2015), we assessed whether the S1PLs of B. thailandensis 
contributed to intracellular survival in phagocytic cells. Murine macrophages were 
infected with wildtype or S1PL-deficient B. thailandensis and intracellular 
replication was assessed between 2 and 6 hpi. As shown in Figure 4.8, wildtype 
B. thailandensis exhibited significant intracellular growth between the 2 and 6 
hour time points. In contrast, the two S1PL-deficient mutants showed no growth 
over the same period, with the number of viable bacteria significantly reduced 
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relative to the wildtype by 6 hpi. This attenuated intracellular phenotype indicates 
that the S1PLs of B. thailandensis play a role in intracellular replication.  
 
Figure 4.8. S1PL-deficient B. thailandensis exhibits reduced intracellular 
replication in macrophages. J774A.1 macrophages were infected with B. thailandensis 
wildtype and S1PL mutants (MOI 10). Viable intracellular bacteria were quantified at 2 
and 6 hpi by spotting serial dilutions of macrophage lysates. For each strain, bacterial 
survival was normalised to the CFU counts observed at 2 hpi and presented as relative 
bacterial survival (%) so as to visualise intracellular replication between 2 and 6 hpi. Data 
represent the mean +SEM of three independent experiments. *, p<0.01 and **, p<0.001. 
 
4.2.2.4 Inactivation of B. thailandensis’ S1PLs increases the bacteria co-
localisation with LAMP-1-containing phagosomes 
To determine whether the S1PL mutants’ survival deficiency in macrophages was 
due to impaired ability in escaping from the phagosomes, localisation of RFP-
expressing B. thailandensis strains with the lysosomal marker LAMP-1 was 
assessed by immunofluorescence microscopy (Figure 4.9 (A)). LAMP-1, which is 
required for fusion of lysosomes with phagosomes (Huynh et al., 2007), is 
recruited during the late stage of phagosome maturation. Colocalisation of 
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bacteria with LAMP-1 therefore indicates bacteria that have failed to escape into 
the cytosol and remain within the maturing phagosomes. 
As shown in Figure 4.9 (B), the percentage of wildtype bacteria associated with 
LAMP-1 was only 17% and 13% at 2 and 6 hpi, respectively, suggesting that the 
wildtype strain was rarely confined within late phagosomes at indicated time 
points. In contrast, the inactivation of B. thailandensis’ S1PLs resulted in more 
than 50% of bacteria co-localised with LAMP-1-containing phagosomes at the 
same time points (Figure 4.9-B). The data presented here suggest that the 
bacterial intracellular survival defect described above is due to inefficient 
phagosomal escape.  
 
4.2.3 Impact of Burkholderia thailandensis S1PLs on host cells 
4.2.3.1 Cellular damage in macrophages 
Monitoring the integrity of the mammalian host cell membrane is commonly used 
as an indicator of virulence in bacteria. The cellular damage in host cells can be 
measured by the disruption of the plasma membrane and respective release of 
lactate dehydrogenase (LDH) from dead or dying cells (Wand et al., 2011). 
In order to further investigate the role of B. thailandensis S1PLs in virulence and 
impact on the host cells, we determined the LDH release using the CytoTox96 kit 
(Promega) in infected J774A.1 macrophages. Briefly, the cells were challenged 
with B. thailandensis wildtype and S1PL-inactivation mutants and the supernatant 
recovered at different time point after infection. At 12 hours infection the levels of 
LDH were kept low and comparable to the uninfected cells (Figure 4.10). After 24 
hours infection we observed a slight increase (not significant; p>0.05) in the LDH 
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levels, but there is no difference between the S1PL-deficent mutants and wildtype 
strain (Figure 4.10).  
A 
 
B 
 
Figure 4.9. S1PL-deficient B. thailandensis show increased co-localisation with 
LAMP-1-containing vesicles in macrophages. (A) Representative micrographs 
showing the LAMP-1 association of intracellular RFP-expressing B. thailandensis 
wildtype, BTH_II0309 and BTH_II0311 mutant strains in J77A.1 cells. Following killing of 
extracellular bacteria, infected macrophages were stained with rabbit anti-LAMP-1 and 
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goat anti-rabbit IgG-Alexa 488 and nuclei stained with DAPI. Right insets represent 
magnified images of boxed areas and the yellow arrows indicate bacterial colocalisation 
with LAMP-1. Scale bar represents 10 µm. (B) Quantitative analysis of bacterial 
colocalisation with LAMP-1. For each independent experiment, positive or negative 
colocalisation was assessed for 100 intracellular bacteria per strain to achieve a 
percentage colocalisation. Data represent the mean +SEM of three independent 
experiments. ***, p<0.0001. 
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Figure 4.10. Detection of LDH release in J774A.1 macrophages infected with B. 
thailandensis BTH_II0309 and BTH_II0311 mutants. Cells incubated with bacteria for 
30 min at a MOI of 1. Extracellular bacteria were killed with 1 mg/ml kanamycin for 1 
hour and the supernatants recovered at 12 and 24 hours post extracellular killing. Cell 
damage was determined using the LDH release assay and calculated via the equation: 
(OD490 infected cells-OD490 uninfected cells). Each value represents the mean +SEM of 
three independent experiments. 
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4.2.3.2 Impact of B. thailandensis infection on macrophages S1P levels  
Given the function of S1PL in degrading S1P, together with the observation that 
B. thailandensis encode two functional S1PLs secreted intracellularly during 
macrophages infection, we sought to determine whether B. thailandensis 
infection significantly alters the S1P levels in the host cells. Murine macrophages 
were infected with either B. thailandensis wildtype or S1PL-deficient mutants for 
2 and 6 hours (MOI 10) and 24 hours (MOI 1), with the host S1P levels monitored 
using a competitive S1P ELISA kit (Echelon Biosciences). As shown in Figure 
4.11 (A), both in macrophages infected with wildtype or S1PL-deficient mutants 
no differences were detected in the S1P levels in comparison with non-infected 
cells at either 2 or 6 hpi.  Moreover, the S1P levels of B. thailandensis-infected 
macrophages remained unaffected between 2 and 6 hpi. Nevertheless, 
BTH_II0311-infected cells presented lower S1P levels relative to wildtype B. 
thailandensis at 6 hpi. To enable a 24 h infection without jeopardising host cell 
viability, macrophages were infected with B. thailandensis strains at a MOI of 1. 
As shown in Figure 4.11 (B), at 24 h infection Burkholderia-infected macrophages 
exhibited higher levels of S1P relative to non-infected cells, though only the 
wildtype strain presented a significant difference. 
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Figure 4.11. Investigating the impact of B. thailandensis infection on the host S1P 
levels. (A) J77A.1 cells were infected with B. thailandensis strains (MOI 10) or left 
uninfected for 2 and 6 hpi. (B) J77A.1 cells were infected with B. thailandensis strains 
(MOI 1) or left uninfected for 24 hpi. Macrophages were lysed in 400 µl of lysis buffer 
with 1X Protease inhibitor cocktail without EDTA (Invitrogen). Protein concentration was 
measured and lysates samples were added at 75 μg protein/well to the Echelon S1P 
ELISA plate and the absorbance determined at 450 nm using a microplate reader. Each 
value represents the mean +SEM of three independent experiments. *, p<0.05.  
 
125 
 
4.3 Discussion  
Through the characterisation of the Burkholderia-encoded S1PLs, this Chapter 
establishes that S1PL contributes directly to virulence, and adds to our 
knowledge of Burkholderia intracellular survival strategies. Amongst the diverse 
cellular processes regulated by S1P is phagosome maturation. In the context of 
macrophage activity, S1P triggers an increase in cytosolic Ca2+ (Blom et al., 
2005), which plays a critical role in endosome-endosome and phagosome-
lysosome fusion (Colombo et al., 1997). Furthermore, S1P stimulates actin 
assembly (Kuehnel et al., 2009; Treede et al., 2007), a process that can influence 
both particle ingestion and subsequent phagosome-lysosome fusion. Data 
presented herein are consistent with the Burkholderia-encoded S1PLs disrupting 
endogenous S1P signalling pathways, thus impairing the process of phagosome 
maturation and promoting intracellular survival. We propose this mechanism acts 
in concert with documented Burkholderia intracellular survival strategies, 
including the Bsa Type III secretion system that facilitates escape from endocytic 
vacuoles (Stevens et al., 2002). Whilst our data suggest that the Burkholderia 
S1PLs are not effectors of the Bsa system, S1PL secretion is similarly regulated 
in a pH-dependent manner and can be observed during macrophage infection.  
 
The targeting of the Burkholderia S1PLs following their secretion within the 
infected host cell remains enigmatic. Eukaryotic S1PL is predominantly localised 
to the endoplasmic reticulum (ER) membrane (Ikeda et al., 2004) where the S1P 
substrate is found in high abundance, whilst the previously described L. 
pneumophila orthologue appears targeted to the host cell mitochondria (Degtyar 
et al., 2009) and the endoplasmic reticulum (Rolando et al., 2016). The 
Burkholderia S1PLs do not show conclusive localisation to either of these cellular 
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compartments (Figures 4.4 and 4.5), nor does their sequence provide any clues 
as to their intracellular targeting. It should be stressed that the biosynthesis of 
S1P is very dynamic – both temporally and spatially. For example, whilst 
sphingosine kinase 1 (SphK1) is primarily a cytosolic protein in unstimulated cells, 
it rapidly translocates to the plasma membrane, intracellular organelles (including 
the phagosome; Thompson et al., 2005) and cytoskeleton in response to diverse 
cellular stimuli (Siow and Wattenberg, 2011). SphK1 translocation is very rapid, 
with a half-time of 3-5 seconds. Consequently, high resolution mapping of the 
temporal and spatial secretion of Burkholderia S1PLs during infection of host cells 
will be fundamental to providing mechanistic insight into their precise role in 
pathogenesis and host S1P pathway disruption. 
 
This highly dynamic nature of S1P biosynthesis may also explain why we have 
not detected significant changes in the S1P levels during infection. Intriguingly, 
Burkholderia infection did not alter the S1P levels relative to uninfected cells at 2 
and 6 hpi (Figure 4.11 (A)). Whilst S1P is abundant in blood (where it is produced 
by erythrocytes; Pappu et al., 2007), S1P levels in most tissues are kept low by 
endogenous S1PL or S1P phosphatase activities and the cellular processes 
controlled by S1P are tightly regulated in a spatial-temporal manner (Spiegel and 
Milstien 2011; Le Stunff et al., 2002). Thus, measuring changes in S1P levels is 
a difficult task, particularly in cells undergoing different metabolic stages. The lack 
of synchronisation during macrophages infection could explain our results, as the 
cell lysates loaded in the S1P ELISA would include a pool of both uninfected cells 
and cells at different stages of infection, thus diminishing the detection of a 
putative S1P disruption induced by infection. Lastly, S1P ELISA also displays 
cross reactivity towards sphingosylphosphorylcholine (SPC) (O´Brien et al., 
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2009). SPC is a lipid structurally and functionally distinct from S1P yet is widely 
present in eukaryotic organisms (Nixon et al., 2008; Desai et al., 1993), thus its 
putative detection during our assays may hinder the determination of the actual 
intracellular concentration of host S1P during infection. Consequently, alternative 
methods based on Liquid chromatography coupled to tandem mass spectrometry 
should be considered in future studies, since it offers a more sensitive and robust 
detection of specific sphingolipids (Bode and Gräler 2012), hence providing a 
more accurate measure of intracellular S1P in macrophages.  
 
Whilst this is the second report of a virulence-associated bacterial-encoded 
S1PL, our study adds to reports of bacteria sensing and/or modulating the S1P 
pathway via distinct mechanisms. The S1PL orthologue of L. pneumophila 
(LegS2) has been identified as a type IV secretion system effector that is targeted 
to host cell mitochondria and/or ER and is required for efficient infection in a mice 
model and to inhibit the autophagy response during macrophages infection 
(Rolando et al., 2016, Degtyar et al., 2009). Mycobacterium tuberculosis targets 
S1P activity within macrophages by inhibiting the activation and phagosomal 
translocation of sphingosine kinase (SK), responsible for the phosphorylation of 
sphingosine to S1P. The subsequent impairment of the S1P-dependent increase 
in cytosolic Ca2+ promotes intracellular survival of Mycobacterium (Malik et al., 
2003). The mycobacterial effector responsible for the inhibition of sphingosine 
kinase remains to be identified. Shigella flexneri has recently been reported to 
suppress the host inflammatory response by lowering host S1P levels through 
the transcriptional upregulation of host S1P lyase and S1P phosphatase-
encoding genes and the parallel downregulation of SK (Kim et al., 2014). Again, 
the molecular events that underlie the S1P pathway inhibition by Shigella remain 
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to be defined. Moreover, a sphingosine-responsive transcription factor SphR has 
recently been described in Pseudomonas aeruginosa and implicated in 
conferring resistance to antimicrobial sphingosine and promoting survival in a 
murine infection model (LaBauve and Wargo, 2014). Together, these studies 
highlight the host S1P axis as an emerging field in bacterial pathogenesis and 
host-microbe interactions.  
 
In conclusion, B. thailandensis S1PLs are secreted in a pH-dependent manner, 
with secretion being observed during intracellular infection. S1PL-deficient 
mutants displayed attenuation in a larval infection model and impaired 
intracellular replication in murine macrophages. This latter phenomenon was 
associated with increased bacterial colocalisation with the lysosomal marker 
LAMP-1, either indicating an inability of the S1PL-deficient mutants to evade 
phagosome maturation or S1PLs affect the rate at which the bacteria escape 
from the phagosomes into the cytoplasm. The data shown in this Chapter 4 
established bacterial-encoded S1PL as a novel virulence determinant of B. 
thailandensis. 
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Chapter 5 – Role of Burkholderia 
pseudomallei S1PLs in pathogenesis 
 
5.1 Introduction  
Phagocytic cells are considered the first-line of defence in host immune response 
against B. pseudomallei infection (Sim et al., 2009). However, B. pseudomallei 
possesses an extensive arsenal of virulence-associated genes that promote 
bacteria invasion, survival and replication in macrophages via the modulation of 
key host cellular processes (reviewed in Stone et al., 2014; Allwood et al., 2011). 
In spite of substantial research advancements in B. pseudomallei, there are still 
large gaps in understanding this pathogen intracellular life cycle and its 
interactions with the host. A thorough comprehension of this intracellular stage is 
critical in order to unravel the molecular basis of melioidosis pathogenesis and 
develop novel therapeutic strategies. 
In Chapter 3, BPSS2021 and BPSS2025 have been identified as encoding S1PL 
homologues in B. pseudomallei. The S1PLs sequence analysis revealed 
conserved amino acids reported to be essential for S1PL activity in yeast. 
Furthermore, in collaboration with Dominic Campopiano´s group (University of 
Edinburgh) both S1PLs were cloned, purified and confirmed to possess S1PL 
enzymatic activity in vitro (McLean et al., Unpublished data). However, the reason 
why Burkholderia has two S1PL-encoding genes and whether the proteins form 
homo or hetero-oligomers remain uncertain. Importantly, in Chapter 4 we 
demonstrated that the closely related B. thailandensis encodes two S1PLs 
secreted during infection of host cells, and that they play an important role in 
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pathogenesis, particularly in promoting intracellular survival within macrophages 
by disrupting the maturation of the phagosome (Chapter 4). Due to genetic 
intractability of B. thailandensis we were unable to produce double S1PL mutants, 
though the ability to generate double mutants in B. pseudomallei K96243 (Müller 
et al., 2012), allow us to assess whether the deletion of both genes exhibit a more 
pronounced phenotype.  
Based on S1P-S1PL literature and our B. thailandensis studies, it is hypothesised 
that B. pseudomallei-encoded S1PLs represent a novel virulence determinant 
required for bacteria survival within immune cells, contributing to melioidosis 
pathogenesis. 
 
The aim of this chapter was to evaluate the role of B. pseudomallei BPSS2021 
and BPSS2025 in the context of intracellular survival and replication in 
macrophages. Unmarked single and double S1PL-deletion mutants were 
constructed via SacB-based mutagenesis and validated by whole genome 
sequencing, thus allowing the phenotypic comparison between single and double 
mutant. Notably, both B. pseudomallei S1PL mutants’ displayed a comparable 
reduction in intracellular replication within murine macrophages. In addition, the 
role of BPSS2025 was assessed in a murine model of infection, further confirming 
the role of the Burkholderia S1PLs in pathogenesis.  
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5.2 Results  
5.2.1 Production of B. pseudomallei S1PLs mutants and validation 
5.2.1.1 Production of single and double-S1PL deletion mutants 
The adopted strategy to delete BPSS2025 and BPSS2021 is outlined in Figure 
5.1 and Figure 5.2 (Logue et al., 2009). First, the pDM4 deletion construct 
containing either BPSS2025 or BPSS2021 flanking regions (depicted in Figure 
5.1) were transformed into E. coli GT115. The plasmid was transferred by 
triparental mating into wildtype B. pseudomallei K96243. The first cross-over 
event integrated the knockout deletion allele into the host chromosome by 
homologous recombination. Merodiploid integrants were identified on selective 
media containing chloramphenicol and the pDM4 backbone was excised from the 
bacteria genome in a second cross-over recombination induced by sucrose 
counter-selection (Figure 5.2). Sucrose-resistant colonies were screened for 
chloramphenicol susceptibility and appropriate gene deletion validated using two 
sets of PCR reactions, one using primers binding within the wildtype gene and 
the other using primers binding downstream and upstream the target gene, 
generating a shorter PCR product for the mutant strain. From seven putative B. 
pseudomallei ΔBPSS2025 colonies tested, one mutant was identified (Figure 
5.3). From 16 putative B. pseudomallei ΔBPSS2021 colonies screened, one 
mutant was potentially identified since the BPSS2021 gene was not detected by 
PCR. However, the second PCR containing the primers binding downstream and 
upstream region of BPSS2021, used to confirm that the gene has been replaced 
by a truncated version, repeatedly failed (data not shown).   
Attempt to produce a double BPSS2025+BPSS2021 unmarked deletion mutant 
was made by transferring pDM4::BPSS2021 into the PCR validated B. 
132 
 
pseudomallei ΔBPSS2025 mutant and the mutagenesis strategy depicted in 
figure 5.2 was carried out. From 16 colonies screened, three colonies were 
identified as putative BPSS2025+BPSS2021 deletion mutant. Yet again, only the 
PCR to screen the absence of the target genes (BPSS2021 and BPSS2025) 
worked, while the PCR to amplify the deletion allele of BPSS2021 failed once 
more. For further validation, the PCR-validated ΔBPSS2025 mutant, the one 
putative ΔBPSS2021 mutant and the three putative double 
BPSS2025+BPSS2021 deletion mutants were subjected to whole genome 
sequencing.  
In the meantime, given the difficulty experienced during the deletion process of 
BPSS2021, an alternative approach for the construction of a double S1PL mutant 
was carried out. The plasmid pGPΩTp::BPSS2021 (for details see section 2.5.2) 
was transferred by triparental mating into ΔBPSS2025 and insertional inactivation 
of BPSS2021 was confirmed by appropriate PCR (data not shown), giving rise to 
B. pseudomallei double S1PL-deficient mutant (designated ΔBPSS2025+ 
ΩTp::BPSS2021). 
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Figure 5.1. Construction of pDM4 suicide vector containing a knockout cassette 
to either delete BPSS2025 or BPSS2021. The 600 bp flanking regions, downstream 
(yellow) and upstream (red) of the target genes (BPSS2025 and BPSS2021) were 
amplified by PCR, purified and fused together using second PCR reaction to create the 
knockout cassette (1,200 bp) or in the case of BPSS2021 due to a repeated failure to 
amplify the upstream region, the knockout cassette was produced by gene synthesis 
(Invitrogen). Both the knockout cassette and pDM4 were digested with the appropriate 
restriction enzymes and cloned to create pDM4::BPSS2025 or pDM4::BPSS2021. 
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Figure 5.2. Schematic representation of unmarked deletion mutant in B. 
pseudomallei, using SacB-based mutagenesis. Either pDM4::BPSS2025 or 
pDM4::BPSS2021 were conjugated individually into B. pseudomallei K96243 wildtype to 
create a ΔBPSS2025 and ΔBPSS2021 deletion mutant. Diagram adapted from Logue et 
al. (2009). pDM4 suicide plasmid containing the knockout cassettes was integrated into 
the genome by homologous recombination (e.g. Step 1). After the first-cross over, the 
merodiploid integrant (e.g. Step 2) was selected for chloramphenicol resistance. The 
pDM4 backbone was excised from the genome by sucrose-counter selection, resulting 
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in allelic exchange and the generation of S1PL deletion mutant or wildtype revertant (e.g. 
Step 3). 
 
5.2.1.2 Validation of B. pseudomallei S1PL-deletion mutants by whole 
genome sequencing   
In order to confirm the correct deletion of the target genes without off-target 
effects on neighbouring genes, genomic DNA was extracted from the putative 
BPSS2025 and BPSS2021 single and double mutants plus the B. pseudomallei 
K96243 strain and sent for whole genome sequencing (Exeter sequencing 
Services, University of Exeter). 
The data obtained from the genome sequencing was assembled against the B. 
pseudomallei K96243 reference genome using the Integrative Genomics Viewer 
(IGV) tool (Robinson et al., 2011). As shown in figure 5.4, the B. pseudomallei 
ΔBPSS2025 sequenced genome analysis revealed a ~1500 bp missing region 
that corresponds to BPSS2025 gene in the wildtype strain, thus confirming the 
clean deletion of the target gene. In contrast, all putative ΔBPSS2021 and double 
BPSS2025+BPSS2021 deletion mutant strains showed the same deletion of 
approximately 373729 bp spanning genes BPSS1956-BPSS2240 (data not 
shown), indicating unanticipated large-scale deletion during BPSS2021 
mutagenesis, which was verified by PCR analysis of genes flanking BPSS2021 
and BPSS2025. As shown in figure 5.5, the PCR was negative for all the genes 
tested in the putative ΔBPSS2021 and double BPSS2025+BPSS2021 deletion 
mutants, while for wildtype strain (positive control) the expected PCR-amplicons 
were obtained, therefore the performed PCR corroborates with the whole 
genome sequencing data. Altogether, these results confirm the appropriate 
deletion of BPSS2025 in ΔBPSS2025 mutant without affecting the flanking 
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genes, whilst ΔBPSS2021 and double BPSS2025+BPSS2021 deletion mutant 
strains showed severe modifications in the genome, giving rise to bacteria strains 
unsuitable for phenotypic characterisation.  
The characterisation of B. pseudomallei S1PL mutants in pathogenesis will be 
addressed using ΔBPSS2025 and ΔBPSS2025+ΩTp::BPSS2021 (ΔBPSS2025 
with insertional inactivation of BPSS2021) strain. 
 
Figure 5.3. PCR confirmation of BPSS2025 unmarked deletion validation. Left PCR 
shows the amplification of BPSS2025, with an expected product of ~1500 bp for Wt 
strain. Right PCR shows the amplification of primers binding the flanking region of 
BPSS2025. In the Wt is expected a product size of ~3100 bp, whilst in the deletion 
mutant is predicted a ~1600 bp band.  Lanes 1-7 – putative ΔBPSS2025 mutants; Wt – 
B. pseudomallei K96243 gDNA; N – negative control (water); M – DNA ladder marker 
Gene Ruler™ 1000 bp Plus (Invitrogen). The lack of a BPSS2025 band together with the 
presence of a ~1600 bp band in BPSS2025 flanking region PCR confirms the deletion 
of BPSS2025. Red arrow indicates the PCR validated ΔBPSS2025 mutant.
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Figure 5.4. View of aligned reads of B. pseudomallei S1PL mutants at genomic region BPSS2021-BPSS2025.  
Coverage plot and alignments from paired-end reads of B. pseudomallei S1PL mutant strains and wildtype strain mapped against the 
annotated reference genome B. pseudomallei K96243 (RefSeq: GCF_000011545.1) using IGV software. Alignments are represented as 
grey polygons and reads mismatching the reference are indicated by colour (Red-insertion; Blue-deletion; Light Blue-unknown mutations). 
This figure showed that the missing region in the ΔBPSS2025 mutant strain, shown in the second track (from top) within the red frame 
corresponds to the BPSS2025 gene in the wildtype strain. An unexpected large-scale deletion is visible for ΔBPSS2021 and double 
BPSS2025+BPSS2021 deletion mutant. For visualisation clarity, only one strain of double BPSS2025+BPSS2021 deletion mutant is shown 
in the figure (the remaining putative mutants presented similar genotype).     
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Figure 5.5. PCR screening of BPSS2019-BPSS2027 genes in putative ΔBPSS2021 
and double BPSS2025+BPSS2021 deletion mutant strains. Genomic DNA from the 
putative S1PLs-deletion mutants sent for whole genome sequencing was used as DNA 
template for PCR using primers to amplify fragments internal to the genes BPSS2019, 
BPSS2020, BPSS2021, BPSS2022, BPSS2023, BPSS2024, BPSS2025, BPSS2026 
and BPSS2027.  M – DNA ladder marker Gene Ruler™ 100 bp Plus (Invitrogen); 1 – 
putative ΔBPSS2021 mutant; 2-4 – double BPSS2025+BPSS2021 deletion mutant; Wt 
– B. pseudomallei K96243 gDNA and N – negative control (water). This PCR analysis 
confirms the absence of genes in the BPSS2021-BPSS2025 genomic region, consistent 
with the large-scale deletion predicted by genomic sequencing.  
 
  
139 
 
5.2.2 Role of B. pseudomallei S1PLs in virulence 
5.2.2.1 Single and double B. pseudomallei S1PL mutants show defective 
intracellular replication in macrophages 
A vital stage in the pathogenesis of melioidosis is the ability of B. pseudomallei 
to survive and replicate within macrophages (Stone et al., 2014).Therefore, the 
effect of S1PLs deletion on B. pseudomallei survival and growth in a phagocytic 
cell line was determined by infection of J774.1 murine macrophages with either 
wildtype B. pseudomallei K96243, ΔBPSS2025 or 
ΔBPSS2025+ΩTp::BPSS2021. As shown in Figure 5.6 wildtype strain showed 
significant growth over the 6 hpi, with approximately 4-fold increase between 2 
and 6 h time point. In clear contrast, single and double S1PL-deletion mutants 
displayed deficient intracellular growth over the same period of infection, 
presenting a significant reduction in the bacteria levels relative to wildtype. 
Notably, both single (ΔBPSS2025) and double (ΔBPSS2025+ ΩTp::BPSS2021) 
S1PL-deletion mutants exhibited similar intracellular growth impairment, 
suggesting that deletion of single S1PL is sufficient to abolish completely the 
S1PL function in virulence.    
Given the observation that both single and double S1PL-deletion mutant 
presented indistinguishable phenotype, the complementation was carried out 
only for ΔBPSS2025 (see section 2.5.2). As shown in figure 5.7 the defective 
intracellular growth phenotype observed in ΔBPSS2025 was partially restored by 
complementation with BPSS2025, with the number of intracellular bacteria 
significantly increased relative to mutant strain by 6 hpi, yet not as wildtype levels 
(Figure 5.7. Taken together, these results indicate that the presence of both 
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S1PLs genes is required for efficient intracellular survival of B. pseudomallei 
within macrophages. 
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Figure 5.6. Both B. pseudomallei single and double S1PL-deletion displayed 
reduced intracellular replication in macrophages. J774A.1 macrophages were 
infected either with B. pseudomallei wildtype (Bp Wt), ΔBPSS2025 or 
ΔBPSS2025+ΩTp::BPSS2021 (double S1PL mutant) at an MOI of 10. Viable 
intracellular bacteria were quantified at 2, 4 and 6 hpi by spotting serial dilutions of 
macrophage lysates. For each strain, bacterial survival was normalised to the CFU 
counts observed at 2 hpi and presented as relative bacterial survival (%) so as to 
visualise intracellular replication between 2 and 6 hpi. Data represent the mean + SEM 
of three independent experiments. *** p<0.0001. 
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Figure 5.7. Complementation of B. pseudomallei ΔBPSS2025 partially restored the 
intracellular replication in macrophages to wildtype levels. (A) J774A.1 
macrophages were infected either with B. pseudomallei wildtype (Bp Wt), ΔBPSS2025 
or ΔBPSS2025+BPSS2025 (complementation strain) at an MOI of 10. Viable 
intracellular bacteria were quantified at 2, 4 and 6 hpi by spotting serial dilutions of 
macrophage lysates. For each strain, bacterial survival was normalised to the CFU 
counts observed at 2 hpi and presented as relative bacterial survival (%) so as to 
visualise intracellular replication between 2 and 6 hpi. Data represent the mean + SEM 
of two independent experiments. * p<0.05; ** p<0.001; *** p<0.0001. 
 
5.2.2.2 B. pseudomallei S1PL mutant is attenuated in vivo 
A BALB/c mouse infection model was conducted in order to further investigate 
the role of B. pseudomallei S1PL in virulence in vivo. The mouse model was 
performed by Dr Andrew Scott, DSTL, Porton Down. Five mice per group were 
challenged via intraperitoneal route with three different inocula of wildtype, 
ΔBPSS2025 mutant or ΔBPSS2025+BPSS2025 complementation strain and 
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signs for disease or death were monitored over 35 days. All mice challenged with 
a dose of ~4 x 104 CFU of B. pseudomallei wildtype succumbed to infection by 
day 18, with a median time of death of 12 days. Remarkably, mice inoculated with 
the same inoculum of ΔBPSS2025 mutant resulted in 80% survival over the 35 
days, showing a significant attenuation compared to wildtype strain (Figure 5.8 
A; p<0.0001). Unexpectedly, the complementation strain did not restored the 
wildtype phenotype, as observed in the macrophages infection model (Figure 
5.7).  Though, of the 10 surviving mice infected with either ~4 x 103 or ~4 x 104 
CFU of complementation strain, 3 were chronically infected with bacteria that 
were fully sensitive to tetracycline (A. Scott; personal communication), thus 
indicating that the bacteria has lost the plasmid and consequently is not 
complemented anymore.  
Furthermore, the median lethal dose (LD50) of 3.8 x 103 CFU for mice challenged 
with wildtype was considerable lower compared to both ΔBPSS2025 and 
complementation strains (LD50 of 1.7 x 105 CFU and 1.8 x 105 CFU, respectively). 
In addition, the colonisation data of spleen, liver and lung of surviving mice that 
have been challenged with the mutant strain resulted in strikingly lower CFU 
levels in the organs relative to wildtype strain, presenting 1200-fold, 710-fold and 
730-fold decrease in bacterial load, respectively (Figure 5.9). Moreover, the 
challenge with the mutant strain resulted in undetectable CFU levels in two out of 
four mice at 35 days post infection. Remarkably, the spleen of colonised animals 
with the wildtype strain increased notably in weight compared to ΔBPSS2025 
mutant (mean weight of 1.18 g and 0.15 g, respectively) (data not shown). Taken 
together, the data present herein suggests that B. pseudomallei BPSS2025 alone 
is required for full virulence in vivo.  
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Figure 5.8. Virulence of BPSS2025 mutant in BALB/c mice. Five mice were 
challenged with strains of B. pseudomallei by the intraperitoneal route. The mice were 
monitored for signs of disease for 35 days after which the surviving animals were culled. 
The survival curve  shows mice challenged with 3.8 x 104 CFU B. pseudomallei Wt (Bp 
Wt), 5.6 x 104 CFU B. pseudomallei ΔBPSS2025 or 5.4 x 104 CFU 
ΔBPSS2025+BPSS2025 (complementation strain). Log-Rank test confirmed a 
significant increase in mice survival between ΔBPSS2025 and the complementation 
strain compared to wildtype strain (p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
A                                                                     B 
B
p
 W
t

B
P
S
S
2
0
2
5
 

B
P
S
S
2
0
2
5
+
B
P
S
S
2
0
2
5
 
0
2 0 0 0
4 0 0 0
6 0 0 0
1 .01 0 7
2 .01 0 7
3 .01 0 7
C
F
U
/S
p
le
e
n
B
p
 W
t

B
P
S
S
2
0
2
5
 

B
P
S
S
2
0
2
5
+
B
P
S
S
2
0
2
5
 
0
1 0 0
2 0 0
3 0 0
21 0 4
41 0 4
61 0 4
C
F
U
/L
u
n
g
 
C 
B
p
 W
t

B
P
S
S
2
0
2
5
 

B
P
S
S
2
0
2
5
+
B
P
S
S
2
0
2
5
 
0
2 0 0
4 0 0
6 0 0
11 0 5
21 0 5
C
F
U
/L
iv
e
r
 
Figure 5.9. The mean bacterial burden in (A) spleens, (B) lungs and (C) liver of surviving 
mice, 35 days post challenge with approximately 3.8 x 104 CFU B. pseudomallei Wt (Bp 
Wt), 5.6 x 104 CFU ΔBPSS2025 or 5.4 x 104 CFU ΔBPSS2025+BPSS2025. In mice 
infected with wildtype strain is evident higher CFU levels in the different organs 
compared to ΔBPSS2025 and ΔBPSS2025+BPSS2025. 
 
 
 
 
145 
 
5.3 Discussion   
The ability of B. pseudomallei to invade, survive and replicate inside of non-
phagocytic and phagocytic cells is the hallmark of melioidosis infection and 
attests the aptness of the bacteria to evade the host bactericidal mechanisms. 
Following the characterisation of S1PL unmarked deletion mutants, the work 
presented in this chapter established B. pseudomallei-encoded S1PL as a novel 
virulence determinant required for an effective intracellular survival/replication in 
macrophages and full virulence in vivo. 
 
After internalisation by phagocytes, B. pseudomallei is able to escape from the 
endocytic vesicles into the host cytosol, where it starts the replication and 
dissemination (Wiersinga et al., 2012). The endosome escape is attributed in part 
to the T3SS3 (Stevens et al., 2002), though its direct contribution to intracellular 
survival and replication is less clear as whilst bsaZ and bsaQ mutants show 
defective vesicle escape at earlier infection time points in macrophages, the 
mutants are found free in the cytosol at later time points (Burtnick et al., 2008; 
Muangsombut et al., 2008). Moreover, it has been demonstrated that bsaZ 
mutant shows reduced bacteria levels at earlier time points but after 12 h infection 
the bacteria count is similar to wildtype bacteria (Burtnick et al., 2008). 
Furthermore, Muangsombut et al. (2008) have found that a T3SS3-deficient 
mutant (ΔbsaQ) shows no differences compared to wildtype regarding the 
number of intracellular bacteria. Therefore, whilst these studies show T3SS3 
mutants exhibit defective endosome evasion, eventually the bacteria are able to 
escape into the cytosol, thus suggesting that others virulence determinants 
involved in phagosomal escape and consequently intracellular survival may 
remain unidentified.   
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In the context of the innate immune response, S1P is a critical regulator of 
macrophage function, influencing phagosome-lysosome fusion by triggering the 
mobilization of intracellular Ca2+ (Blom et al., 2005). Intracellular pathogens that 
preferentially target macrophages employ diverse strategies to circumvent their 
killing mechanism, and disruption of S1P-mediated phagosome maturation is one 
such strategy. This is exemplified by Mycobacterium tuberculosis, which inhibits 
the activation and phagosomal translocation of SphK, thus blocking the S1P-
dependent increase in cytosolic Ca2+ and impairing phagosome maturation 
(Thompson et al., 2005; Malik et al., 2003). We have previously shown that by 
putative disruption of the S1P axis, B. thailandensis delays phagosome 
maturation, leading to intracellular survival and replication (Chapter 4). 
Consistent with these observations, data presented in the current chapter reveal 
that B. pseudomallei S1PL mutants also showed defective intracellular growth in 
macrophages, consistent with B. pseudomallei-encoded S1PL playing a role in 
pathogenesis by subverting the S1P function in macrophages and acting in 
concert with other known virulence determinants to promote phagosome escape 
and intracellular survival.  
 
A study conducted in BALB/c mice infected with B. pseudomallei  has shown that 
the depletion of macrophages in vivo resulted in increased mortality of mice 
compared to control group, thus confirming the importance of appropriate 
macrophages activity in controlling B. pseudomallei dissemination during the 
early stages of infection in vivo (Breitbach et al., 2006). Therefore, given the 
increased S1PL mutant susceptibility to macrophage activity and possibly other 
professional phagocytic cells, it is tempting to speculate that the significant 
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attenuation of B. pseudomallei S1PL mutant in the mouse infection model is due 
to impaired ability to overcome the innate immune response encountered during 
the early stage of infection in vivo. A prompt initial elimination of bacteria by the 
host macrophages may have occurred and hindered the bacterial dissemination 
throughout the organs, which is consistent with the mutant attenuation phenotype 
and the striking decrease in the number of CFU recovered from the organs of the 
surviving animals compared to wildtype. Accordingly, no changes in the spleen 
size were found, in contrast with the spleens recovered from the wildtype-infected 
mice, where organ enlargement and increased weight was observed, which is 
consistent with splenomegaly, a common clinical feature of melioidosis both in 
mice and humans (Wiersinga et al., 2012, Hoppe et al., 1999). These 
observations support the finding that bacterial-encoded S1PL may play a role in 
establishing the infection and contribute for melioidosis pathogenesis in vivo. 
 
Oddly, the complementation strain showed a marked attenuation in the mice 
infection model, in contrast with the partial complementation achieved in the 
macrophages intracellular survival (Figure 5.7). Based on experimental evidence, 
numerous complemented colonies recovered from the mice were sensitive to 
tetracycline. Thus, one can hypothesise that overexpression of S1PL may carry 
a significant burden to the bacteria in a stressful in vivo environment, therefore 
leading to removal of the plasmid. This resultant loss of BPSS2025 
complementation during the infection may possibly explain the lack of phenotypic 
restoration observed in the mice infection model. 
 
The ability to produce mutants in B. pseudomallei is fundamental to 
understanding the putative virulence-associated genes involved in pathogenesis. 
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Numerous studies have shown that most B. pseudomallei strains, including 
K96243, are naturally transformable and easy to genetically manipulate using a 
wide range of mutagenesis strategies (reviewed by Galyov et al., 2010). 
However, in the course of our study we found particularly problematic the PCR-
amplification of BPSS2021 flanking regions. Moreover, several attempts to delete 
BPS2021 in single and double S1PLs-deletion mutants via SacB mutagenesis 
(Logue et al., 2009) were made until we finally obtained putative BPSS2021 
deletion mutant strains. However, the whole genome sequencing analysis of the 
putative BPSS2021 deletion strains revealed considerable discrepancies on the 
bacteria genome compared to wildtype (Figure 5.4, suggesting that following the 
second cross-over (via sucrose-counter selection) the respective BPSS2021 
genomic region went through unanticipated genetic recombination, giving rise to 
a large chromosomal deletion or modification. Interestingly, Johnson and 
colleagues observed similar inadvertent loss of genes and a significant genomic 
alteration in E. coli, following a comparable sucrose-mediated mutagenesis. The 
authors suggest that secondary mutations in the neighbouring genes may occur 
due to aberrant plasmid integration/excision using allelic exchange mutagenesis 
systems (Johnson et al., 2003). Therefore, a mutagenesis strategy based on 
suicide vector insertion (Flannagan et al., 2007) was utilised to inactivate 
BPSS2021 in ΔBPSS2025 mutant and generate a double S1PLs-deficient 
mutant. 
 
Although a BPSS2021 single deletion mutant was not characterised in this study, 
given the high degree of amino acid similarity between BPSS2021 and 
BPSS2025 (Chapter 3), we can speculate that a BPSS2021-deletion mutant 
would produce a phenotype comparable to ΔBPSS2025, as was observed with 
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the BTH_II0309 and BTH_II0311 mutants in B. thailandensis. Notably, individual 
deletion of BPSS2025 in B. pseudomallei K96243 resulted in an intracellular 
survival defect equivalent to complete S1PL disruption, as verified for 
ΔBPSS2025+ΔBPSS2021 mutant (Figure 5.6. Curiously, in Chapter 3 the native 
PAGE analysis of His-tagged S1PLs revealed the presence of oligomer 
complexes, although not conclusive whether they form homo or hetero-
oligomers. In addition, the BACTH data indicated that BTH_II0309 is able to form 
homo-oligomers, yet it failed to detect the formation of S1PL hetero- oligomers. 
Nevertheless, in the course of the yeast complementation studies we observed 
that the degree of complementation was higher (fully restoring the wildtype 
phenotype) when BTH_II0309 and BTH_II0311 were co-expressed in S. 
cerevisiae Δdpl1, suggesting that a S1PL hetero-oligomer may indeed be 
required for optimal enzymatic activity (Chapter 3). Altogether, such observations 
would explain why the single BPSS2025 deletion displayed a phenotype 
indistinguishable from the double B. pseudomallei S1PL-inactivation mutant, as 
individual S1PL deletion would disrupt the putative hetero-oligomer and impair 
most of the S1PL function essential for the bacteria to survive and replicate 
efficiently in the intracellular environment. Comparative biochemical 
characterisation, in particular the enzymatic activity of S1PL in vitro with either 
single or both proteins present, would be needed to confirm this hypothesis. 
 
In conclusion, using deletion mutagenesis and relevant infection models, the 
work presented in this chapter has demonstrated the importance of B. 
pseudomallei BPSS2025 in bacteria intracellular survival within macrophages 
and in virulence in BALB/c mice infection model, further suggesting a novel 
strategy employed by B. pseudomallei to subvert the host immune defences and 
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contribute to the pathogenesis of melioidosis. In addition, based on our 
observations, targeting the S1P pathway warrant investigation as therapeutic 
strategy for the control of infection by B. pseudomallei, which will be investigated 
in detail in Chapter 6.  
 
 
Chapter 6 – Effect of S1P and S1P 
modulators on the course of 
Burkholderia infection in macrophages 
6.1 Introduction  
Intracellular bacterial infections, including those caused by Burkholderia 
pseudomallei pose a major global health burden affecting millions of people 
annually. The intracellular location provides protection against immune defences 
and antimicrobial therapy, and can also facilitate dissemination within the host. 
The majority of antibiotics are ineffective against intracellular pathogens due to 
limited cellular penetration or intracellular retention (Skyberg et al., 2012), whilst 
increasing rates of resistance often limit the efficacy of those antibiotics that do 
possess intracellular activity. Consequently, intracellular infections are difficult to 
eradicate, and are a major cause of persistent or recurrent infections worldwide. 
New therapeutic strategies are urgently required, the rational design of which 
demands a full appreciation of the mechanisms employed by intracellular bacteria 
to subvert the host cells immune response. 
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In the course of this study, we identified a novel strategy employed by 
Burkholderia to subvert the host cells in which they reside – the targeting of the 
host S1P axis. S1P is a bioactive sphingolipid metabolite that exerts a large 
number of effects as it can function as an intracellular second messenger as well 
as acting in an autocrine and/or paracrine manner to activate five distinct G 
protein-coupled cell surface receptors (GPCRs; S1PR1-5) (Spiegel and Milstien, 
2011). S1P is involved in numerous biological processes and the S1P pathway 
has been described as a “cellular rheostat that determines cell survival or death” 
(Alvarez et al., 2007). Moreover, the role of S1P extends beyond the regulation 
of cell survival. S1P has been implicated in numerous pathophysiological 
conditions (Maceyka and Spiegel, 2014) and infectious diseases (Arish et al., 
2015). Therefore, a growing body of research has been focused on the 
development of S1P signalling pathway modulators as a therapeutic strategy for 
such diseases. Presently, a wide range of chemical compounds, targeting the 
S1P synthesis, degradation and the S1PR1-5, are already commercially available 
and/or under clinical trials (Kunkel et al., 2013). Since the discovery of these 
compounds, research on pathogenic bacteria such as Mycobacterium, Bordetella 
and Francisella has shown the benefits of targeting the S1P signalling as anti-
infective strategy (Skerry et al., 2015; Bar-Haim et al., 2008; Garg et al., 2004). 
Consistent with the results presented in chapters 4 and 5, suggesting that S1P 
axis is targeted during Burkholderia infection in macrophages, we hypothesised 
that the modulation of S1P signalling could be of therapeutic benefit against the 
intracellular infection.  
 
In the present chapter, we established that treatment of infected macrophages 
with either exogenous S1P or a specific agonist of S1P receptor 1 (CYM-5442) 
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increases the association of Burkholderia with the lysosome marker LAMP-1 and 
reduces intracellular survival. Thus specific modulators of the S1PR1-mediated 
pathway may represent a therapeutic strategy for the treatment of intracellular 
infections, particularly for B. pseudomallei infection. 
 
6.2 Results  
6.2.1 Impact of S1P signalling modulators on Burkholderia infection 
6.2.1.1 Treatment of Burkholderia-infected macrophages with S1P 
increases bacterial killing 
In Chapters 4 and 5 we demonstrated that Burkholderia S1PL activity is required 
for intracellular survival, presumably due to their role in depleting the cellular pool 
of S1P and thus impairing S1P-dependent pathways that contribute to the 
bactericidal activity of macrophages. Thus we sought to determine whether 
adding exogenous S1P would essentially reverse this phenomenon, promoting 
full activation of these bactericidal mechanisms. Macrophages were infected with 
either wildtype B. thailandensis or B. pseudomallei prior to treatment with S1P 
(which does not possess direct antimicrobial activity; Figure 6.1), and the 
intracellular survival of bacteria was assessed at indicated time points post-
treatment. As shown in Figure 6.2 (A-B), S1P-treated macrophages exhibit 
reduced bacterial survival for both B. thailandensis and B. pseudomallei strains 
following 6 hours treatment. Moreover, this reduction in viable intracellular 
bacteria correlates with an increase in their colocalisation with LAMP-1 (Figure 
6.3), comparable to that observed for B. thailandensis S1PL-deficient mutants 
(Chapter 4). 
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Figure 6.1. Antimicrobial effect of S1P. B. thailandensis wildtype was incubated for 2 
h at 37ºC in saline buffer supplemented with either 50 µM of S1P or left untreated. Serial 
dilutions were made and viable bacteria enumerated by plating onto LB agar plates. 
Bacterial viability was relative to non-treated control group and presented as relative 
bacteria cfu (%). Bars and error bars represent the mean + SEM of three independent 
experiments. NS, p>0.05 
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Figure 6.2. Treatment of Burkholderia-infected macrophages with S1P enhances 
bacterial killing. J774A.1 macrophages were infected (MOI of 10) with either wildtype 
B. thailandensis (A) or B. pseudomallei (B) for 2 h, prior to treating with 5 µM of S1P 
(alongside relevant carrier only controls). Viable intracellular bacteria were quantified 
and percentage survival calculated relative to control group at the indicated time point. 
In panels A and B, data represent mean + SEM of three independent experiments. * p < 
0.05 and *** p < 0.001.  
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B 
 
Figure 6.3. Infected-macrophages treated with S1P increase bacterial 
colocalisation with LAMP-1. (A) Representative micrographs showing LAMP-1 
colocalisation of RFP-expressing B. thailandensis in infected macrophages with or 
without S1P treatment (5 µM final concentration). Right insets represent magnified 
images of boxed areas with yellow arrows indicating bacterial colocalisation with LAMP-
1. Scale bar represents 10 µm. (B) Quantitative analysis of bacterial colocalisation with 
LAMP-1 following S1P treatment (relative to carrier control). For each independent 
experiment, positive or negative colocalisation was assessed for 100 intracellular 
bacteria per strain to achieve a percentage colocalisation. In panel B, data represent 
mean + SEM of three independent experiments. * p < 0.01. 
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6.2.1.2 S1PR1-selective agonist treatment reduces intracellular survival of 
bacteria in macrophages  
The expression patterns and function of the five S1PRs that mediate the 
extracellular activities of S1P vary across different cells and tissues (Spiegel and 
Milstien, 2011). Consequently, the impaired Burkholderia intracellular survival 
observed above may be due to activation of solely one or more host cell 
receptors. Therefore, when considering the therapeutic use of S1PR agonists, it 
is desirable to identify the most relevant target receptors and avoid those 
associated with off-target (and potentially detrimental) effects. Murine 
macrophages reportedly express just S1PR1 and S1PR2 (Hughes et al., 2008), 
and whilst there are no reported mono-selective S1PR2 agonists, several S1PR1-
selective agonists have been described. Therefore, we chose to assess the 
impact of S1P pathway modulation on the bactericidal activity of infected 
macrophages using the S1PR1-selective agonist, CYM-5442 (Gonzalez-Cabrera 
et al., 2008). Equally to S1P, CYM-5442 did not show direct bactericidal activity 
(Figure 6.4. Notably, CYM-5442 elicited a significant reduction in bacterial 
survival following 6 hours for both B. thailandensis and B. pseudomallei (Figure 
6.5, that is comparable to the reduction observed in S1P-treated cells (Figure 
6.2). Based on these results, we conclude that S1P pathway modulation is an 
attractive therapeutic strategy for the treatment of intracellular bacterial 
infections, with beneficial bactericidal activity attributable to the specific activation 
of the S1PR1 pathway. 
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Figure 6.4. Antimicrobial effect of CYM-5442. B. thailandensis wildtype was incubated 
static for 6 h at 37ºC in Leibovitz L-15 medium either supplemented with 1 µM of CYM-
5442 or left untreated. Serial dilutions were made and viable bacteria enumerated by 
plating onto LB agar plates. Bacterial viability was relative to non-treated control group 
and presented as relative bacteria cfu (%). Bars and error bars represent the mean + 
SEM of two independent experiments. NS, p>0.05  
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Figure 6.5. Burkholderia-infected macrophages treated with an S1PR1 agonist 
enhances bacterial killing. J774A.1 macrophages were infected (MOI of 10) with either 
wildtype B. thailandensis (A) or B. pseudomallei (B) for 2 h, prior to treating with 0.5 µM 
of CYM-5442 (alongside relevant carrier only controls). Viable intracellular bacteria were 
quantified and percentage survival calculated relative to control group at the indicated 
time point. Data represent mean + SEM of three independent experiments. ** p < 0.01 
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6.2.1.3 S1PL inhibition with THI does not affect the intracellular bacteria 
survival in murine macrophages  
An alternative strategy for targeting the S1P pathway is to inhibit the host cell 
S1PL, thus blocking the degradation of intracellular S1P. We sought to determine 
whether use of a putative S1PL inhibitor replicated any of the beneficial activities 
observed with the S1PR agonists. Infected-macrophages with wildtype B. 
thailandensis were treated with THI (2-Acetyl-4-tetrahydroxybutyl imidazole), a 
food colorant reported to inhibit the S1PL activity and promote the increase of 
S1P concentration in lymphoid tissues (Schwab et al., 2005). The bacteria 
survival within J774A.1 cells was assessed at 2 and 6 h post THI treatment. As 
shown in figure 6.6 the application of THI in B. thailandensis-infected 
macrophages did not impair the intracellular bacteria survival.  
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Figure 6.6. Treatment of Burkholderia-infected macrophages with a S1PL inhibitor 
shows no effect in bacteria killing. J774A.1 macrophages were infected (MOI of 10) 
with B. thailandensis for 2 h, prior to treating with THI (50 µg/mL), alongside relevant 
carrier only controls (PBS). Viable intracellular bacteria were quantified at indicated time 
points and percentage survival calculated relative to controls. Data represent mean + 
SEM of three independent experiments. 
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6.2.2 Transcriptomic profiling of murine macrophages treated with S1P 
signalling modulators 
In order to improve our understanding of how S1P receptor agonists promote 
bacterial killing in infected macrophages (Figures 6.2 and 6.5), we used RNA-seq 
to perform global gene expression profiling of non-infected murine macrophages 
treated with either S1P or CYM-5442, with the aim of identifying the signalling 
networks activated by each agonist. 
 
6.2.2.1 RNA-seq data overview  
Based on the data gathered from macrophages infection assays treated with S1P 
signalling modulators, we observed that macrophages treated with 5 µM and 0.5 
µM of S1P and CYM-5442, respectively, elicited a significant antimicrobial 
response against B. thailandensis and B. pseudomallei (Figures 6.2 and 6.5). 
Thus, for the RNA-seq experiment, we treated non-infected J77A.1 cells with 
equivalent S1P and CYM-5442 concentrations as utilised for the bacterial 
intracellular survival assays. However, instead of several time-points (as 
performed for the infection assay) we collected the eukaryotic RNA from the 
treated macrophages at one single time-point. It has been demonstrated that the 
incubation of HEK293 cells with 0.5 µM of  CYM-5442 stimulates the activation 
of S1PR1 as rapid as 2 min post treatment and peaking at 60 min (comparable 
S1PR1 activation was observed with S1P at 30 min post treatment) (Gonzalez-
Cabrera et al., 2008). Therefore, we decided to perform the transcriptomic 
analysis in uninfected cells treated for 1 h either with S1P or CYM-5442 in order 
to increase the chances of capturing the downstream signalling pathway 
triggered by the activation of S1PR1. 
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In Figure 6.7, is shown the global gene expression for all the pairwise 
comparisons possible between the different treatment conditions by cufflink 
analysis. Genes in the RNA-seq data not significantly differentially regulated were 
not included in any further analysis. The genes differentially expressed observed 
in the volcano plot were grouped as shown in Figure 6.8. For the relevant 
biological pairwise comparisons, we observed 84 and 31 genes differentially 
regulated in CYM-5442 and S1P-treated macrophages, respectively. However, it 
was evident that the non-relevant biological pairwise comparisons (i.e. S1PC vs 
CYMC, S1P vs CYMC, CYM vs S1P and CYM vs S1PC) also displayed similar 
numbers of differently expressed genes. Genes that were common to both the 
relevant and non-relevant comparisons were identified and removed from the 
data set, since they likely represent false-positive regulated genes resultant from 
the RNA-seq analysis. Additionally, intergenic regions were removed from any 
further analysis. Following removal of the presumed false-positives and the 
intergenic regions, only 33 and 6 genes remained which were differentially 
expressed in the CYM-5442 and S1P-treated macrophages respectively (Tables 
6.1 and 6.2). This unexpected low number of differentially regulated genes could 
be explained by the high variability between the replicates (Figure 6.9), resultant 
from an unanticipated problem while performing the experiment or the 1 h 
treatment with the compounds was not enough to elicit a significant response. 
Furthermore, despite the observation of statistical differentially expressed genes 
in this study, given the relatively low fold-change compared to control group, we 
need to be cautious in interpreting those results to avoid misleading conclusions. 
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Figure 6.7. Total genes regulated in macrophages treated with either S1P or CYM-
5442. CummeRbund volcano plot showing an overview of gene regulation between the 
different macrophages treatments. Six technical replicates per condition were used for 
RNA-seq analysis. Genes differentially regulated are indicated in red. Gene-level 
expression was statistically significant using FDR-adjusted p-value of < 0.05. The Mus 
musculus (Mouse) GRCm38 genome was used to map the RNA-seq reads. CYM, CYM-
5442 treatment; CYMC, CYM-5442 control; S1P, S1P treatment; S1PC, S1P control.  
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Figure 6.8. Diagram presenting the total number of genes significantly 
differentially-expressed in pairwise comparisons of the different cell treatment 
groups. CYM, CYM-5442 treatment; CYMC, CYM-5442 control; S1P, S1P treatment; 
S1PC, S1P control 
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Figure 6.9. RNA-seq dendrogram of technical replicates from murine 
macrophages treated either with S1P and CYM-5442. The dendrogram shows that 
the six technical replicates for each condition (0-5) do not cluster together as would be 
expected, thus suggesting a high level of variability within the same group samples or 
the lack of significant differences between the distinct treatment groups. CYM, CYM-
5442 treatment; CYMC, CYM-5442 control; S1P, S1P treatment; S1PC, S1P control 
 
6.2.2.2 Impact of S1P receptor agonists on macrophages gene expression 
Analysis of the relative expression levels of 28474 transcripts showed that in total 
33 and 6 genes were differentially expressed in murine macrophages treated with 
either CYM-5442 or S1P for 1 h, respectively. Curiously, none of the genes 
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identified here are directly associated with the reported S1PR1-5 signalling 
pathway available in KEGG (Kyoto Encyclopedia of Genes and Genomes) 
(Kanehisa et al., 2016; Kanehisa and Goto, 2000).  The differentially expressed 
genes shown in Table 6.1 and 6.2 were divided into several categories, based on 
biological function, in order to simplify subsequent analysis. The cells treated with 
CYM-5442 displayed 25 genes with expression levels induced and 8 genes 
down-regulated. Although the identified genes are not directly involved in the 
recognised S1PR signalling pathway, some of the genes are implicated in the 
regulation of vital biological processes or associated to immune response. Amid 
the up-regulated genes were those involved in proinflammatory response, such 
as Crlf2, a member of the type I cytokine receptor family and the Colony 
Stimulating Factor 2 Receptor (Csf2ra); growth factors (Tgfb1); signalling genes 
related to GPCR  pathway (Akt1s1, Ncor2 and Scaf1) and cell survival and 
apoptosis (Ints1 and Bbc3). Other induced gene was the transcription factor 
Nfkbib (Nuclear factor-Kappa-B Inhibitor Beta), which has been shown to inhibit 
NF-Kappa-B, a key molecule for the transcription of a wide range of inflammatory-
related genes (Chen et al., 2004).  
Among the down-regulated genes were Tnf, a cytokine that belongs to the tumor 
necrosis factor superfamily and has been shown to promote a proinflammatory 
response in activated macrophages (Wajant et al., 2003) as well as the 
chemokine Cxlc2, which is involved in immunoregulatory and inflammatory 
processes (King et al., 2000; Tekamp-Olson et al., 1990). Also, the gene Rgs1 
(Regulator of G-protein signalling 1), which encodes a protein that acts as a 
negative regulator of G-protein signalling and has been shown to play a role in 
chemokine signalling, was significantly repressed (Moratz et al., 2000; Druey et 
al., 1996). 
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Given the fact that S1P is the native ligand of the S1PR1-5, we expected a broader 
signalling pathway response compared to CYM-5442, a selective S1PR1 agonist. 
However, the number of genes differentialy expressed in cells treated with 
exogenous S1P was remarkably low. The only notable gene that was differentially 
regulated following S1P treatment was Tnf, which showed downregulation 
comparable to that observed following CYM-5442 treatment. 
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Table 6.1. Genes differentially expressed 1 h post CYM-5442 treatment in macrophages. Genes up-regulated (+) or down-regulated (-) in comparison 
with the carrier control (H2O). 
Function and gene 
gene id 
Annotation 
log2 
(fold_change) 
Regulation 
 
Immune response 
and Inflammation 
 
   
H2-Q4 Histocompatibility 2, Q region locus 4 0.3 + 
Tnf Tumor necrosis factor 0.4 - 
Csf2ra Colony stimulating factor 2 receptor, alpha 0.4 + 
Cxcl2 Chemokine (C-X-C Motif) Ligand 2 0.4 - 
Crlf2 Cytokine Receptor-Like Factor 2 0.6 + 
Tgfb1 Transforming Growth Factor, Beta 1 0.4 + 
Metabolic 
process/Apoptosis 
 
   
Tysnd1 Trypsin domain containing 1 0.5 + 
Rpl36 Ribosomal protein L36 0.3 + 
Rpl35a Ribosomal protein L35A 0.3 - 
Ints1 Integrator Complex Subunit 1 0.3 + 
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Bbc3 BCL2 Binding Component 3 0.6 + 
Rplp2 Ribosomal Protein, Large, P2 0.3 + 
Lars2 Leucyl-TRNA Synthetase 2, Mitochondrial 0.6 - 
Signalling    
Rgs1 Regulator of G-protein signalling 1 0.3 - 
Dohh Deoxyhypusine hydroxylase 0.4 + 
Akt1s1 AKT1 Substrate 1 (Proline-Rich) 0.5 + 
Transcription    
Hlx H2.0-like homeobox 0.4 + 
Basp1 Brain abundant, membrane attached signal 
protein 1 
0.3 + 
Bmyc Myelocytomatosis oncogene 0.7 + 
Ncor2 Nuclear Receptor Corepressor 2 0.3 + 
Nfkbib NF-Kappa-B Inhibitor Beta 0.4 + 
Scaf1 SR-Related CTD-Associated Factor 1 0.4 + 
Cellular 
component and 
Organisation 
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A230046K03Rik RIKEN cDNA A230046K03 gene 0.3 - 
Gas2l1 Growth arrest-specific 2 like 1 0.4 + 
Bola1 BolA-Like 1 (E. Coli) 0.6 + 
Tuba1b Tubulin, alpha 1B 0.3 - 
Ccdc85b Coiled-coil domain containing 85B 1.0 + 
Ccdc88b Coiled-Coil Domain Containing 88B 0.3 + 
H2afx H2A Histone Family, Member X 0.3 + 
Electron transport    
Slc39a10 Zinc Transporter ZIP10 0.3 - 
Atp13a2 ATPase Type 13A2 0.3 + 
Other    
Snhg7 Small nucleolar RNA, H/ACA box 17 0.8 + 
2810428I15Rik RIKEN cDNA 2810428I15 gene 0.5 + 
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Table 6.2. Genes differentially expressed at 1 h post S1P treatment in macrophages. 
Genes up-regulated (+) or down-regulated (-) in comparison with the carrier control 
(methanol). 
Function and gene 
gene id 
Annotation 
log2 
(fold_change) 
Regulation 
 
Immune response 
and Inflammation 
 
   
H2-Q1 histocompatibility 2, Q region 
locus 1 
1.3 - 
Tnf tumor necrosis factor 0.3 - 
Metabolic 
process/Apoptosis 
 
   
Sik1 Salt-Inducible Kinase 1 0.4 + 
Bc1 brain cytoplasmic RNA 1 0.3 - 
Signalling    
Nr4a1 Nuclear Hormone Receptor 
NUR/77 
0.5 + 
1810011O10Rik RIKEN cDNA 1810011O10 
gene 
0.4 - 
 
 
6.3 Discussion  
The pivotal role played by S1P in immune function has prompted studies of S1P 
modulation as a novel strategy to target fungal, viral or bacterial infections (Arish 
et al., 2015). Herein, we observed that treating infected macrophages with S1P 
resulted in increased association of Burkholderia with lysosome associated 
phagosomes and impaired intracellular survival. In addition, Burkholderia 
infected-macrophages treated with S1P exhibited an increase of intracellular 
bacteria trapped within mature phagolysosomes, thus resulting in lessened 
bacteria survival. Similarly, Mycobacterium-infected type II alveolar epithelial 
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cells treated with extracellular S1P, which is not directly antimicrobial, induced 
phagolysosome maturation and acidification via phospholipase D activation, 
resulting in reduced intracellular mycobacterial viability (Greco et al., 2010). 
Interestingly, it has been demonstrated that S1P play a key role in intracellular 
Ca2+ mobilisation (Young and Nahorski, 2002), and in the context of 
Mycobacterium infection studies, the levels of cytosolic Ca2+ have been directly 
implicated in phagosome maturation in infected macrophages (Malik et al., 2003). 
In addition, a study by Anes et al (2003) reported that exogenous S1P has a 
significant impact on the modulation of the actin assembly in Mycobacterium-
infected macrophages, thereby promoting the efficient alignment of the 
phagosome for lysosome fusion and respective phagolysosome maturation 
(Anes et al., 2003). Thus, one may speculate that similar molecular events also 
sustain our observations, though further experiments are required. Altogether, 
this enhanced mycobactericidal activity of macrophages, which was also 
observed in vitro (Garg et al., 2004), is comparable to the observations reported 
herein with B. pseudomallei and B. thailandensis.  
 
Notably, whilst the enhanced antimicrobial response in cells treated with either 
exogenous S1P or CYM-5442 displayed similar levels of bacteria killing, the S1P 
concentration was 10-fold higher than CYM-5442. The rationale for using such 
S1P concentration was a similar study conducted with Mycobacterium, where it 
was shown that human macrophages treated with 5 µM of S1P inhibited the 
intracellular growth of Mycobacterium smegmatis (Garg et al., 2004). Although, 
the extracellular use of S1P would suggest a receptor-mediated mechanism, 
given the relatively high S1P concentration (5 µM) used in this study, one cannot 
exclude the hypothesis that the antimicrobial effect observed could be due to S1P 
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surpassing the host cell membrane and act directly at the intracellular level 
leading to a bactericidal effect (Weigert et al., 2009).  
Furthermore, in this study we aimed to modulate the S1P signalling pathway by 
targeting the S1PL activity via the use of THI (a S1PL inhibitor), though we could 
not observe any favourable effect regarding the bacteria killing. Curiously, a 
recent report have shown that the use of cell-culture media (e.g. Dulbecco's 
Modified Eagle's Medium) weakens the effect of THI in vitro, since it contains 
excess of vitamin B6 (an important co-factor for S1PL activity) that leads to S1PL 
activation (Ohtoyo et al., 2015). This finding may explain why we could not see a 
significant phenotype for this cell-based infection model and should be taken in 
consideration. 
 
S1P has been widely implicated in human health and infectious diseases, and 
the therapeutic opportunities around S1P pathway modulation are numerous. In 
many cases, the aim is to reduce infection-associated immunopathology. For 
example, S1P agonists suppress the cytokine storm triggered by influenza 
infection, reducing immunopathology and associated mortality (Teijaro et al., 
2014; Walsh  et al., 2011) Similarly, S1P decreases inflammation in a murine 
model of lipopolysaccharide-mediated acute lung injury (Peng et al., 2004), whilst 
the S1PR agonist AAL-R reduces inflammatory cytokine production and lung 
pathology in a Bordetella pertussis infection model (Skerry et al., 2015). Such 
studies are perhaps consistent with our observation that S1P and/or CYM-5442 
treatment of macrophages elicitied a downregulation of genes involved in 
proinflammatory responses, such as Tnf (Wajant et al., 2003) and Cxcl2 
(Tekamp-Olson et al., 1990).  
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Whilst the reduction in lung pathology observed in the B. pertussis model 
occurred without any impact on bacterial burden (Skerry et al., 2015), other 
studies have observed reduced bacterial burden in relevant infection models 
following treatment with S1P or related compounds, associated with either direct 
or indirect antimicrobial activity. One further anti-infective strategy involving S1P 
modulation focuses on its critical role in regulating immune cell trafficking. This is 
exemplified by a study of Francisella tularensis infection, in which it was shown 
that dendritic cells play a role in trafficking the pathogen from the airways (Bar-
Haim et al., 2008). Intranasal administration of FTY720 impaired dendritic cell 
migration, reducing the dissemination of the pathogen in infected mice. In 
addition, intravenous injection of S1P reduces both the bacterial burden and 
pulmonary tissue damage in mycobacteria-infected mice, a phenomenon thought 
to combine S1P-induced lymphopenia (thus reducing T-cell-associated 
immunopathology) with an S1P-mediated increase in the antimicrobial activity of 
macrophages (Garg et al., 2004).  
The examples above highlight the potential benefits of targeting the S1P pathway 
as an anti-infective strategy. However, such an approach is unlikely to be 
universally applicable, as the benefits of S1P modulation will depend on the 
precise nature of the host-pathogen interaction and the associated immunological 
events that promote pathogen clearance and/or dissemination. This is 
exemplified by a study in which FTY720 treatment adversely affected the immune 
response and clearance of Citrobacter rodentium from a murine model of 
gastrointestinal infection (Murphy et al., 2012).  
 
It is notable from this study and those reported previously that the benefits of S1P 
pathway modulation in relation to infection have been observed with intracellular 
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pathogens (Mycobacterium, Burkholderia and Francisella), suggesting this is a 
particular area in which S1P-based anti-infective therapies may be 
advantageous. Another major consideration is the mechanism by which the S1P 
pathway should be modulated. Different signalling pathways are activated 
depending on whether the stimulus is exogenous S1P acting via cell surface 
receptors, or intracellular S1P produced by SphK. This is starkly illustrated by 
studies of the role of the S1P pathway in the immune response to C. neoformans, 
where exogenous S1P increases phagocytosis (McQuiston et al., 2011), whilst 
SphK decreases it (McQuiston et al., 2010). Identification of the specific S1P-
mediated pathways that offer therapeutic benefit is critical so that they can be 
activated in the most appropriate manner. Here, an attempt to depict the 
signalling pathway associated with macrophages-S1P receptor modulation was 
made following a transcriptomic analysis approach. However, given the scarce 
number of genes differentially expressed, the low fold-change between 
treatments, and the variability between technical replicates it was not possible to 
draw clear conclusions regarding the S1PR-mediated signalling pathways 
triggered by exogenous S1P or a specific S1PR1 agonist, CYM-5442. 
Nevertheless, among the genes differentially regulated was evident that 
approximately 30% of the identified genes are involved in inflammatory response 
and cell survival, consistent with a role for S1PR1 in these processes. 
 
In conclusion, the activation of the S1PR1-mediated signalling pathway enhances 
phagocytic killing of intracellular Burkholderia, further highlighting the potential 
therapeutic benefits of S1P pathway modulation for the treatment of infectious 
diseases, particularly those caused by intracellular pathogens. 
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Chapter 7 – General discussion and 
conclusion  
B. pseudomallei, the causative agent of melioidosis, is a facultative intracellular 
pathogenic bacteria and a major cause of severe bacteremic infections in 
endemic regions (Limmathurotsakul et al., 2016). Regardless of recent advances 
in understanding the bacteria pathogenesis and their interactions with the host, 
there are no available vaccines. On one hand, the intrinsic resistance to wide 
spectrum of antibiotics is a major concern and poses a natural obstacle to treat 
B. pseudomallei infections. (Wiersinga et al., 2012, Limmathurotsakul and 
Peacock, 2011). On the other hand, conventional therapies, which are based on 
drugs targeting essential genes thus suppressing the bacteria growth, can 
intensify the selective pressure leading to an increase in drug resistance in the 
bacterial population (Davies and Davies, 2010). Thus, there is a requirement for 
a continuous effort on melioidosis research in order to develop novel therapeutic 
strategies. 
The identification of key virulence determinants or the cognate substrates 
required for bacteria survival and dissemination inside the host can putatively be 
used as therapeutic targets. This approach aims to reduce the ability of the 
bacteria to cause disease and simultaneously help the host to eliminate the 
pathogen from the organism, without increasing the bacterial resistance to drugs 
(Sousa et al., 2015). In this study, we aimed to identify and characterise novel 
virulence determinants in B. pseudomallei in order to investigate their potential 
as antimicrobial targets. 
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There is a growing body of evidence that various intracellular pathogens are able 
to disrupt the S1P-axis pathway for their own benefit, promoting the 
microorganism survival and pathogenesis within the host (Arish et al., 2015, 
Heung et al., 2006). This is exemplified by numerous studies involving distinct 
bacterial species, from Mycobacterium tuberculosis, M. smegmatis, M. avium and 
Shigella flexneri to Legionella pneumophila (Rolando et al., 2016, Kim et al., 
2014, Prakash et al., 2010; Yadav et al., 2006, Thompson et al., 2005). In 
particular, L. pneumophila has been shown to possess a functional S1PL-like 
protein (Degtyar et al., 2009) that is essential to inhibit the autophagy response 
during macrophages infection and to support an efficient infection in a murine 
model, further highlighting the impact of sphingolipids signalling in bacterial 
pathogenesis (Rolando et al., 2016).   
 
In this study we identified and characterised S1PL orthologues in B. thailandensis 
and B. pseudomallei. Herein we confirmed that Burkholderia S1PLs are 
functionally equivalent to eukaryotic S1PL following a S. cerevisiae 
complementation model (Chapter 3). Curiously, there are no other reports of 
bacterial or eukaryotic organisms possessing two distinct genes encoding an 
S1PL as in B. thailandensis and B. pseudomallei. Further characterisation 
revealed that each of the B. thailandensis S1PL proteins were able to partially 
complement S. cerevisiae Δdpl1 resistance to sphingosine, however the higher 
degree of sphingosine resistance conferred by co-expression of BTH_II0309 and 
BTH_II0311 in S. cerevisiae Δdpl1 suggests that both proteins may be required 
for optimal enzymatic activity. In addition, the phenotypic characterisation of a 
single (BPSS2025) and double (BPSS2021 and BPSS2025) S1PL deletion 
mutant in B. pseudomallei revealed indistinguishable phenotypes, thus 
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supporting the hypothesis that both proteins are necessary for full S1PL function 
in Burkholderia.  
Importantly, studies have shown that the formation of S1PL oligomers in S. 
cerevisiae is essential for appropriate enzymatic function in vivo (Mukhopadhyay 
et al., 2008). Moreover, McLean and colleagues have demonstrated that both 
BPSS2021 and BPSS2025 purify as dimers when expressed in E. coli by size 
exclusion chromatography (McLean et al., personal communication), and the 
native PAGE data described in Chapter 3 is consistent with the formation of 
trimers and hexamers. However, attempts to elucidate whether the S1PL proteins 
form hetero or homo-oligomers, either by co-purification and respective LC-MS 
or BACTH system, were inconclusive. Further biochemical characterisation of the 
proteins would be necessary to address that question. Namely, to understand the 
benefit of encoding two distinct S1PLs one could perform an enzymatic assay in 
vitro with purified S1PLs and determine the levels of S1P degradation in the 
presence of either single or both proteins to address whether the proteins may 
form a complex with higher catalytic activity. In addition, an S1PL inhibitor could 
be used for structural studies on Burkholderia S1PL enzymes. Weiler et al (2014) 
described a novel compound able to block the catalytic function of S1PL via 
binding to a pocket that includes residues from both units of the mammalian S1PL 
dimer (Weiler et al., 2014). Thus, the affinity of the inhibitor for the Burkholderia 
S1PL may vary depending on whether it exists as a homodimer or a heterodimer, 
due to the slight sequence variation between the two proteins. 
 
In Chapters 4 and 5 the role of S1PLs in Burkholderia pathogenesis was 
addressed in three different infection models: a macrophage in vitro model, a 
Galleria mellonella model and BALB/c mice infection model. Remarkably, 
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Burkholderia S1PLs have shown to be required for full virulence in all of the 
models.  
Macrophages play an important role in controlling B. pseudomallei infection in 
vivo, therefore one key aspect of melioidosis pathogenesis is the ability of B. 
pseudomallei to survive and replicate inside phagocytic cells (Galyov et al., 2010, 
Breitbach et al., 2006). Notably, both B. thailandensis and B. pseudomallei S1PL 
mutants showed defective intracellular net replication in macrophages. The 
LAMP-1 (a “read-out” protein for phagosome fusion with the lysosome) 
colocalisation analysis by  immunofluorescence microscopy demonstrated that 
S1PL mutants are significantly more prone to be retained within phagolysosomes  
of macrophages compared to wildtype, which may explain why both B. 
thailandensis and B. pseudomallei S1PL mutants displayed reduced intracellular 
replication. S1P has been shown to increase the levels of cytosolic Ca2+ (Blom et 
al., 2005), which is required for proper phagolysosome maturation (Colombo et 
al., 1997). Futhermore, it has been described that the disruption of S1P-mediated 
phagosome maturation is one of the strategies followed by pathogens, such as 
M. tuberculosis, to avoid being killed by the antimicrobial activity of  macrophages 
(Thompson et al., 2005; Malik et al., 2003). Altogether, these observations are 
consistent with the hypothesis of Burkholderia-encoded S1PLs disrupting S1P 
signalling pathway, and consequently impairing the process of phagosome 
maturation and promoting intracellular survival. Unfortunately, in an attempt to 
determine the impact of Burkholderia infection on intracellular S1P we could not 
detect significant changes in S1P levels relative to uninfected cells. This 
observation is likely associated to the limitation of the S1P ELISA method 
together with the low levels of intracellular S1P or the highly dynamic nature of 
S1P biosynthesis (Spiegel and Milstien 2011; Le Stunff et al., 2002). Similarly, in 
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a study showing that the L. pneumophila sphingosine-1-phosphate lyase (LpSPL) 
activity during THP-1 infection inhibits the formation of autophagosomes,  the 
authors failed to detect intracellular S1P by electrospray ionisation-mass 
spectrometry (ESI-MS), reportedly due to S1P low cellular levels (Rolando et al., 
2016). Nevertheless, the authors established that LpSPL activity in infected host 
cells was sufficient to prevent a rise in sphingosine levels, thus contributing to 
lessen the antibacterial response of macrophages (Rolando et al., 2016). 
Therefore, given the challenging task of monitoring alterations in S1P levels, 
future work could involve the measurement of major sphingolipids by mass 
spectrometry and assess the impact of Burkholderia S1PL in the sphingolipids 
balance. 
 
Herein we propose that Burkholderia encoded-S1PL acts in concert with 
documented intracellular survival strategies, such as the Bsa Type III secretion 
system (T3SS) to facilitate escape from endocytic vacuoles (Stevens et al., 
2002). The detection of both S1PLs by immunoblotting in a Bsa-deficient 
mutant´s supernatant indicated that Burkholderia S1PLs are not effectors of the 
Bsa system. Though, S1PL secretion is similarly regulated in a pH-dependent 
manner and can be observed during macrophage infection. These observations 
suggest that S1PLs secretion may be induced by the lower pH found inside the 
phagosomes compared to the relative neutral pH present in the cytosol of 
eukaryotic cells (Canton et al., 2014, Flannagan et al., 2009, Dri et al., 2002). 
Notwithstanding the enigmatic mechanism of S1PL secretion, we can speculate 
that other secretion systems may be involved in S1PL secretion. The genomes 
of B. thailandensis and B. pseudomallei encode an impressive number of 
secretion systems, including T2SS, three T3SS, T5SS, T6SS and Twin Arginine 
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Translocation (Tat) system (Wagley et al., 2014, Campos et al., 2013, Burtnick et 
al., 2011, Shalom et al., 2007, DeShazer et al., 1999). Therefore, further 
mutagenesis work in order to inactivate each of the secretion system mentioned, 
following putative S1PL detection in the supernatants could help to address which 
mechanism is associated to Burkholderia-encoded S1PL secretion. 
 
In a BALB/c infection model we observed a significant attenuation of BPSS2025 
deletion mutant. This observation was consistent with the impaired dissemination 
of the mutant strain in the spleen, lung and liver of the infected animals and 
increased mice survival compared to wildtype B. pseudomallei. Therefore, the 
hypothesis of Burkholderia-encoded S1PL playing a role in pathogenesis is 
further supported by our in vivo infection model. Several studies have shown that 
B. pseudomallei strains impaired in intracellular survival in vitro, namely via the 
inactivation of Bsa T3SS or presenting defective actin-comet tails formation, are 
attenuated in mice (Pilatz et al., 2006, Stevens et al., 2004, Stevens et al., 2002), 
thus suggesting that the molecular mechanisms associated to intracellular 
survival in vitro are also fundamental for bacteria pathogenesis in vivo, which is 
consistent with the B. pseudomallei S1PL mutant attenuation observed in our 
study, for both infection models.  
 
The critical role of S1P-axis in immune cell response and trafficking has been 
extensively described in the literature (Spiegel and Milstien, 2011, Serra and 
Saba, 2010). Recent studies have shown that S1P pathway modulation, namely 
via S1PR agonists/antagonist and protein inhibitors, has therapeutic potential for 
the treatment of immune disorders as well as targeting viral, fungal and bacterial 
infections (Arish et al., 2015, Kunkel et al., 2013). Furthermore, it has been shown 
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that S1P modulation through numerous compounds can be used safely in 
animals and humans (Kunkel et al., 2013). Importantly, in the current study we 
confirmed by immunofluorescence microscopy and macrophages survival assay 
that Burkholderia-infected cells treated with exogenous S1P resulted in increased 
association of bacteria with phagolysosomes and impaired intracellular survival, 
respectively. Additionally, we established that macrophages treated with a 
specific S1PR1 agonist, such as CYM-5442 (Gonzalez-Cabrera et al., 2008), 
resulted in similar impaired intracellular survival. In future work would be 
interesting to investigate the impact of (4-benzylphthalazin-1-yl)-2-
methylpiperazin-1-yl]nicotinonitrile (a selective S1PL inhibitor) as anti-virulence 
agent, since it could potentially inhibit the bacterial S1PL, whilst simultaneously 
modulating host S1P (Weiler et al., 2014).  
 
In an attempt to elucidate which S1P-mediated signalling cascade was 
associated to the antimicrobial activity observed in infected-macrophages, we 
performed transcriptomic analysis on cells treated with either S1P or CYM-5442. 
Unfortunately, the transcriptomic data from macrophages treated with both 
compounds, failed to give a clear answer regarding the antimicrobial pathway 
associated with macrophages-S1PR signalling. The reason why we could not 
observe significant changes in gene expression remains unclear. However, one 
can speculate that the 1 h incubation with the compounds was not enough to elicit 
a more marked gene regulation upon treatment. In spite of the failure to detect a 
significant alteration in gene expression, that does not exclude the occurrence of 
a noteworthy downstream signalling response. It is reported that post-
translational modifications upon S1PR interaction with distinct ligands play an 
important role in cell signalling and contribute for the reported S1P-axis function 
183 
 
(Blaho and Hla, 2014, Gonzalez-Cabrera et al., 2008). Therefore, 
phosphoproteomic analysis on macrophages treated with different S1PR 
agonists could help to unravel the signal transduction associated with the 
antimicrobial response. 
Nevertheless, the impaired intracellular survival presented herein is consistent 
with recent observations in the context of Mycobacterium infection. For instance, 
S1P signalling modulation via the addition of extracellular S1P in Mycobacterium-
infected cells, promoted the efficient phagolysosome maturation and consequent 
acidification, resulting in increased bacteria killing (Greco et al., 2009). Similarly, 
Garg et al (2004) demonstrated that phospholipase D activation mediated by S1P 
treatment, induced an antimycobacterial activity in macrophages through the 
acidification of bacteria-containing phagosomes (Garg et al., 2004). Interestingly, 
in vitro observations are supported by experiments conducted in vivo. For 
example, intravenous administration of S1P in mycobacteria-infected mice 
showed reduction both in the bacterial load and pulmonary tissue damage (Garg 
et al., 2004). Therefore, future work on B. pseudomallei-infected mice treated with 
S1PR agonists or S1PL inhibitors could address important pending questions, 
namely whether  targeting S1P-axis in vivo represents an efficient antimicrobial 
therapy to treat melioidosis. 
 
In conclusion, the data presented in this thesis shows that B. thailandensis and 
B. pseudomallei encode two distinct S1PLs functionally equivalent to eukaryotic 
S1PL. Furthermore, it was demonstrated that Burkholderia-encoded S1PL is 
secreted during macrophages infection and is required for efficient phagosomal 
escape and intracellular survival. In addition, single deletion of S1PL revealed 
reduced virulence in BALB/c mice infection model. Taken together, this study 
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highlighted Burkholderia-encoded S1PLs as a novel strategy employed by the 
bacteria to subvert the normal cellular functions of the host cells, therefore 
contributing to B. pseudomallei pathogenesis. Importantly, herein was shown that 
the activation of the S1PR1-mediated signalling pathway enhances macrophages 
antimicrobial activity towards intracellular Burkholderia, further highlighting the 
potential therapeutic benefits of S1P pathway modulation for the treatment of 
intracellular infections and providing interesting scope for future work. 
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